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 ABSTRACT 
Lymphatic endothelial cells (LECs) are loosely overlapping cells that line the lymphatic 
vasculature.  In tissues, LECs are often located directly beneath the mucosal epithelial layer, and 
therefore, are likely to be among the first cells that come in contact with incoming pathogens 
and/or vaccine antigens and adjuvants when there is a breakage at the epithelial barrier.  We are 
only starting to appreciate the role of LECs in the development of host innate and adaptive 
immune responses during infection or vaccine administration.  This is largely due to the 
difficulties in studying LECs in vivo and the challenges in obtaining pure LEC cultures for study 
ex vivo.  My work focused on isolation and establishment of primary LEC cultures derived from 
different tissue origins of commonly used animal models – ferrets and rhesus macaques – and 
assessment of the potential of these LECs to respond to pathogen-associated molecular patterns 
(PAMPs) or a subset of microbes (SIV/HIV-1).  In addition, I also partially compared the 
phenotype and functionality of LECs to dendritic cells (DCs), an immune cell type that acts as a 
“bridge” between the host innate and adaptive immunity.  My findings revealed that LECs were 
highly heterogeneous in their gene expression profiles.  They also endogenously expressed 
multiple known viral entry and restriction factors for SIV/HIV-1.  LECs responded to several 
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PAMPs by producing proinflammatory cytokines/chemokines that are known to recruit immune 
cells to sites of inflammation.  However, LECs were not highly susceptible or permissible to 
infection using genetically engineered, single-cycle competent SIV/HIV-1 or wild-type SIV.  
Interestingly, LECs expressed phenotypic markers that have been shown to be expressed by DCs 
and showed some functional similarities.  LECs were able to take up and process model antigens, 
although it was not determined if these antigens were presented by MHC I and II molecules.  
These findings are of public health importance because they expand our knowledge of the 
emerging potential of LECs as key players in innate immunity during pathogen-host interactions 
or vaccinations.  Improving our understanding of LECs will positively impact our knowledge of 
mucosal infections and will help in development of improved treatment and vaccination 
strategies.  These primary cells will serve as tools to study LEC immunobiology and will also be 
useful in development of vaccines/therapeutics for human diseases of public health importance 
that target LEC and/or its crosstalk with other immune cells. 
 v 
TABLE OF CONTENTS 
DEDICATION.......................................................................................................................... XIV 
PREFACE ................................................................................................................................... XV 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 LYMPHATIC ENDOTHELIUM....................................................................... 1 
1.1.1 Historical perspective ................................................................................... 1 
1.1.2 Structure and function ................................................................................. 3 
1.1.3 Role in health and disease ............................................................................ 6 
1.1.3.1 Removal of fluids ................................................................................... 6 
1.1.3.2 Immune surveillance and immune cell trafficking ............................ 7 
1.1.3.3 Lipid adsorption in the gut ................................................................. 10 
1.2 LYMPHATIC ENDOTHELIAL CELLS (LECS) ......................................... 11 
1.2.1 LEC phenotypic markers ........................................................................... 11 
1.2.1.1 LEC markers ....................................................................................... 12 
1.2.1.2 Newly defined LEC markers .............................................................. 16 
1.2.1.3 Other associated LEC markers ......................................................... 17 
1.2.2 In vitro models for study of LECs ............................................................. 18 
1.2.2.1 Isolation, culture, and molecular profiling ....................................... 18 
1.2.3 In vivo model for study of LECs ................................................................ 20 
 vi 
1.2.3.1 Genetically modified mice models ..................................................... 20 
1.2.3.2 Zebrafish (Danio rerio)model ............................................................. 22 
1.2.3.3 Tadpole (Xenopus laevis) model ......................................................... 23 
1.3 EMERGING ROLE OF LYMPHATIC ENDOTHELIAL CELLS IN 
IMMUNOMODULATION ................................................................................................ 23 
1.3.1 Role in inflammation and pathological conditions .................................. 24 
1.3.2 Emerging role of LECs in immunity and tolerance ................................. 26 
1.4 ANIMAL MODELS FOR STUDY OF HUMAN DISEASES ....................... 29 
1.4.1 Ferrets as animal models ............................................................................ 29 
1.4.2 Nonhuman primate models ........................................................................ 31 
1.5 SIV/HIV AND THE LYMPHATIC ENDOTHELIUM ................................. 34 
1.5.1 Mucosal transmission and early stage infection of SIV/HIV .................. 35 
1.5.2 Potential role of LECs in local expansion and dissemination of SIV/HIV  
 ....................................................................................................................... 39 
1.6 SUMMARY ........................................................................................................ 41 
2.0 STUDY PREMISE ..................................................................................................... 42 
2.1 RATIONALE ..................................................................................................... 42 
2.2 SPECIFIC AIMS ............................................................................................... 44 
3.0 ISOLATION, CHARACTERIZATION, AND FUNCTIONAL ANALYSIS OF 
PRIMARY FERRET LYMPHATIC ENDOTHELIAL CELLS ........................................... 46 
3.1 PREFACE .......................................................................................................... 47 
3.2 ABSTRACT........................................................................................................ 48 
3.3 INTRODUCTION ............................................................................................. 50 
 vii 
3.4 MATERIALS AND METHODS ...................................................................... 53 
3.5 RESULTS ........................................................................................................... 57 
3.6 DISCUSSION ..................................................................................................... 74 
3.7 ACKNOWLEDGEMENTS .............................................................................. 77 
4.0 FUNCTIONAL ANALYSIS OF MACAQUE LYMPHATIC ENDOTHELIAL 
CELLS: GENE EXPRESSION PROFILES AND INFECTIVITY STUDIES WITH SIV . 78 
4.1 PREFACE .......................................................................................................... 79 
4.2 ABSTRACT........................................................................................................ 80 
4.3 INTRODUCTION ............................................................................................. 81 
4.4 MATERIALS AND METHODS ...................................................................... 83 
4.5 RESULTS ........................................................................................................... 90 
4.6 DISCUSSION ................................................................................................... 116 
4.7 ACKNOWLEDGEMENTS ............................................................................ 119 
5.0 FINAL DISCUSSION .............................................................................................. 121 
5.1 OVERVIEW OF DISSERTATION FINDINGS .......................................... 122 
5.2 IMPORTANCE OF IN VITRO MODELS FOR STUDYING LYMPHATIC 
ENDOTHELIAL CELLS ................................................................................................ 124 
5.3 HETEROGENEITY OF LYMPHATIC ENDOTHELIAL CELLS .......... 128 
5.3.1 Plasticity and heterogeneity of lymphatic endothelial cells................... 129 
5.3.2 Lymphatic endothelial cell and tissue microenvironments ................... 132 
5.3.3 Lymphatic endothelial cell reprogramming and viral infections ......... 134 
5.4 LYMPHATIC ENDOTHELIAL CELLS INNATE IMMUNITY ROLE IN 
PATHOGEN-HOST INTERACTIONS ......................................................................... 135 
 viii 
5.4.1 Pattern recognition receptors .................................................................. 135 
5.4.2 LECs as targets for TLR ligand vaccine adjuvants ............................... 137 
5.4.3 Viral restriction factors ............................................................................ 139 
5.5 LYMPHATIC ENDOTHELIAL CELLS AS POTENTIAL TARGETS FOR 
PATHOGENS ................................................................................................................... 141 
5.5.1 Viral entry factors ..................................................................................... 143 
5.5.2 Other immune receptors .......................................................................... 144 
6.0 OVERALL SUMMARY .......................................................................................... 146 
6.1 MODEL ONE:  PATHOGEN RECOGNITION RECEPTOR SENSING OF 
PATHOGENS AND PRODUCTION OF PROINFLAMMATORY CYTOKINE AND 
CHEMOKINES ................................................................................................................ 146 
6.2 MODEL TWO: ANTIGEN UPTAKE, PROCESSING, AND ARCHIVING .  
  ........................................................................................................................... 147 
6.3 MODEL THREE: EXPRESSION OF INTRINSIC CELLULAR VIRAL 
RESTRICTION FACTORS ............................................................................................ 148 
7.0 PUBLIC HEALTH SIGNIFICANCE .................................................................... 150 
8.0 FUTURE DIRECTIONS ......................................................................................... 152 
8.1 DEVELOPMENT OF 3D IN VITRO CULTURE OF LECS ..................... 152 
8.2 PROFILING OF IMMUNE RECEPTORS EXPRESSED BY PRIMARY 
LECS  ........................................................................................................................... 153 
8.3 PROFILING OF MICRORNAS EXPRESSED BY PRIMARY LECS ..... 153 
8.4 ANTIGEN PRESENTATION VIA MHC I AND MHC II BY LECS ........ 154 
 
 ix 
APPENDIX: 3D MODEL OF PRIMARY HUMAN AND MACAQUE LECS .................. 155 
BIBLIOGRAPHY ..................................................................................................................... 158 
 x 
 LIST OF TABLES 
Table 1. Genetically modified mouse models for LEC markers and their lymphatic vascular 
phenotypes. ................................................................................................................................... 22 
Table 2. Nucleotide sequence relatedness of ferret LEC marker cDNAs to other animal species.
....................................................................................................................................................... 58 
Table 3. Primers and sequences used for standard and real-time RT-PCR. ................................. 59 
Table 4. Spearman’s correlation analyses of mRNA expression levels in TLR ligand treated 
ferret LECs. ................................................................................................................................... 70 
Table 5. List of purchased Taqman assays and in-house designed primer sequences for real time 
RT-PCR......................................................................................................................................... 88 
Table 6. Animal IDs and type of tissues for derivation of primary macaque LECs. .................... 90 
 xi 
LIST OF FIGURES 
Figure 1. An overview of the blood (cardiovascular) system and the lymphatic vasculature 
system. ............................................................................................................................................ 2 
Figure 2. Schematic of the lymphatic vasculature in adult human. ................................................ 5 
Figure 3. Lymphatic endothelium during homeostasis and proinflammatory conditions. ............. 9 
Figure 4. Schematic representation of SIV/HIV-1 virus transmission, stages of infection, and 
their potential interventions. ......................................................................................................... 38 
Figure 5. Phylogenetic analysis of the ferret podoplanin cDNA nucleotide sequence. ................ 60 
Figure 6. Ferret lung LECs grown in culture show the typical cobblestone shape. ..................... 62 
Figure 7. Ferret LECs express multiple LEC marker mRNAs. .................................................... 63 
Figure 8. Primary ferret LECs respond strongly to poly I:C. ....................................................... 66 
Figure 9. Ferret lung LEC responses to different TLR ligands. ................................................... 69 
Figure 10. Chemotactic responses of ferret CCR6+ responder cells to LEC culture supernatants 
after TLR ligand stimulation. ........................................................................................................ 71 
Figure 11. In situ hybridization localization of ferret CCL21 mRNA in ferret lymph node, lung, 
spleen, and jejunal tissues. ............................................................................................................ 73 
Figure 12. Primary macaque LECs show the typical cobbled-stone morphology of endothelial 
cells and form monolayers when cultured on collagen-coated 2D surfaces. ................................ 91 
Figure 13. Primary macaque LECs are highly heterogeneous. ..................................................... 93 
 xii 
Figure 14. Macaque jejunal LECs share similar gene expression profiles with model human 
dermal LECs. ................................................................................................................................ 96 
Figure 15. Macaque jejunal LECs express the LEC surface markers podoplanin and LYVE-1. . 98 
Figure 16. Primary macaque LECs sorted with antibodies against LEC surface markers (anti-
human podoplanin and anti-human LYVE-1) share similar profiles as the unsorted primary 
macaque LEC when cultured in collagen-coated 2D surface. ...................................................... 99 
Figure 17. Poly I:C induces robust proinflammatory chemokines production by primary macaque 
LECs. .......................................................................................................................................... 100 
Figure 18. Primary macaque LECs express known viral restriction and entry factors for SIV and 
HIV-1 endogenously and their expression levels are upregulated by poly I:C treatment. ......... 104 
Figure 19. Primary macaque LECs share similar RNA expression profiles with primary human 
LECs before and after treatment of poly I:C as examined NanoString RNA profiling. ............. 106 
Figure 20. Primary macaque jejunal LECs respond in varying degrees to stimulation with several 
PRR ligands. ............................................................................................................................... 108 
Figure 21. Primary macaque jejunal LECs express multiple endogenous TLRs. ...................... 109 
Figure 22. Primary macaque jejunal LECs are able to take up and process antigen. ................. 110 
Figure 23. Macaque jejunal LECs are not susceptible to infection VSVG-pseudotyped SIV and 
HIV-1 virus as well as wild type SIV (SIVmac239), and their cellular milieus are not permissible 
for viral reverse transcription to occur. ....................................................................................... 114 
Figure 24. Innate Immune Potential of LECs - Model One ........................................................ 147 
Figure 25. Innate Immune Potential of LECs - Model Two ....................................................... 148 
Figure 26. Innate Immune Potential of LECs - Model Three ..................................................... 149 
 xiii 
DEDICATION 
For Mom and Dad 
 xiv 
PREFACE 
In his book entitled Out of Our Minds: Learning to be Creative, Sir Ken Robinson wrote, “What 
we become as our lives evolve depends on the quality of our experiences here and now.”   
 
And I fully agree with that statement.  This dissertation would not have been possible without the 
encouragement, support, and love that I received from so many people.  I do not have words to 
adequately convey my deepest and sincerest gratitude to each and every one of you, and it is my 
hope that this body of work is yours as much as it is mine. 
 
To my advisor and mentor, Dr. Todd A. Reinhart:  Thank you for fostering in me the passion, 
enthusiasm, and tremendous desire to understand the beauty and complexity of immunology.  I 
have benefited greatly from the opportunity to work and to grow as a scientist under your 
mentorship and guidance.  You helped “flick” the switch in me that allowed me to discover and 
continue to explore my lifelong journey as a scientist and a scholar.  It is my sincerest hope that 
moving forward in my career from your lab I will take with me not only the technical skills but 
also the qualities of a dedicated academician.  Dr. Reinhart – from the bottom of my heart, thank 
you.   
 
 xv 
To my dissertation committee members, Drs. Todd A. Reinhart, Ernesto T. A. Marques, Frank J. 
Jenkins, and Robert E. Ferrell:  Thank you for the willingness to serve on my committee, and for 
the insightful suggestions, comments, and discussions throughout the course of my doctoral 
studies.  It has been an invaluable experience and an honor to work with all of you.  
 
To my lab family, especially Carissa, Beth, Nicole, and Cynthia:  Thank you for your friendship.  
There’s an anonymous quote that says, “Good friends are hard to find, harder to leave, and 
impossible to forget.”  I will always treasure our friendships and I know that I have found 
lifelong friends in each one of you. 
 
To my own family, especially my dad, my late mom, and my siblings:  Thank you for your love.  
Thank you for your understanding.  And for tolerating my absence on so many important family 
occasions.  Dad – thank you for telling me not to be afraid to try just because I might fail.  Mom 
– thank you for telling me that not all things are good but not all things are bad either.  And, I 
know that you are now a star that shines your light down on me, guiding me as always.  Diana 
and Jeffery – thank you for filling the shoes of the eldest borne on so many occasions on my 
behalf.  I could not have asked for a better sister and brother-in-law.    
 
And finally to you, the reader:  Thank you for your interest in this body of work. 
 
 
 xvi 
1.0  INTRODUCTION 
1.1 LYMPHATIC ENDOTHELIUM 
1.1.1 Historical perspective 
The mammalian vascular system is made of two highly related but functionally distinct and 
specialized vasculature networks, namely the blood vasculature and the lymphatic vasculature (1, 
2).  These vasculature systems both are made of similarly extensive networks of capillaries and 
vessels.  However, due to its importance in the blood vascular (cardiovascular) system, the blood 
vasculature has received far more attention than its sister vasculature, the lymphatic vasculature.  
The blood vascular system is a closed circulatory system pumped by the heart, which main 
function is to deliver oxygen to cells in organs (3).  In contrast, the lymphatic vascular system is 
a blunt, open-ended, unidirectional system, which main function is to return excess tissue fluids, 
cells, and macromolecules, collectively in the form of lymph, from the interstitial spaces of 
tissues and organs to draining lymph nodes and eventually to the blood circulation through the 
thoracic duct or cisterna chili that joined to the subclavian veins (Figure 1) (4).   
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Figure 1. An overview of the blood (cardiovascular) system and the lymphatic vasculature system. 
 
The blood vasculature network is a circular and closed network, in which the blood leaves from and returns to the 
heart.  The lymphatic vasculature is a linear and an opened network, in which the lymphatic capillaries at the 
peripheral tissues drain the interstitial fluids (lymph) containing cells, proteins, and macromolecules and transport it 
back to the blood vasculature network through lymph node via afferent lymphatics and the lymphatic-blood junction 
at the end of the thoracic duct via efferent lymphatics.  Figure adapted from (4) with permission.  
 
The lymphatic system was first described by a number of astute ancient Greek physicians 
between 300BC to 199AD, including both Aristotle and Hippocrates (5).  Aristotle in his 
observation described the lymphatic vessels as “fibers that take a position between blood vessels 
and nerves, which contain a colorless liquid”, meanwhile Hippocrates described the lymphatic 
vessels in the axillary lymph node as “vessels containing white blood” (5, 6).  In the year 1622, 
an Italian professor in anatomy and surgery named Gasparo Aselli published an observation 
describing the lymphatic structure and course of the lymphatic vessels in the canine mesentery, 
which he named “lacteal vessels” (5).  However, Aselli’s work did not describe much on the 
function of these vessels.  It was not until the mid-18th century (between the years 1740 to 1787) 
that the actual function of the lymphatic vasculature and the lymphatic system was first described 
by the findings of three British anatomists -- William Hunter, William Hewson, and William 
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Cruikshank, in which they described the lymphatic vessel function was to absorb liquid waste in 
the body (5).  A closer observation by Hewson reported that lymphatic vessels evolved to 
produce a substance called lymph, which contained smaller particles and were essential to body 
growth and health (7).  Advancement in microscopy techniques and the use of in vivo vital 
stains, contrast substances, and radionuclide substances enabled visualization and documentation 
of lymphatic capillaries and vessels in the organs in the absence or presence of diseases in the 
next centuries (5).  Identification of sentinel lymph node and other secondary lymphoid organs 
highlighted the importance of the lymphatic system, comprised of the lymphatics as well as the 
lymphoid organs, in inflammation and pathological conditions (8-11).  
Despite the long list of history and medical breakthroughs, exploration of the lymphatic 
vasculature function at the molecular and cellular levels is still challenging.  Our appreciation on 
how knowledge of the lymphatics has evolved over the centuries when combined with recent 
discoveries of lymphatic endothelium-specific markers and growth factors as well as growing 
availability of small animal and in vitro models in lymphatic research will hopefully provide us 
with tools to impact future challenges and potential breakthroughs in the field.     
1.1.2 Structure and function 
The lymphatic vasculature is made of highly branched networks of endothelium that penetrate 
most vascularized organs and tissues with the exception of the central nervous system and 
avascular tissues such as the cartilage, and the bone (3, 12, 13).  Because of its leakiness, the 
blood vessels are usually located near the lymphatics, which are responsible for removal of the 
extravasated fluids from the interstitial tissues spaces back to the blood circulation (14).   
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The lymphatic endothelium consists of distinct compartments, such as initial capillaries, 
pre-collecting, and collecting vessels (2, 4, 14, 15).  The initial lymphatic capillaries are the 
thinnest capillaries and are made of blind-ended structures, which lack a basement membrane 
and are directly anchored to the extracellular matrix by fibrillin-anchoring filaments (Figure 2C) 
(4, 15, 16).  The luminal walls of these capillaries are lined by a single layer of loosely 
overlapping cells (Figure 2B) that form button-like junctions (13, 14, 17), which under high 
interstitial pressure conditions are pulled open by the anchoring filaments and allow lymph to 
flow unidirectionally from the interstitial spaces into the capillaries and then subsequently into 
the pre-collecting and collecting vessels (14).  The pre-collecting vessels connect the lymphatic 
capillaries to the collecting vessels.  Unlike the initial capillaries, the pre-collectors are also lined 
by irregular layers of smooth muscle, which contribute to their role in both lymph absorption and 
propulsion (4, 15, 18).  The main function of the collecting lymphatic vessels is to transport 
lymph and thus these vessels are lined by cells that form continuous tight zipper-like junctions as 
well as a basement membrane and continuous muscular layer that help propel lymph flow (4, 17, 
19).  The collecting vessels function very much like the veins in which they contain bileaflet 
one-way valves that prevent retrograde flow of the lymph (3, 4, 19).  The collecting vessels are 
connected to lymph nodes where lymph is filtered (Figure 1) and thus can be discerned into pre- 
(afferent) and post-nodal (efferent) lymphatic vessels (18).  The lymph flows out from the lymph 
nodes via the efferent lymphatics and eventually drains into the thoracic duct and is returned to 
the bloodstream via the veins at the right jugulo-subclavian junction (Figure 2A) (2). 
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Figure 2. Schematic of the lymphatic vasculature in adult human. 
 
The lymphatic vasculature network is made of a complex network of open-ended, thin-walled capillaries and 
collecting vessels.  The lymphatic vasculature transports the lymph unidirectionally from the interstitium and returns 
it to the blood circulation via the thoracic duct at the junction of the jugular and subclavian veins at the base of the 
neck (2A).  Lymphatic capillaries are connected to the larger connecting lymphatic vessel by the precollecting 
lymphatic vessel (2B).  The lymphatic capillaries are blunt-ended and are made of overlapping, single layer of cells 
endothelial cells anchored by fibrillin filaments.  The anchoring filaments attach endothelial cells to the extracellular 
matrices and prevent the capillaries from collapsing.  Under the conditions when interstitial pressure increases due to 
fluid accumulation, the anchoring filaments pull the lymphatic endothelial cells and open the cell-to-cell junction of 
the overlapping cells to allow lymph and others (immune cells or antigens) to enter the lumen of the lymphatics 
(2C).  Figure adapted from (2) with permission.  
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1.1.3 Role in health and disease 
1.1.3.1 Removal of fluids 
The unique structural features of the lymphatic vasculature make it highly suitable and well-
adapted to function as a drainage system for removal of excess interstitial fluids in order to 
maintain tissues homeostasis.  In healthy or steady-state conditions, the extravasation of fluids 
from the blood vasculature is balanced by the lymphatics through drainage and return to the 
blood circulation (16).  The afferent lymphatics transport the interstitial fluids into the draining 
lymph nodes of which are filtrated and reabsorbed into the bloodstream in the lymph nodes or 
are transported via efferent lymphatics to be returned to the blood circulation via thoracic duct 
through the jugular and subclavian veins (4, 10, 16).  Lymphatic malfunctions result in 
accumulation of tissue fluids in the interstitium and often times caused swelling and pain in the 
afflicted area.  This condition is known as lymphedema and may occur when filtration and 
reabsorption of excess interstitial fluids back into the blood circulatory exceeds the lymphatic 
drainage for an extended period of time.  The accumulation of these protein-rich fluids are also 
associated with inflammatory reactions, tissue fibrosis, and susceptibility to infections (10).   
Lymphedema can be classified into primary (hereditary) lymphedema or secondary 
(acquired) lymphedema.  Primary (hereditary) lymphedema is due to genetic defects that affect 
the lymphatic development at birth or usually start appearing around puberty (3, 10).  Secondary 
(acquired) lymphedema is mainly caused by compromised lymphatic functions due to infections, 
surgery, or radiation (3).  The most common form of secondary lymphedema is caused by 
parasitic filarial worm infections which causes blockage of lymph flow and remodeling of the 
infected lymphatics (20-22).  Lymphatic filariasis currently affects more than 100 million people 
worldwide in over 80 countries, mostly in tropical Africa and Asia (3, 22). 
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1.1.3.2 Immune surveillance and immune cell trafficking  
The extensive networks formed by the lymphatic endothelium make them an ideal conduit for 
antigen and immune cell transport during immune surveillance (23).  In steady state conditions, 
naïve and semi-naïve immune cells such lymphocytes and DCs are transported along with lymph 
to the bloodstream for recirculation via the lymph node (4).  Constant sampling of the lymph for 
host self-antigens by resident immune cells at the draining lymph node provides a constant 
update on the antigen statuses that are critical for host tolerance (Figure 3) (13, 24).  
Soluble foreign antigens can either be directly transported to the draining lymph node via 
the lymphatics or loaded onto antigen-presenting cells (APCs) such as DCs before migration 
from the periphery to the draining lymph node via the afferent lymphatics (25).  During an 
infection or an induction of inflammation, the regional lymph node provides a unique 
microenvironment that facilitates optimal encounters between naïve T cells and B cells with 
foreign antigens for mounting of cell-mediated and humoral adaptive immunity (Figure 3) (23, 
26).  Thus, the lymphatic vessels are critical key structural components in the microarchitecture 
of the lymph node for proper activation of the immune response and also the subsequent 
dissemination of the activated effector cells (T cells and B cells) to the blood circulation via the 
efferent lymphatics during inflammation (13, 27).   
 More recent discoveries have revealed that the lymphatic endothelium is far from just a 
passive conduit for immune cell trafficking.  Evidence from several studies showed that the 
lymphatic endothelium plays an active role in mediating the entry of activated DCs and 
lymphocytes into the afferent lymphatics through expression of chemokines (homeostasis and 
proinflammatory signals) (Figure 3) (23, 28-32) and adhesion molecules (33, 34).  In both steady 
state and inflammatory conditions, DC transmigration into the lumen of the afferent lymphatic 
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capillaries is driven by the interaction of chemokine receptors, such as CCR7, with CCL21 and 
CCL19, which are generated by the lymphatic endothelium (28, 29, 35).  Lymphatic vessels in 
the skin produce the chemokine CXCL12 after antigen exposure and thus trigger chemotactic 
migration of dermal DCs (36).  A more recent study showed that another chemokine, CX3CL1, 
is also expressed by activated lymphatics during inflammation and are responsible for recruiting 
DCs and leukocytes expressing the cognate receptor, CX3CR1, resulting in migration towards 
lymphatic endothelium (31).  Adhesion molecules such as VCAM-1 and ICAM-1 facilitate the 
initial attachment, rolling, and transmigration of leukocytes into the luminal sides of activated 
lymphatics vessels (33, 34).    
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 Figure 3. Lymphatic endothelium during homeostasis and proinflammatory conditions. 
 
During a homeostasis or steady state condition, immune surveillance carried out by resident immune cells such as 
DCs at the peripheral tissues is orchestrated by the homeostasis signals secreted by the lymphatic endothelium.  
Homeostasis signals (chemokines) mediate migration of DCs towards the blunt-ended lymphatic capillaries, and into 
the draining lymph node via the afferent lymphatics.  During an infection or inflammatory condition, 
proinflammatory signals (cytokines/chemokines) facilitate the migration of antigen-loaded mature DCs travel to the 
draining lymph node, and trigger the activation of naïve T cells and B cells.  Activated T cells and B cells then exit 
the lymph node via the efferent lymphatics, into the blood circulation, and finally the inflammation site to begin 
their effector functions.  Proinflammatory cytokines/chemokines secretion by the lymphatic capillaries facilitate the 
trafficking of these effector immune cells to the site of inflammation by creating local proinflammatory within the 
local peripheral tissue environment.  
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1.1.3.3 Lipid adsorption in the gut 
Another important physiological function of the lymphatic endothelium is the adsorption and 
transports of intestinal nutrients, especially lipids and fat-soluble vitamins (1, 2, 9-11).  High 
molecular weight molecules and colloids are often taken up by specialized lymphatic vessels in 
the villi known as lacteals (2).  Unfortunately, knowledge on the mechanisms of lipid 
macromolecule uptake into lacteals is still rudimentary and it is still unclear whether these 
macromolecules are being modified in any way to facilitate their uptake into lymphatics (37).  
However, it is very likely that the structure of the lymphatics and lymph propulsion play a major 
role in facilitating the uptake processes.  It is well established that the integrity of the intestinal 
lymphatic structure affects the survival of genetically modified mice at birth (38) and is directly 
responsible for the onset of obesity in adult-mice due to accumulation of adipose tissues (39).  
Fat deposits have been shown to accumulate surrounding the leaky lymphatics and often times 
lead to tissue fibrosis and chronic lymphedema in mice and humans (39, 40).  Research on the 
mechanisms of dietary fat adsorption by intestinal lymphatics is essential in order to appreciate 
the role of intestinal lymphatics in diseases associated with malabsorptions and vitamin 
deficiencies and well as potential insight into advancement of intestinal lymphatic drug transport 
(41).     
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1.2 LYMPHATIC ENDOTHELIAL CELLS (LECS) 
The lymphatic endothelial cells (LECs) line the wall of the lymphatic endothelium and share the 
similar apico-basal polarity and flat morphology as the blood endothelial cells (BECs) (42), 
making them impossible to distinguish from each other in in vitro 2D cultures.  The origin of 
LECs remains not completely understood although increasing evidence seems to be supporting 
one of the popular models which proposes that peripheral lymphatics develop from the cardinal 
vein and gain their lymphatic competence and commitment at the embryonic level (9).  However, 
due to their specialized biological functions, there have been tremendous efforts in identifying 
specific markers that allow discrimination of LECs and BECs.   
1.2.1 LEC phenotypic markers 
Recent discoveries of LEC markers have significantly contributed to more in-depth studies of 
physiological role the lymphatic endothelium and its function at the cellular and molecular levels 
(43).  These LEC markers not only allow for discrimination of LECs and BECs at the 
histological level but also facilitate isolation of pure cultures of both cell populations for studies 
in vitro.  Several phenotypic markers have been considered specific for characterization of LECs 
in the literature.  The classical LEC markers such as the fms-like tyrosine kinase receptor 
VEGFR-3 (Flt4) (44-46), mucin-type transmembrane glycoprotein podoplanin (47, 48), 
hyaluronan receptor LYVE-1 (49), transcription factor Prox-1 (38, 50), and the CC-chemokine 
ligand-21 (CCL21) (51) have been used for analysis of lymphatic vasculature in histological 
11 
sections and also as targets for obtaining pure LEC populations using target-specific antibodies.  
Advances in molecular biology have allowed for molecular profiling of LECs and BECs at the 
transcriptome level and thus resulted in identification of newer markers for their discrimination.  
Discoveries of newly defined LEC markers such as stabilin-1 (STAB-1), reelin, and COLEC-12 
(42, 52, 53), as well as other LEC-associated markers (1, 54-57) have led to better understanding 
of the function of the lymphatic endothelium at the cellular and molecular levels. 
1.2.1.1 LEC markers 
VEGFR-3 
Vascular endothelial growth factor receptor-3 (VEGFR-3), also known as Flt4, is a member of a 
subfamily of receptor protein tyrosine kinases and is structurally related to the other members of 
the fms-like tyrosine kinase receptors, VEGFR-1 (Flt1) and VEGFR-2 (Flk1/KDR).  However, 
unlike VEGFR-1 and VEGFR-2, which bind to the endothelial growth factor VEGF-A, VEGFR-
3 binds to the lymphatic specific endothelial growth factors, VEGF-C and VEGF-D (43, 58).  
Two alternatively spliced isoforms of VEGFR-3 with different lengths of cytoplasmic domains 
have been reported but it is still unclear if these two isoforms differ in their signaling properties 
(59).  Interestingly, VEGFR-3 is expressed by both blood and lymphatic vessels during the 
embryonic stage, evidence that corroborates the notion that lymphatic endothelium originates 
from sprouting of the cardinal vein (44, 45, 60).  However, later in the fetal development 
VEGFR-3 expression is restricted to the lymphatics and plays an essential role in formation of 
the lymphatic vessels as well as differentiation and proliferation of LEC-lineage cells (44, 45).  
VEGFR-3 knock out mice display abnormalities in their blood vessel development which lead to 
fatalities (61) and inhibition of endogenous VEGFR-3 signaling using soluble VEGFR-3, which 
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competes with ligand binding with the endogenous VEGFR-3 resulted in lymphatic regression in 
several organs of the transgenic mice (62).  Administration of a specific antibody that blocked 
the binding of VEGFR-3 to VEGF-C also resulted in impaired lymphatic sprouting in adult mice.  
However, the pre-existing lymphatic vessels did not seem to be affected (63).  VEGFR-3 
expression also has been detected on cells of the hematopoietic system (64), suggesting a 
common stem cell origin of hematopoietic and endothelial cells.  Although VEGFR-3 expression 
is limited to the lymphatics in healthy adult tissues, it is expressed on blood capillaries in 
pathological conditions such as tumor neovascularization and chronic inflammatory wounds 
(65).  Thus, the use of VEGFR-3 alone as a marker to differentiate LECs from BECs generally is 
not sufficient and combination with other LEC markers is needed for characterization.     
Podoplanin 
Podoplanin is a mucin-type membrane surface glycoprotein that is highly expressed by LECs but 
not BECs in vivo and in vitro (50, 51, 53, 66).  Additionally, podoplanin is also expressed by 
other cell types including kidney podocytes, osteocytes, and lung alveolar and corneal epithelial 
cells (67).  Podoplanin expression by the lymphatic endothelium was first discovered by 
immunohistochemistry as it was found to colocalize with VEGFR-3 in normal lymphatic 
endothelium and in vascular tumor of lymphatic origin (47, 48).  Since then podoplanin 
expression has been associated with the lymphatic endothelium in many organs of healthy 
individuals, including the skin, kidney, and lung (68), as well as various human tumors of 
lymphatic origin (69).  Podoplanin expression on LECs contributes to active recruitment of 
mononuclear leukocytes into the basolateral surface of the lymphatic endothelium through 
interaction with CCL21 (70).  Podoplanin knock out mice die immediately after birth due to 
respiratory failure which results from defective formation of alveolar spaces and impaired 
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lymphatic transport (66).  In vitro studies using overexpression and siRNA knock down showed 
that podoplanin plays an important role in LEC migration, cell adhesion, and tube formation 
(66).  It is also possible that podoplanin plays a role in regulating transmigration of immune cells 
across the lymphatic endothelium (23).  Podoplanin is one of the most highly expressed LEC 
markers in lymphatic endothelium (23), and its absence from BECs in physiological or 
pathological conditions makes it a strong and reliable marker for LEC and BEC discrimination. 
LYVE-1 
Lymphatic vessel endothelial receptor-1 (LYVE-1) is a homolog of the blood endothelial 
hyaluronic acid (HA) receptor CD44, and is mostly associated with the lymphatic endothelium 
(49).  Histological analysis of LYVE-1 expression showed that it is highly expressed on both the 
luminal and the abluminal sides of the lymphatic capillaries (71).  LYVE-1 is also expressed by 
other cells types including activated macrophages and sinusoidal endothelium of the liver and the 
spleen, where high molecular weight HA is absorbed and degraded (72).  HA is known to be a 
key mediator of cell migration and is degraded in regional lymph nodes and liver (73).  
Therefore, HA interaction with LYVE-1 enables cells with surface HA such as lymphocytes and 
leukocytes to adhere to and migrate through the lymphatic endothelium to the draining lymph 
node (74).  This was shown when migration of antigen-loaded DCs from the footpad of mice to 
the draining lymph node was abrogated by administration of antibody that binds LYVE-1 (71).  
However, interestingly, despite the known importance of LYVE-1 in lymphatic vessel function, 
mice lacking the LYVE-1 gene develop normal lymphatic vasculature and function (74, 75).  
Histological analysis of normal and tumor-associated lymphatics in murine and human tissues 
revealed that LYVE-1 expression is selectively expressed by LECs but not BECs (12, 75, 76) 
and analysis at the mRNA level showed no expression of LYVE-1 by BECs after birth (68).  
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These findings confirmed the specificity of LYVE-1 expression to that of LECs and not BECs, 
thus making it an important LEC marker.    
Prox-1 
Prospero-related homeobox gene-1 (Prox-1) is the mammalian homolog of the Drosophila 
homeobox gene prospero, a transcription factor that is responsible for lineage specification of 
LECs during embryonic lymphatic development (38, 77).  Prox-1 expression localizes with 
VEGFR-3 in mouse embryo as early as day 8.5 in cells of lymphatic competence and is found to 
co-localize within the same location with LYVE-1 in the lymphatic endothelium later in 
development (60).  In Prox-1 knock out mice the lymphatics fail to develop whereas the blood 
vessels appear to be unaffected (38).  Prox-1 is regarded as the master regulator of LEC lineage 
and has the potency to reprogram BECs into LEC-like phenotype (50, 78-81).  Prox-1 expression 
in normal adult rat tissues showed that it is exclusive to LECs (68).  Prox-1 represses BEC 
markers (50) and Prox-1 knock out mice fail to express other LEC markers, underscoring the 
importance of Prox-1 in lineage commitment and differentiation of LECs (38).  The expression 
of the lymphatic-specific transcription factor Prox-1 is mutually exclusive with that of the blood 
vascular-specific marker PAL-E in tissues obtained from healthy adult and lymphedema patients 
(82) as well as in esophageal lymphatics of the monkey (83).  Thus, Prox-1 serves as an 
important key marker of LECs in normal and pathological conditions during disease.      
CCL21 
Aside from lymphatic vessels, CCL21 is expressed by T-zone stromal cells (84) as well as high 
endothelial venules (HEVs) (85) in mice.  Nevertheless, its expression in humans was observed 
to be conserved to the lymphatics and not the blood vessels (86, 87).  CCL21 is a homeostatic 
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chemokine that binds to the CC-chemokine receptor 7 (CCR7) expressed by naïve and activated 
leukocytes, including neutrophils, lymphocytes (T cells and B cells), and antigen presenting cells 
(DCs) (32, 33, 88-90).  CCL21 is constitutively expressed by the lymphatics and mediates 
migration and entry of neutrophils (32), T cells (30, 90, 91), as well as DCs (29, 92) from the 
periphery to the draining lymph nodes via afferent lymphatics (30, 93).  In situ hybridization 
analysis of CCL21 mRNA distribution in nonhuman primate lymph nodes showed that 
CCL21expression is higher at the afferent lymphatics compared to the efferent lymphatics (93).  
However, in the lymph node CCL21 is also expressed in the paracortex by stromal cells such as 
the fibroblastic reticular cells (FRCs) (94), thus limiting its use as lymphatic-specific marker in 
secondary lymphoid organs.  
1.2.1.2 Newly defined LEC markers 
Comprehensive analyses based on microarray data have identified new markers for 
characterization and differentiation of LECs and BECs (42, 50, 53).  Immunohistochemical 
staining of widely used endothelial cell models and human tissues showed that expression of 
novel LEC markers such as reelin, stabilin-1 (also known as CLEVER-1), and collectin placenta 
12 (COLEC12) colocalized with known LEC markers podoplanin and LYVE-1(42).  Reelin is 
involved in NOTCH-signaling, which is important for LEC/BEC specialization and vasculature 
development (95).  CLEVER-1 is expressed constitutively by lymphatic vessels in normal and 
cancerous human skin tissues (96, 97).  CLEVER-1 also is involved in regulation of leukocyte 
migration to draining lymph nodes via lymphatics as well as leukocyte entry to sites of 
inflammation via inflamed vessels (96, 98).  Thus, CLEVER-1 expression by lymphatic 
endothelium is an attractive target for development of therapeutic drugs that modulate leukocytes 
migration during disease conditions such as cancer metastasis via lymphatics (99).  
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Immunohistochemical analysis of human lymph nodes, inflamed tonsils, and malignant tissues 
showed that COLEC12 expression strongly co-localized with the LEC marker, LYVE-1 (42).        
1.2.1.3 Other associated LEC markers 
More recently, additional markers have been demonstrated to be strongly associated with LECs 
such as atypical chemokine receptor D6, interleukin-7 (IL-7), and spinster 2 (Spns2), and CD40.  
D6 is expressed on the luminal side of the lymphatic endothelium and has been shown to be 
expressed by lymphatics in skin and lung tissues as well as secondary lymphoid and placental 
tissues (100).  D6 is involved in scavenging subsets of inflammatory and homeostatic CC 
chemokines by binding the ligands, internalizing, and degrading them (101-103).  Therefore, D6 
is fundamental in regulation of inflammation as well as innate and adaptive immune responses 
through coordination of leukocyte migration to the lymph nodes via the afferent lymphatics (54, 
55, 104, 105).  Analysis of sorted LECs derived from human lymph node showed substantial 
expression of IL-7 (57).  IL-7 secretion by stromal cells, including LECs and FRCs, is critical for 
reconstruction and remodeling of distinct microenvironments in lymph nodes for optimal 
interaction between IL-7Rα+ T cells and DCs in the subcapsular sinus (57).  Sphingosine-1-
phosphate (S1P) is a signaling molecule required for egress of lymphocytes such as T cells and B 
cells in and out of the lymphatic network including the lymph node (56).  S1P is made in the 
cytoplasm as well as the nucleus and thus needs to be transported out of the cells for it to 
function.  Spns2 is an S1P transporter molecule and plays an important role in regulation of S1P 
levels in blood and lymph node (56).  Spns2 knock out mice have been reported to have lower 
levels of plasma S1P than wild type mice and exhibit altered lymphatics that appeared collapsed 
(56).  CD40 is expressed by many cell types such as fibroblasts, epithelial cells, and endothelial 
cells (106).  In endothelial cells, CD40 interaction with T cells expressing CD40 ligand (or 
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CD154) results in activation of endothelial cells including regulation of kinases and/or 
transcription factors that affect immune-inflammatory responses triggered by endothelial cell-T 
cell crosstalk (107).     
1.2.2 In vitro models for study of LECs  
LECs and BECs are specialized cell types that are well adapted to their specific functions.  Gene 
expression profiles of both types of endothelial cells will provide a basis for understanding the 
molecular characteristics of both LECs and BECs (51).  To unravel these complex functional 
differences of LECs and BECs, relatively pure in vitro cultures of both cell types are crucial 
tools for study.  Isolation and culture of bona-fide LECs has been challenging due to 
contamination by BECs, and vice versa, as well as contamination by other stromal cells such as 
fibroblasts and keratinocytes (108, 109).  In addition, isolated LECs often are low in yields and 
have short life spans.  Recent discoveries of LEC markers and growth factors have made it 
possible to positively or negatively select for LECs using specific antibodies to culture them in 
vitro and study their functions.  Various techniques of cell immortalization have also been 
utilized to establish more stable cell lines to study LECs properties and functions. 
1.2.2.1 Isolation, culture, and molecular profiling 
In vitro models of LECs have been established using various isolation methods, which includes 
mechanical and enzymatic digestion of the tissues followed by immunoselection using antibodies 
against LEC markers such as podoplanin, VEGFR-3, and LYVE-, alone or in combination with 
antibodies against common endothelial markers, such as CD31 (PECAM-1).  LECs have been 
isolated for culture by positive selection using antibodies specific to podoplanin (51, 108), 
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VEGFR-3 (110), LYVE-1 (52) as well as negative selection using antibodies specific for BECs 
such as CD34 and E-selectin (53).  Primary human LECs were also isolated from human skin 
tissues from patients with lymphedema using a combination of immunoselection with anti-
podoplanin and anti-LYVE-1 antibodies (111).  Similarly, primary human LECs from cases of 
chronic tonsillitis were isolated using a combination of antibodies against CD31 and podoplanin 
expressed on LECs (109).  Transiently expressed endothelial cell markers, upon treatment with 
certain stimuli such as cytokines, were also used in some cases.  E-selectin specific antibody was 
used to obtain pure cultures of primary endothelial cells from mixed cultures containing 
fibroblasts and keratinocytes from human neonatal foreskin after stimulation with TNF-α (112).  
Establishment of in vitro LEC cultures is also made possible through identification of growth 
factors that enhance survival, growth, and proliferation of primary LECs, such as VEGF-C and 
VEGF-D (113-116).  A recent study showed that cord blood derived CD34+/VEGFR-3+ cells 
cultured in the presence of VEGF-C in standard 2D monolayers were able to differentiate to 
become more LEC-like and expressed LEC markers, LYVE-1 and Prox-1 (114). 
In vitro cultures of relatively pure LEC populations have enabled molecular 
characterization of LEC expression profiles by microarray analysis.  These large datasets 
provided means to identify newer markers to distinguish lymphatic and blood vessels as well as 
their specialized functions in health and disease.  Information on diseased and malignant tissues 
from patients also potentially identifies diagnostic markers as well as novel markers for 
therapeutics development.  However, in vitro culture of primary cells likely alters their 
phenotypes to some extent.  Adaptation to 2D culture has been reported to result in upregulation 
and/or downregulation of genes found in in vitro cultured LECs and BECs when compared to 
native cells isolated directly from tissues (53).  Another challenge faced in in vitro culture of 
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primary LECs is their short lifespan.  Several efforts have been made to increase the lifespans of 
primary LECs by transduction of oncogenic viral antigens such as SV40 T antigen (117) or 
infection by a retrovirus containing the coding region of the human telomerase reverse 
transcriptase (hTERT) (118).   
In addition, in vitro studies using primary LECs from human tissues poses a lot of 
challenges to follow up in vivo.  Therefore, in vitro cultures of LECs from commonly used 
animal models are attractive alternatives for study of LECs and their function in lymphatic 
diseases.  Primary LECs have been isolated from different animal species including bovine 
(119), ovine (120), canine (121, 122), and murine (123-130) as well as different tissue origin 
including skin (129), lymphatic vessels/thoracic duct (121, 122), and lymph node (130).  
Conditionally immortalized primary mouse LECs were isolated from genetically modified mice 
and used to establish stable and long-term culture of mouse LECs in vitro (128).  
1.2.3 In vivo model for study of LECs 
1.2.3.1 Genetically modified mice models 
Studies of knock out and transgenic mice have revealed a number of genes that are crucial for 
embryonic lymphatic vasculature development and growth including final remodeling of 
lymphatic capillaries and collecting lymphatic vessels (1, 19).  Among these are genetically 
modified mice lacking the LEC markers Prox-1, VEGFR-3, LYVE-1, or podoplanin (Table 1).  
Knock out mouse models lacking the LEC marker Prox-1 (Prox-1 -/-), which is a transcription 
factor for controlling LEC-lineage specification, showed that these mice lacked LECs, failed to 
develop lymphatic vasculatures (38, 39).  Mice lacking the tyrosine kinase growth factor 
receptor, VEGFR-3 (VEGFR-3 -/-) or with mutated VEGFR-3 (+/Chy, ENU-induced mutation) 
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failed to undergo lymphatic sprouting followed by cutaneous hypoplasia (61, 131).  The critical 
role of VEGFR-3 signaling in early lymphatic development in mice was confirmed when mice 
lacking its ligand, VEGF-C (VEGF-C -/-) showed complete lack of lymphatic vasculature and 
died of prenatally due to accumulation of fluid in the tissues (115).  Interestingly, knock out mice 
lacking the hyaluronan receptor, LYVE-1 (LYVE-1 -/-) showed no defect in lymphatic 
vasculature formation and function (132).  However, knock out mice lacking the membrane 
glycoprotein, podoplanin (PDPN -/-) developed subtle defects in their lymphatic vasculature 
formation and were able to live until adulthood but developed severe lymphedema due to 
inefficient lymphatic drainage and transport (66).  Transgenic mice generated using a bacterial 
artificial chromosome (BAC) cre-lox system revealed that interleukin-7 (IL-7) is expressed by 
mouse LECs and is important for remodeling of lymph node microarchitecture (57).  In addition, 
transgenic mouse models are also used to study impaired lymphatic drainage due to gene defects.  
The transgenic mouse model, K14-VEGFR-3-Ig, expresses soluble VEGFR-3-Ig via the keratin 
14 promoter, which restricts the growth of lymphatics in the skin.  K14-VEGFR-3-Ig mouse 
displays defective lymphatic growth and drainage that is restricted to the skin resulting in a 
lymphedema-like phenotype (62) with associated impaired humoral immunity and tolerance 
(133).  More recently, a novel transgenic mouse model, K14-hIL8 was developed, which 
expressed human interleukin-8 (IL-8).  The model demonstrated that human IL-8 could promote 
embryonic lymphangiogenesis and improved amelioration of lymphedema with lymphatic 
regeneration, suggestive of therapeutic potential of IL-8 in treatment of post-surgical 
lymphedema (134). 
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Table 1. Genetically modified mouse models for LEC markers and their lymphatic vascular phenotypes. 
 
Gene/LEC marker Mouse model Function Phenotype 
Prox-1 Knock out (global) Transcription factor No LECs (-/-), chylous 
ascites (+/-), no lymphatic 
vasculature 
VEGFR-3 Knock out 
(global), +/Chy 
(ENU-induced 
mutation) 
Growth factor receptor Defective formation and 
sprouting of lymphatic 
vasculature, hypoplastic  
lymphatic vessel  
VEGFR-3 Transgenic (K14) Growth factor receptor Hypoplastic lymphatic 
vessel 
LYVE-1 Knock out (global) Hyaluronan receptor No defect in lymphatic 
formation and interstitial 
lymphatic flow 
Podoplanin Knock out (global) Membrane glycoprotein Impaired lymphatic 
transport, lymphedema 
VEGF-C Knock out (global) Ligand for VEGFR-3 No lymphatic vasculature 
(adapted from (1) and (19) with permission.) 
 
1.2.3.2 Zebrafish (Danio rerio)model 
The zebrafish shares the same morphological, molecular, and functional characteristics of 
lymphatic vessels with other vertebrates (135).  Immunohistochemical analysis of lymphatic 
vessels in adult zebrafish revealed that they expressed Prox-1 (136).  However, the zebrafish 
model has proven to be an excellent model to study the early development of the lymphatics as 
the lymphatic vessels are easily observed in zebrafish compared to mouse.  Lymphatic 
development in the zebrafish depends on VEGF-C and VEGFR-3 signaling (137).  Recently, 
VEGF-D was shown to be able to compensate for loss of VEGF-C in lymphatic sprouting of in 
the zebrafish head (138).  Furthermore, the zebrafish model was proven to be a useful model in 
screening and identification of potential lymphangiogenesis inhibitor compounds for treatment 
and management of tumor metastasis (139).  Thus, the zebrafish model is a promising model not 
only for the functional study of lymphatics but also is a valuable tool for screening for potential 
therapeutics. 
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1.2.3.3 Tadpole (Xenopus laevis) model 
The tadpole is a popular model in the study of developmental biology due to its ease of genetic 
manipulation and its potential as a prolific egg layer (140).  The tadpole model is an attractive 
model for lymphatic study as the lymphatic vessels are easily distinguished by injection of dye 
(140).  More importantly, the lymphatic vessels in this model are structurally and functionally 
similar to those of vertebrates and were shown to express Prox-1.  Knock down of Prox-1 
resulted in failure of lymphatics to develop, whereas knock down of VEGF-C resulted in 
lymphatic defects and development of a lymphedematous phenotype by the tadpoles (140).  The 
mechanisms that govern the lymphatic development in the tadpole model are highly similar to 
the mammalians.  Therefore, the tadpole model is a promising model for screening of candidate 
genes that are important for lymphatic development and disease. 
1.3 EMERGING ROLE OF LYMPHATIC ENDOTHELIAL CELLS IN 
IMMUNOMODULATION 
The lymphatic vasculature responds to changes in tissue microenvironments, potentially 
resulting in a physiological condition known as lymphangiogenesis (11, 141, 142), in which the 
lymphatic network undergoes proliferative expansion and remodeling due to lymphatic sprouting 
and enlargement of existing vessels.  Lymphangiogenesis is the hallmark of many pathological 
conditions including infection, inflammation, wound injury, fat metabolism, hypertension, and 
cancer metastasis.  Inflammation-induced inflammatory mediators such as growth factors and 
cytokines/chemokines alter the gene expression profiles of LECs and affect their function.  In 
addition, LECs secrete subsets of chemokines and their expression is upregulated in response to 
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inflammatory signals.  LECs also express a group of pattern recognition receptors (PRRs) known 
as toll-like receptors (TLRs) that recognize pathogen-associated molecular patterns (PAMPs) – 
common conserved motifs found on microbes.  Increased TLRs expression has been linked to a 
number of autoimmune as well as chronic inflammatory diseases.  Thus, LECs likely are integral 
players in mechanisms involved in regulation of host responses to pathogens through initiation of 
innate and adaptive immunity as well as host tolerance to self-antigens. 
1.3.1 Role in inflammation and pathological conditions 
The inflammation-induced vascular growth factors VEGF-C and VEGF-D are known for their 
lymphangiogenic properties.  VEGF-C signaling via its receptor VEGFR-3 leads to proliferation 
and migration of LECs suggesting that inflammatory conditions mediate lymphatic formation 
(143).  VEGF-C and VEGF-D are produced in inflamed tissues by stromal cells such as 
fibroblasts and keratinocytes as well as immune cells such as macrophages (26, 144).  
Inflammation-induced lymphangiogenesis in mouse cornea can be blocked by macrophage 
depletion (144) and CD11b+ macrophages can transdifferentiate into LECs (145).  Interestingly, 
contradicting findings have been reported on the effects of contact hypersensitivity (CHS) 
induced inflammation on LECs.  An earlier report using LECs isolated from inflamed murine 
skin induced by CHS showed that LEC markers such as LYVE-1, Prox-1, and VEGFR-3 were 
down-regulated, therefore making LEC markers attractive diagnostic and therapeutic targets 
(92).  A later study using CHS-induced inflamed murine skin LECs showed that while LECs 
showed evidence of proliferation, they produced growth factors and chemokines that caused 
lymphatic vessel dilation and leakiness and thus reduction in lymphatic drainage function (146).   
24 
Inflammatory conditions increase the expression of VEGFR-3 by LECs and enhance their 
sensitivity to VEGF-C and VEGF-D signaling (10).  Inflammatory signaling mediator such as 
transcription factor nuclear factor κB (NFκB) activate Prox-1 expression in LECs and in turn, 
increase the expression of other LEC markers, including VEGFR-3 (147).  LECs also show 
increased expression of inter-cellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1) after treatment with inflammatory mediator, tumor necrosis factor-alpha 
(TNF-α) (148).  ICAM-1 and VCAM-1 are important molecules for transmigration of DCs and 
leukocytes into the lymphatics en route to the draining lymph node (33).  Lymph nodes have 
highly dynamic and compartmentalized microarchitecture that is optimized for immune cell 
interaction with antigens and/or APCs.  In addition, lymph node stromal cells also have 
microanatomic specializations and are important regulators of vascular proliferation and growth 
(26).  Fibroblastic reticular cells (FRCs) are major producers of VEGF in lymph nodes (26).  
VEGF-expressing FRCs induced proliferation and migration of LECs.  Lymphadenopathy or 
enlargement of lymph nodes is a common feature in inflammatory and autoimmune diseases (8).  
Inflammatory conditions created by dermal macrophage-associated cytokines induce 
upregulation of LEC surface marker CLEVER-1, which promotes infiltration of tumor cells into 
lymph nodes (97).  Lymphangiogenesis also occurs in lymph nodes due to production of VEGF 
by follicular B cells (25).  VEGF-C and VEGF-D signaling in the lymph node has been shown to 
facilitate tumor-associated lymphangiogenesis and promote lymph node metastasis (149).  
Blocking VEGF-C or VEGF-D signaling through VEGFR-3 using target-specific antibodies or 
siRNAs inhibits tumor-associated lymphangiogenesis and metastasis in lymph node (150).   
Tumor-associated lymphangiogenesis may represent the first step in tumor dissemination 
to distal lymph nodes and organs for a variety of common human carcinomas and melanomas 
25 
(151, 152).  In tumors associated with infection by oncogenic virus such as Kaposi’s sarcoma 
herpesvirus (KSHV or also known as human herpesvirus-8), infected BECs are reprogramed to 
express LEC markers by stabilizing the LEC-lineage transcription factor, Prox-1 (153).  BEC-to-
LEC reprogramming also resulted in morphological transformation of LECs into spindle-like 
cells, the most common characteristic of KS tumor (153).  Lymphatic remodeling due to 
structural and functional alteration of LECs is also associated with several pathophysiological 
conditions in chronic inflammation such as asthma, psoriasis, rheumatoid arthritis, and, 
inflammatory bowel disease (IBD) (9, 154).  However, lymphangiogenesis in chronic 
inflammatory conditions has been reported to have a double-edged sword effect as it contributes 
to maintenance and persistence of inflammation rather than resolving it due to loss of LEC 
drainage function (9).  Defective lymphangiogenesis in the lung during inflammation often 
results in bronchial lymphedema and airflow stagnation (141).  Inhibition of TNF-α expression 
and signaling significantly reduced inflammation-mediated lymphangiogenesis in the lung (154).  
The role of growth factors, cytokines, and chemokines in modification of LECs during 
inflammation and other pathophysiological conditions remains an important research focus. 
1.3.2 Emerging role of LECs in immunity and tolerance 
LECs are presumably among the first stromal cell types that come in contact with invading 
foreign antigens that are able to cross an epithelial barrier.  LEC’s role in transport of immune 
cells for initiation of host innate as well as adaptive immune response is well established.  
Peripheral LECs near the mucosal epithelium constitutively express the homeostasis chemokine, 
CCL21, and the expression increases during inflammatory-induced immune responses to 
pathogens or immunization.  CCL21 is essential in host immune surveillance during homeostasis 
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for trafficking of immune cells expressing the cognate receptor, CCR7, such as DCs, T cells, and 
B cells.  CCL21 is also important for transmigration of antigen loaded DCs from the peripheral 
into the lymphatic vessels, and subsequently to the draining lymph node (34, 93).  LECs also 
express other chemokines (31, 36, 70) and adhesion molecules (70, 89) that participate in the 
recruitment of naïve T cells and B cells into the lymphatic vessel from the tissue parenchyma.  In 
addition LEC-derived chemokines and signaling molecules are crucial in maintenance of lymph 
node microarchitecture and compartmentalization of immune cells (57, 155).  Lymph node LECs 
lining the subcapsular sinus may act as gatekeeper and direct antigen-loaded DCs that enter the 
lymph node into the T cell zone and thus allow activation of downstream adaptive immune 
response (57). LECs also play an important role in trafficking of activated immune cells from the 
lymph nodes.  LEC-derived signaling molecule such as S1P facilitate the egress of T cells from 
lymph nodes via the efferent lymphatics (156, 157).  Studies using LYVE-1 deficient mice 
showed absence of S1P production and retention of lymphocytes in the lymph node (158).  
The active roles of LECs in innate immunity are highlighted by the expression of 
multiple functional TLRs, which enable them to sense incoming foreign antigens or microbes 
(159, 160).  More recent data showed that peripheral and lymph node LECs express MHC I and 
II molecules as well as their known costimulatory molecules, albeit to much lower levels 
compared to professional APCs such as DCs.  Even though MHC I expression has been reported 
in peripheral and lymph node LECs, the expression of MHC II was observed only in the lymph 
node LECs but not the peripheral tissue lymphatics, suggesting that there is a functional 
immunological difference between LECs in these two anatomical locations (161, 162).  Cross-
presentation of self-antigens on MHC I by LECs led to quiescent DCs, which suppressed 
activation and induced apoptosis of autoreactive CD8+ T cells (163), suggesting that antigen 
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presentation by LECs participates in induction of tolerance in the periphery.  In addition to their 
role in inducing tolerance to autoreactive T cells, LECs have been reported to scavenge, 
endocytose, and cross-present to tumor cells expressing OVA as foreign antigen, which resulted 
in lymphangiogenesis and protection of tumor cells from CD8+ T cells (164).  Cross-
presentation of non-self antigens by LECs is responsible for rejection of grafts in organ 
transplantation (165).  Furthermore, mouse LECs were demonstrated to capture and archive 
antigens derived from viral infections with influenza and vesicular stomatitis virus, and that these 
antigens not only persisted for prolonged time within LECs but were also able to improve 
effector functions of circulating memory CD8+ T cells (166).     
Interaction between MHC II molecules expressed by LECs with CD4+ T cells is less well 
described.  MHC II molecules are expressed by lymph node LECs in low levels during steady 
state conditions and the expression is upregulated under proinflammatory conditions (162, 167).  
However, MHC II expression by LECs has only been demonstrated in the lymph node and not in 
non-lymphoid tissue lymphatics.  In addition, lymph node LECs do not express the traditional 
costimulatory molecules required for MHC II-antigen presentation to CD4+ T cells such as 
CD80 and CD86 although they do express LFA-1 (CD58), which can act as an unconventional 
alternative binding receptor to CD2 for activation of CD4+ T cells (162).  However, data from 
allogeneic coculture of LECs and CD4+ T cells failed to induce CD4+ T cell proliferation or 
cytokine production, and coculture of IFN-γ-activated LECs with DCs and CD4+ T cells also 
resulted in impaired proliferation of CD4+ T cells by DCs, suggesting that potential LEC-
associated mechanisms were responsible for the impaired T cell activation (162).  Thus, taken 
together these data highlight the emerging contribution of LECs to modulation of local 
microenvironments as well as the functions of immune cells such as DCs and T cells.   
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1.4 ANIMAL MODELS FOR STUDY OF HUMAN DISEASES 
Animal models of human diseases are crucial for translation of scientific discoveries into 
meaningful applications in studying disease pathobiology and development of new biomarkers or 
therapeutics (168).  Animal models overcome the limitations of in vitro tissue culture models and 
can often serve as surrogates for study of human disease pathologies and immune responses as 
well as study of toxicity and efficacy prediction of newly developed therapeutics.  The ideal 
animal model should replicate very closely the disease outcome, its underlying causality, and its 
mechanism of action in humans (169).  In addition to that, such models preferably should have 
similar genetic properties to humans and also similar in response to infectious agents or 
therapeutics.  Several animal models currently exist for many human diseases including 
bacterial/viral infections, cancers, neurologic, pulmonary, chronic, and metabolic diseases (170).  
However, the predictive value of any single animal model or a collection of animal models in 
fully recapitulating the human host remains a constant challenge.   
1.4.1 Ferrets as animal models 
Ferrets are becoming an increasingly popular small animal model for study of many human 
diseases, including reproductive biology (171-173), cancer (174), and infectious diseases of viral 
and bacterial origin (159, 175-181).  The ferret model is a commonly used model for infectious 
diseases and is considered the “gold standard” to model human influenza infection since the 
1930s (182).  Ferrets are naturally susceptible to infection with various strains of human 
influenza viruses.  In addition, ferrets show disease presentation and clinical symptoms that are 
similar to humans.  The severity of influenza disease in ferrets depends on the specific strain of 
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influenza virus used (183).  Seasonal influenza causes mild to moderate upper respiratory tract 
infections in ferrets (182, 184).  In contrast, highly pathogenic influenza infection is 
characterized by severe pathology and rapid progression of the disease (185).  Infected ferrets 
not only share pathological changes but also similar cytokine responses to humans when infected 
with influenza virus.  Therefore, ferrets are often used as models to evaluate antivirals as well as 
vaccine efficacies for prevention of influenza infection and pathogenesis (186).  Ferrets are 
instrumental in evaluating the efficacies of influenza vaccine candidates as well as vaccine 
adjuvants in inducing robust innate and adaptive host immune responses.  Experimental vaccine 
formulations, for example, using known TLR ligands as adjuvants, have been demonstrated to 
enhance immune responses and prevent the spread of influenza virus to susceptible animals after 
vaccination (187). 
Ferrets easily transmit influenza to each other thus making them ideal small animal 
model for influenza virus transmission (185).  Transmission models for influenza have been 
studied by measuring the efficiency of influenza virus to spread from infected ferret to naïve 
ferret in the presence or absence of direct contact.  The development of aerosol delivery systems 
using ferrets allows for more accurate recapitulation of natural transmission of influenza (183).  
As observed in humans, highly pathogenic influenza viruses transmit poorly when compared to 
seasonal influenzas.  The ferret model has also been used to compare the transmissibility of 
antiviral resistant influenza viruses.  These studies provide an important estimate of public health 
threat posed by antiviral drug resistant influenza viruses.  The ferret model has proven to be an 
advantageous small animal model to study both pathogenicity and transmissibility of different 
influenza virus strains.      
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1.4.2 Nonhuman primate models 
Nonhuman primate (NHP) models have been instrumental in several areas of biomedical 
research, including drug development such as pharmacokinetic (188, 189), toxicity and efficacy 
of therapeutics (190) as well as normal physiological functions (191), and chemically-induced 
conditions that mimic human diseases (191, 192).  The close genetic similarity between rhesus 
macaques and humans allows for cross-reactivity of commercially available reagents as well as 
ex vivo assays for probing innate and adaptive immune responses of both species upon infection, 
vaccination, or disease progression. 
Since the discovery of HIV-1 and SIV in 1989, there has been widespread use of NHP 
models to study pathogenesis as well as vaccine and therapeutic interventions for HIV/AIDS.  
Unintentional infection of SIV in non-natural hosts such as the Asian macaques resulted in a 
disease that resembled AIDS in human, and thus led to discovery of SIV-macaque pathogenic 
models of HIV-1 infections in humans (193).  There are three commonly used macaque species 
that are susceptible to infection with SIV and developed AIDS-like disease, namely rhesus 
macaques (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), and pigtailed 
macaques (Macaca nemestrina) (193).  The rhesus macaque model is the most established and 
well-characterized NHP model for SIV infection.  SIV infection in rhesus macaques mimics very 
closely HIV-1 infection in humans with respect to the cell types that are susceptible to viral 
infection, the development of disease, and the presentation of similar disease outcomes (194).  
SIV replication in rhesus macaques results in progressive CD4+ T cells depletion in the 
gastrointestinal mucosal sites such as the gut-associated lymphoid tissues (GALT) (195).  In 
addition, SIV replication during primary infection leads to mucosal inflammation and epithelial 
injury that might enhance the pathogenicity of the virus.  Ongoing local SIV replication creates 
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local mucosal inflammatory conditions that attract more CD4+ T cells and DCs to viral 
replication sites, which leads to establishment of hyper-immune activation in the gut (195).  
Establishment of initial infection and dissemination of the replicating virus occur through 
infected DCs (196).  These persistent immune activation and inflammation conditions also result 
in epithelial cell injury in the gut of SIV-infected animals followed by microbial translocation of 
microbes from the lumen of the gut into the parenchyma of mucosal tissues (197).  Translocation 
of these microbes and microbial products from the gut lumen into the gastrointestinal mucosa 
may stimulate innate immune cells of the gut through TLR sensing and signaling pathways, thus 
contributing to the proinflammatory milieu and systemic immune activation during chronic SIV 
infection (198). 
SIV-macaque models have also been instrumental in the development of antiretroviral 
(ART) drugs and therapeutics as well as microbicides against HIV-1.  NHP models have been 
used to study the toxicity, pharmacokenetics, and efficacy of ART such as Tenofovir in 
preclinical testing (199, 200).  Tenofovir is currently one of the most widely used drugs in ART 
regimens for treatment of HIV-1-infected persons (201, 202).  Studies in SIV-infected macaque 
models have also contributed significantly to different interventional aspects of ART drug 
administration for prophylactic prevention and therapeutic treatment of HIV-1 infections in 
humans.  Adult and infant macaques have been used to model the effects of ART drugs 
combinations in preventing SIV infection during early exposure time points via the many viral 
inoculation routes, including oral (203-205), intravaginal (206, 207), and intrarectal (208).  In 
addition, SIV-infected macaque models have contributed to safety testing of ART drugs usage in 
pregnant HIV-1-infected mothers as well as their efficacies in reducing mother-to-infant 
transmission of the virus (209-211).   
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Even though SIV and HIV-1 are closely related at the genetic levels, there are some 
fundamental differences between the two viruses that limit the translational value of the SIV-
macaque model to HIV-1-infected patients.  For example SIV is not sensitive to many drugs that 
are designed to inhibit HIV-1 virus enzymes, such as protease, reverse transcriptase (RT), and 
integrase (193, 212, 213).  In addition, SIV and HIV-1 may use different co-receptors for viral 
entry, and this potentially complicates testing of drugs that target these molecules in macaque 
models (214).  These limitations led to the development of SIV/HIV-1 chimeric viruses known 
as SHIVs, which are designed to either express HIV-1 viral enzymes (215, 216) or HIV-1 viral 
envelope glycoproteins (193, 217), or combinations of both (218, 219).  These recombinant 
viruses enable evaluation of some non-nucleoside RT inhibitors (NNRTIs) that are formerly only 
effective against HIV-1 but not SIV (212, 220), and at the same time provide insights into 
disease pathogenesis in the presence of ART treatment in macaque models.  Highly active 
antiretroviral therapy (HAART) drugs successfully suppress HIV-1 viral replication in infected 
individuals, thus resulting in slower disease progression and longer life spans.  However, the 
emergence of ART- and HAART-resistant virus mutants in drug-treated macaques and humans, 
highlighted the relevance of NHP models in the study of HIV-1 infection in humans.  Macaque 
models have been utilized to gain insights into the emergence as well as clinical implications of 
these drug resistance viruses, with regard to their replication fitness and virulence (221). 
One of the main advantages of SHIVs is that these viruses are able to replicate and persist 
in infected macaque models and can now be used in development and evaluation of vaccines 
against HIV-1 (222).  Passively transferred neutralizing antibodies have been evaluated in SHIV-
infected macaques for their ability to prevent infection by blocking virus entry and binding (223-
225).  SHIV infection in macaques faithfully replicates the acute and rapid phase of HIV-1 
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infection in humans (226, 227), and SIV- and SHIV-mucosal challenge models, primarily via the 
genital or the gastrointestinal routes, are crucial for devising strategies to prevent mucosal 
transmission of HIV (228-230).  Additionally, SHIV-infected macaque models can be utilized in 
studies aimed at inducing vaccine-driven neutralizing antibodies or testing of vaccine-mediated 
protection by candidate vaccines, evaluation of the use of molecular adjuvants in vaccine 
formulations, and validation of vaccine-induced protection during host immune responses to 
vaccinations (223, 231-233).  Ongoing comparison of the SIV-infected or SHIV-infected 
macaque models to HIV-1-infected individuals will lead to our knowledge in development of 
potential cures and intervention strategies to eradicate HIV/AIDS.   
Taken together, animal models such as ferrets and nonhuman primates provide us with 
tools for further improvement and validation of the translational value of these animal models in 
advancing our knowledge to prevent and eradicate important human viral pathogens such as 
influenza and HIV-1.  Isolation of pure LEC populations from these animal models would be 
instrumental tools to understand the involvement and contribution of LECs during host-pathogen 
interactions. 
1.5 SIV/HIV AND THE LYMPHATIC ENDOTHELIUM 
The vast majority of HIV-1 infections occurs through mucosal transmission of the virus.  Sexual 
mucosal transmission, either via the vaginal or rectal, remains as the major routes of viral 
infection in adults (234, 235).  However, in pediatric HIV-1 infection, maternal-to-child 
transmission through the gastrointestinal portal of entry is most likely route, which could occur 
from ingestion of HIV-1-contaminated maternal fluids during delivery or from breast milk (236, 
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237).  Similarly, studies of SIV and SHIV infections in nonhuman primate models demonstrated 
that these viruses are readily transmitted across intact mucosal surfaces such as rectal, vaginal, 
cervical, oral, and penile of these animals (230).  
1.5.1 Mucosal transmission and early stage infection of SIV/HIV 
Establishment of SIV/HIV-1 infection occurs rapidly in the first hours and days after crossing the 
mucosal barriers (238, 239).  Mucosal tissue morphology and integrity, as well as the distribution 
of susceptible and permissible cell types within the mucosae, greatly influence successful 
productive infection and local replication of the virus.  In the NHP model, the critical events that 
determine the establishment of early stage infection of SIV following high dose mucosal 
exposure to SIV begin within hours after the virus crosses the mucosal barrier (Figure 4A) (238, 
240).  The main target cells for SIV (and also HIV-1) infection and replication within the 
mucosae are the resting CD4+ T cells, which then contribute to establishment of initial small 
founder virus populations (240).  These founder virus populations then rapidly undergoes local 
expansion through infection of other cell types, including activated CD4 T cells, macrophages, 
and DCs.  As a result, these infected cells not only produce more viruses but are also 
disseminated first to the draining lymph nodes via the lymphatics, and subsequently to other 
secondary lymphoid tissues and organs (systemic infection) via the bloodstream or the 
lymphatics (240).    
The gastrointestinal (GI) tract is the largest secondary lymphoid organ in the human body 
(241).  During the establishment of the early stages of SIV and HIV-1 acute infection, the 
intestinal gut-associated lymphoid tissues (GALT) serve as the major amplification site of viral 
replication, and remains as major site of viral persistence during chronic infection (235).  The 
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lamina propria is an effector site of the intestinal immune system and contains the largest 
population of T cells, B cells, and other immune cell populations such as DCs, macrophages, 
eosinophils, and mast cells (241).  Thus, it is not surprising that during early stage SIV infection, 
over 60% of resting memory CD4+ T cells in the gut are infected by the virus (239, 242).  
Similarly, in HIV-1-infected individuals, serial GI tract sampling during the early stages of 
infection demonstrated depletion of CD4+ T cells, although somewhat less dramatic than in the 
SIV-macaque model (243-245).  Local expansion and amplification of the founder virus 
population could also impair the intestinal epithelial barrier and increased its permeability.  The 
disruption of the intestinal epithelial barrier function during primary infection in HIV-1-infected 
individuals often coincides with massive depletion of CD4+ T cells in the GALT (245).  The loss 
of the epithelial barrier integrity and permeability leads to microbial translocation of commensal 
gut microbes and microbial products from the gut lumen into the mucosal layer resulting in 
systemic immune activation.  Translocating microbes and microbial products stimulate innate 
immune cells and stromal cells through PRRs and other innate immune receptors, and in turn 
contribute further to the proinflammatory cytokine milieu and systemic immune activation and 
inflammation associated with chronic SIV/HIV-1 infection (197, 245).   
In the SIV-macaque model, key events in the virus-host interaction that enables 
establishment of systemic infection occurs within the first 7 to 10 days after vaginal exposure to 
virus (239).  During the eclipse phase, which occurs approximately 7 days after exposure to the 
virus, SIV viral DNA is detected in the cervical/vaginal tissues but not in the lymphoid tissues, 
suggestive of low level local propagation and expansion of the virus at the portal of entry (Figure 
4C).  This period is known as the window of opportunity, and thus poses several potential 
intervention strategies to prevent early infection and subsequent systemic dissemination of the 
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virus (Figure 4B).  During the first week of infection, the host has the upper hand as the founder 
virus population is still very small with very few infected cells.  Intervention strategies such as 
the use of microbicides and pre-exposure prophylaxis with ART as well as broadly neutralizing 
mucosal antibodies could prevent establishment of the small founder virus population (246).  A 
second intervention strategy that could be applied during the window of opportunity is to prevent 
local expansion of the small founder virus population through vaccine design that improves the 
effector function of the mucosal virus-specific cytotoxic T lymphocyte (CTL) or vaccine design 
that improves the antibody-dependent cellular cytotoxicity (ADCC) of virus-specific antibodies 
(240).        
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 Figure 4. Schematic representation of SIV/HIV-1 virus transmission, stages of infection, and their potential 
interventions. 
 
The diagram shows the key events that occurs following mucosal (vaginal) transmission of SIV/HIV-1 with regards 
to time for interactions between virus and host as well as outline for the maximally time for effective interventions 
to block establishment of the virus during early stage of infection. (4A) In the first hours of infection, virus crosses 
the mucosal epithelial barrier to infect a small number of available target cells to establish a small population of 
founder virus.  These founder viruses infect more naïve target cells that are recruited to the site of infection and 
inflammation and undergo local expansion and amplification.  Once the virus is established at the point of entry, 
dissemination quickly takes place as infected cells including CD4+ T cells, macrophages, and DCs are transported to 
the draining lymph node via the lymphatics.  In the lymph node, amplification of the virus occurs at exponential rate 
due to availability and close proximity of susceptibly infected cells, which then leads to dissemination of virus and 
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also infected cells to distal organs via the lymphatics or blood circulatory system.  (4B) Interventions for mucosal 
transmission of SIV/HIV-1 ideally targets the vulnerability of the virus at the point of entry shortly after exposure.  
Early stage of infection offers multiple intervention opportunities to prevent establishment of the small population of 
founder SIV/HIV-1 viruses, and thus avoiding the systemic phase of infection by the virus.  (4C) The optimal and 
maximal time for interventions at the portal of entry is known as the “window of opportunity”, which occurs 
between 7 to 10 days in SIV-infected macaque models, and could be longer in HIV-1-infected humans.  During the 
first 7 days postinfection, SIV DNA and RNA is undetectable in the lymphoid tissues, and this period is known as 
the “eclipse” phase of the virus.  Following this phase, a number of key events take place, which leads to 
establishment of systemic phase of infection. SIV production grows exponentially in the lymphatic tissues (lymph 
node, spleen, gut), coupled by massive loss of CD4+ T cells in the gut, and establishment of latent/chronic virus 
infection.  Figure adapted from (240) with permission. 
 
 
1.5.2 Potential role of LECs in local expansion and dissemination of SIV/HIV 
Dissemination of SIV/HIV-1 and SIV/HIV-1-infected cells from the portal of entry is made 
possible via the lymphatics.  Lymphatic drainage transports the virus and virus-infected cells to 
the draining lymph nodes, where large numbers of susceptible cells are available in close 
proximity, thus providing optimal conditions for viral production (238).   
Due to their direct interaction with incoming virus or virus-infected cells during 
lymphatic drainage, LECs are likely to have direct or indirect roles during virus-host interaction.  
In vitro studies of primary LECs demonstrated that not only do LECs express functional PRRs 
including TLRs (160, 247, 248), they also secrete functional proinflammatory cytokine and 
chemokines that recruit and modulate immune cells (248).  More recently, LECs have been 
shown to capture and archive viral antigens and vaccine antigens under inflammatory conditions 
for a prolonged period of time and thus contribute to antigen persistence (166).  These 
investigators also showed that the vaccine-elicited antigen persistence improved the effector 
function of circulating memory CD8+ T cells, which positively influenced protective immunity 
of the host.   
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The draining lymph node has been well recognized as the site of induction of host 
adaptive immune responses during an infection or vaccination.  In a recent study, a group of 
researchers sought to map the distribution of LECs in the human lymph node by staining with 
antibodies specific for LECs as well as other immune cells (155).  Interestingly, they found that 
there were two distinct LEC populations in the different sinuses of the human lymph node, and 
this observation was conserved between draining lymph nodes of different peripheral regions, 
namely the axillary, cervical, and mesenteric lymph nodes.  In addition, the study also revealed 
that the paracortical and medullary sinus resident LECs co-expressed the APC marker CD209, 
but the resident LECs found in the subcapsular and trabecular sinuses did not, suggesting that the 
different phenotypes of LECs could have distinct functions depending on their locations within a 
specific organ.  
Altogether, these results highlighted the potential involvement and function of LECs 
during pathogen-host interactions, not only in the context of SIV/HIV-1 but also other viral 
pathogens.  In the context of SIV/HIV-1 infection, LECs may contribute to the local expansion 
of the founder viruses through PRR sensing of the virus and subsequent recruitment of naïve 
immune cells by LEC-induced proinflammatory cytokines/chemokines.  LECs also might play 
an important role in regulating the transport of SIV/HIV-1-infected immune cells in the 
periphery as well as in the draining lymph node.  LECs are important cells in establishment of 
structure and compartmentalization within the lymph node, and thus LECs may be responsible in 
directing antigen-loaded APCs and infected immune cells to populations of naïve immune cells 
in the lymph node.  In addition to that, due to their ability to capture and store antigens LECs 
potentially may become a reservoir for SIV/HIV-1 during chronic infection stage, if viral 
antigens that are taken up are stored in the form of infectious virions.   
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Thus by obtaining better understanding of the different phenotypes of LECs and how 
they may crosstalk with virus and immune cells during host responses to infection/vaccination, 
this will help us better elucidate the process disease development in the context of SIV/HIV-1 
and other infections, and hopefully help us design improved vaccines and therapeutics that target 
the different stages of the disease.    
1.6 SUMMARY 
LECs are key players in regulation of immune cell trafficking during immune surveillance under 
homeostatic and inflammatory conditions.  We are only beginning to understand the 
contributions of LECs to the initiation of host innate and adaptive immune responses during 
infection or vaccination.  It remains to be determined whether LEC interactions with immune 
cells such as DCs and T cells impact the functions of these cells in the absence or presence of 
disease conditions.  Understanding the role of LECs in host immune responses and their 
crosstalk with immune cells in the context of SIV/HIV-1 and other infections can potentially lead 
to discovery of novel targets for therapeutics and vaccines for HIV-1 and other pathogens. 
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2.0  STUDY PREMISE 
2.1 RATIONALE  
Due to their unique location, LECs are likely to be among the first cells to come in contact with 
microbes that cross the epithelial barrier, with first wave, pathogen-induced host inflammatory 
signals, and with vaccine antigens and adjuvants after exposure.  LECs line the initial lymphatic 
vessels, which then form larger collecting lymphatic vessels, and ultimately drain into the lymph 
node.  In the lymph node, LECs are localized in the subcapsular, cortical, and medullary sinuses, 
where they regulate the processes for incoming and exiting APCs, leukocytes, and lymphocytes 
(249).  LECs control these processes through expression of chemoattractant 
chemokines/cytokines (23, 36, 83), signaling molecules (56, 156, 158), and adhesion molecules 
(89, 148, 250) for immune cell recruitment, migration, and homing.  The role of LECs in host 
innate immune responses is highlighted by documented expression of functional PRRs, including 
TLRs that recognize common conserved motifs found on microbes, PAMPs (160, 247, 248).  
TLRs are also expressed by professional antigen presenting cells APCs such as DCs, and LECs 
have also been shown to share several phenotypic characteristics with DCs (93, 155).  Analysis 
of LECs in the lymph node showed that LECs express DC-SIGN (CD209), a known DC marker 
(155).  LECs also have been shown to express MHC I and MHC II molecules but not their 
costimulatory molecules (162, 164, 251).  In addition, LECs have the ability to capture and 
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archive antigens, which results in antigen persistence in the host (166).  These findings led us to 
believe that LECs have more direct involvement than previously appreciated in shaping the host 
innate immune responses during infections or vaccinations, as well as transmission or (or 
resistance to) infectious agents.  
Therefore, my overall hypothesis for this project was that LECs initiate host innate 
immune responses to pathogens through expression of multiple functional PRRs and are 
involved in initial establishment or restriction of infection by viral pathogens through 
expression of intrinsic and cellular viral restriction factors.  I proposed that LECs were active 
participants in immediate host innate immune responses to pathogens and foreign antigens 
through sensing of PRRs and helped create inflammatory environments that attracted other 
immune cells to the sites of infection or vaccine administration.  I also proposed that LECs also 
have the ability to control the spread of viral pathogens, either (1) directly through expression of 
intrinsic and cellular viral restriction factors, or (2) indirectly through antigen uptake and 
processing, and subsequently targeting these antigens to degradation or archiving them for 
optimal contact with APCs such as DCs or T cells.   
Thus, during pathogen-host interactions the role of LECs might not be limited to 
development of initial host innate immunity but also to modulation of the local 
microenvironments within the tissues that could result in alteration of the outcome of an 
infection or disease progression.    
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2.2 SPECIFIC AIMS 
To address my hypothesis, my specific aims were: 
 
Specific Aim 1:  To develop new culture models for ex vivo analysis of LECs. 
Studies of LECs has been hampered by the challenges in obtaining pure in vitro cultures of LECs 
and the inability to mimic the quiescent physiologic state of LECs in vivo using the standard two-
dimensional (2D) cell culture system.  In chapter 3 and 4 of this dissertation, I sought to isolate 
primary LECs from different animals (macaque and ferret) and tissue types (skin, lung, tracheal, 
jejunal, mesenteric lymph node, and thoracic duct) to establish 2D in vitro cultures of homotypic 
primary LEC populations.  These primary LEC populations were used to study the phenotypic 
characteristics and functionality of LECs as well as their interactions with microbes.  
 
Specific Aim 2:  To determine the expression profiles of PRRs by LECs. 
PRR sensing of PAMPs rapidly triggers host innate immune responses through activation of 
complex signaling pathways that induce production of proinflammatory cytokines and 
chemokines to facilitate eradication of pathogens.  PRRs can be classified into three different 
protein families, namely the toll-like receptors (TLRs), the NOD-like receptors (NLRs), and the 
RIG-I-like receptors (RLRs).  Although the expression of multiple functional TLRs has been 
reported in LECs, the expression of NLRs and RLRs has not yet been examined.  In chapter 3 
and 4, I studied in more detailed and more comprehensively the expression profiles of the 
different PRRs express by primary ferret LECs and primary macaque LECs from different 
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animals and tissue types and determined the functionality of these PRRs to respond to their 
known ligands in comparison to their human counterparts (the model human dermal LECs).   
 
Specific Aim 3:  To compare a subset of phenotypic and functional characteristics of DCs 
and LECs. 
Previous data from our laboratory showed that LECs and DCs responded to mycobacterial 
components in a similar fashion and interestingly shared a number of phenotypic characteristics 
(Pegu, unpublished data).  In chapter 4, I examined the phenotypic expression of DC-associated 
markers by primary macaque LECs and also evaluated their functional ability to perform antigen 
uptake and processing of DQ-ovalbumin, which is a hallmark of APCs such as DCs.  
  
Summary:  Altogether, my studies contributed to establishment of accessible tools for studying 
endothelial cell biology of lymphatics from different species and tissue origins.  In addition to 
that, my work on phenotypic and functional characteristics of LECs revealed aspects of LEC 
immunobiology that have not yet been fully explored or understood and could potentially 
contributed to our understanding of innate immunologic functions of LECs for improved 
vaccines and therapeutics design strategies.    
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3.0  ISOLATION, CHARACTERIZATION, AND FUNCTIONAL ANALYSIS OF 
PRIMARY FERRET LYMPHATIC ENDOTHELIAL CELLS 
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This chapter comprises of the completed experiments and published data from studies that were 
performed to isolate and establish primary ferret LEC populations in vitro, as well as studies that 
were undertaken to characterize and evaluate the phenotypic profiles and functional functions of 
the primary ferret LECs in response to known TLR ligands, including poly I:C in in vitro model.  
All of the experiments on primary ferret LECs were performed by Stella Joan Berendam with 
Beth Fallert Junecko’s assistance in in situ images acquisition.   
(Published manuscript) 
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3.1 PREFACE  
In order to begin to understand the potential role of LECs during pathogen-host interactions, I 
sought to obtain and establish in vitro models of primary LECs.  I focused initially on the 
isolation of primary LECs from the commonly used animal model for human diseases, namely 
the ferret model.  Ferrets are becoming increasingly popular small animal models for modelling 
of human respiratory diseases as well as development of vaccines and therapeutics for infectious 
agents of viral origins.  Our group was part of a collaborative group of investigators looking at 
the effect of DNA vaccinations of influenza in ferrets.  Vaccine antigens are likely to travel to 
the draining lymph node via the lymphatics.  Thus, I took the opportunity to ask (1) whether we 
were able to culture primary ferret LECs from different animal ferrets and tissue origins, (2) 
whether these primary LECs maintained their phenotypic and functional characteristics ex vivo 
in a 2D in vitro culture system, and (3) whether the lymphatic distribution in ferret tissues was 
similar to that of humans.  All work was performed by Stella Berendam, with the exception of in 
situ hybridization image acquisition, which was performed by Beth A. Fallert-Junecko. 
This study was accepted for publication in Veterinary Immunology and 
Immunopathology in its entirety and used in this dissertation with permission from the publisher. 
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3.2 ABSTRACT 
The lymphatic endothelium (LE) serves as a conduit for transport of immune cells and soluble 
antigens from peripheral tissues to draining lymph nodes (LNs), contributing to development of 
host immune responses and possibly dissemination of microbes.  Lymphatic endothelial cells 
(LECs) are major constituents of the lymphatic endothelium.  These specialized cells could play 
important roles in initiation of host innate immune responses through sensing of pathogen-
associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs), including toll-
like receptors (TLRs).  LECs secrete pro-inflammatory cytokines and chemokines to create local 
inflammatory conditions for recruitment of naïve antigen presenting cells (APCs) such as 
dendritic cells (DCs) to sites of infection and/or vaccine administration.  In this study, we 
examined the innate immune potential of primary LEC populations derived from multiple tissues 
of an animal model for human infectious diseases -- the ferret.  We generated a total of six 
primary LEC populations from lung, tracheal, and mesenteric LN tissues from three different 
ferrets.  Standard RT-PCR characterization of these primary LECs showed that they varied in 
their expression of LEC markers.  The ferret LECs were examined for their ability to respond to 
poly I:C (TLR3 and RIG-I ligand) and other known TLR ligands as measured by production of 
proinflammatory cytokine (IFN-α, IL-6, IL-10, Mx1, and TNF-α) and chemokine (CCL5, 
CCL20, and CXCL10) mRNAs using real time RT-PCR.  Poly I:C exposure induced robust 
proinflammatory responses by all of the primary ferret LECs.  Chemotaxis was performed to 
determine the functional activity of CCL20 produced by the primary lung LECs and showed that 
the LEC-derived CCL20 was abundant and functional.  Taken together, our results continue to 
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reveal the innate immune potential of primary LECs during pathogen-host interactions and 
expand our understanding of the roles of LECs might play in health and disease in animal 
models.  
 
Keywords (indexing terms) 
Lymphatics, lymphatic endothelial cell, ferret, toll-like receptor, chemokine 
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3.3 INTRODUCTION  
The lymphatic vasculature (LV) is often described as a network of unidirectional, blind-ended 
capillaries and larger collecting vessels made up of a single layer of loosely overlapping cells – 
lymphatic endothelial cells (LECs) (9, 10).  Since the LV is often located within micrometers 
beneath mucosal surfaces, they are likely to be among the first cells to participate in early host 
innate immune responses upon contact with microbes, host inflammatory signals, and vaccine 
antigens.  LECs secrete chemoattractant cytokines (chemokines), such as CCL20, which recruit 
immature DCs to sites of inflammation, and CCL21, which draws antigen-loaded mature DCs 
into the collecting lymphatic vessels and then downstream into the LN paracortices, wherein a 
unique environment is created to optimize activation of adaptive immune responses (28, 84).   
Model human LECs express functional toll-like receptors (TLRs) that recognize multiple 
pathogen-associated molecular patterns (PAMPs) on microbes (160, 247).  TLR activation 
results in signaling that triggers the production of pro-inflammatory cytokines and chemokines, 
including type I interferons (IFNs), that are crucial not only for pathogen clearance during innate 
responses, but also enhance the induction of antigen-specific responses during subsequent 
adaptive immunity (252, 253).  Thus, the use of TLR ligands as vaccine adjuvants to increase 
vaccine efficacy in inducing host immune responses is an attractive strategy for development of 
next generation vaccines.  Recent studies on the use of TLR ligand-conjugated vaccines have 
been promising in non-human primates (254) as well as small animal models such as mice (255, 
256) and ferrets (187).  However, different TLR ligand adjuvants mediate distinct cellular and 
molecular profiles of early innate responses in the periphery and the lymphatic organs of non-
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human primates (254).  Despite their potential, there is still limited understanding of the local 
and systemic immune responses and potential toxicities associated with their use in vivo.  
Ferrets are becoming an increasingly examined small animal model for the study of 
human diseases, including neurobiology (171-173), cancer (174), and infectious diseases of viral 
and bacterial origin (176-178, 180, 181).  The use of the ferret as an animal model for studying 
human respiratory diseases has offered a number of advantages.  First, ferret airways resemble 
and share many anatomical and physiological similarities to humans making them useful for 
study of human respiratory infections (257).  In addition, ferrets are highly susceptible to a 
number of human respiratory pathogens that often require no laboratory adaptation prior to 
infection (183, 184).  Furthermore, ferrets are considered an accurate small animal model to 
study both human and avian influenza (182).  In this regard, the ferret model is used to study not 
only seasonal and highly pathogenic avian influenza virus pathogenicity, but also viral 
transmission (185, 258) and the development of vaccines and antiviral therapeutics (186). 
Despite the utility and increasing use of this animal model there is still a major lack of 
ferret-specific reagents for use in research, despite efforts that have been invested to obtain 
reagents to enable development of ferret-specific assays at the cellular and molecular levels (257, 
259).  Molecular cloning and phylogenetic analysis of ferret immune-related genes provides 
tools to assess the inflammatory cytokine and chemokine profiles in infected animals and 
determine their importance in disease progression and/or clearance of infection (260, 261).  The 
expression of functional TLRs by human LECs (247) has highlighted that the LE could be a 
target for new vaccine adjuvancy strategies, alongside monocytes and DCs.  In this light, we 
isolated, cultured, and characterized primary LECs from multiple ferret tissues, and determined 
their responsiveness to known TLR ligands by measuring the production of proinflammatory 
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cytokine and chemokine mRNAs using real time RT-PCR.  In addition, we also cloned and 
sequenced ferret LEC marker partial cDNAs for in situ hybridization (ISH) analysis to probe the 
lymphatic vasculature in ferret tissues.  Altogether, these findings provide insight into the 
function and microanatomy of ferret lymphatics and establish a foundation for examination of 
the roles of LECs during infection and immunization.   
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3.4 MATERIALS AND METHODS 
Ferrets and Tissue Processing 
The ferrets from which tissues for histological analysis and isolation of LECs were obtained 
were available from other non-infectious studies, and were 6-7 month old females that ranged in 
weight from 695-825g.  These ferrets were vaccinated for Canine Distemper virus, descented, 
and single housed at the University of Pittsburgh.  All animal work was approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee, although the tissues 
contributing to these studies were excess tissues available at necropsy.     
 
RT-PCR, cloning, and phylogenetic analysis of ferret LEC markers 
Due to the lack of complete ferret genomic sequence information, design of ferret-specific 
primers for amplification of ferret cDNAs, including LEC markers (Table 2), was based on 
published canine sequences available in GenBank, National Center for Biotechnology 
Information (NCBI).  Previous analyses of ferret cytokine cDNAs reported that ferret sequences 
were closely related to canine sequences (260).  Total cellular RNAs were obtained from ferret 
lung, spleen, and LN tissues, both untreated and stimulated overnight with unmethylated CpG 
oligonucleotides (ODN), poly I:C, or lipopolysaccharide (LPS).  RNA extractions were 
performed using Trizol (Life Technologies, Rockville, MA, USA) according to the 
manufacturer’s recommendation.  Total RNA (2 µg) was reverse transcribed using oligo-dT 
primer (Promega, Madison, MI, USA) and avian myeloblastosis virus reverse transcriptase 
(Promega, Madison, MI, USA).  The resulting cDNAs for each tissue type were pooled and 
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standard RT-PCR was performed using GoTaq DNA Polymerase (Promega, Madison, MI, USA) 
with ferret-specific primers (Table 3) using PCR conditions as follows: 94°C for 3 min, 94°C for 
30 sec, 58°C for 30 sec, and 72°C 2 min for 35 cycles, followed by 72°C for an additional 10 
min before holding at 4°C.  Amplified products were run on a 1% agarose gel prestained with 
GelRedTM Nucleic Acid Stain (Invitrogen, Carlsbad, CA, USA).  PCR products were purified 
from gel slices using the QIAEX II gel extraction kit (QIAGEN, USA) before subcloning into 
the pGEMT cloning vector (Promega, Madison, MI, USA).  The inserts were sequence verified 
and analyzed using the Vector NTI program (Invitrogen, Life Technologies).  Sequences were 
aligned with corresponding sequences from other species as available through the 
NCBI/GenBank database using the ClustalX 2.1 multiple sequence alignment program (262).  
Phylogenetic trees were generated by the neighbor-joining method after DNA distance 
calculation using the PHYLIP 3.69 program (263), and drawn with Tree View 1.6.6 (264).   
    
Isolation and culture of primary ferret lymphatic endothelial cells from tissues 
LEC isolation was performed as described (108).  Briefly, ferret tissues were mechanically 
digested by mincing with sterile surgical scissors, followed by enzymatic digestion with 0.25% 
trypsin overnight at 4°C.  Digested cells were passed through a 100 µM cell strainer once, and 
twice through 70 µM cell strainers.  Primary LECs were cultured on rat tail collagen I (BD 
Biosciences) coated culture dishes using the EGM2 endothelial specialized medium (Lonza), 
supplemented with 2% FBS, and a final concentration of 100 ng/ml recombinant human VEGF-
C (R&D Systems, Minneapolis, MN, USA).  Cells were grown at 37°C with 5% CO2 until they 
reached 80-90% confluency, and then passaged at between 1:4 to 1:8 splits.  The resulting cell 
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populations were characterized by standard RT-PCR using primers specific for ferret LEC 
markers (Table 3) using PCR conditions described above.      
 
Stimulation of ferret LECs with TLR ligands 
Near confluent monolayers (80-90%) of primary ferret LECs were exposed to ligands for TLRs 1 
to 9 (InvivoGen, San Diego, CA, USA) in parallel with mock treated cultures for each LEC 
population.  Concentrations of TLR agonists were as described (247).  After 24 hr of treatment, 
total RNA extractions were performed using Trizol (Life Technologies, Rockville, MA, USA) 
according to the manufacturer’s recommendation.  Statistical analyses were performed using the 
Prism software package (GraphPad, San Diego, CA).  Paired t-tests were used to compare mock 
versus TLR ligand treated samples because no nonparametric method for paired data can be 
properly applied to sample size less than 6.  A p-value of <0.05 was considered significant. 
  
Real-time RT-PCR 
Primers for real-time RT-PCR measurement of podoplanin, LYVE-1, and CCL20 mRNA levels 
were design based on the ferret sequences presented here (Table 3).  Primers for GAPDH, CCL5, 
CXCL10, IFN-α, IL-6, IL-10, TNF-α, and Mx1 were obtained from published studies (187, 265).  
SYBR Green real-time RT-PCR (comparative Ct method) was performed on an ABI Prism 7000 
Sequence Detection System (Applied Biosystems) as described (266).  All samples were assayed 
in duplicate and with concurrent controls that lacked reverse transcriptase in the cDNA synthesis 
reaction.   
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Chemotaxis 
Chemotaxis assay was performed using murine L1.2 cells engineered to express ferret CCR6 as 
described (261).  Briefly, a total of 200,000 of L1.2.fCCR6 responder cells were loaded on top of 
the porous membrane (ChemoTx® Disposable Chemotaxis System, pore size 5 µm, 
NeuroProbe) in triplicate and incubated at 37°C/5% CO2 for 2 hr in a humid chamber.  The 
number of migrating cells was counted using a hemacytometer.  Chemotactic index (CI) was 
calculated relative to control wells with no chemokine.  Chemically synthesized ferret CCL20 
(261) was used as a control.   
 
In situ hybridization (ISH) 
Paraffin embedded ferret tissue sections were cut at 5 µM and mounted on Superfrost Plus slides 
(Bio-Optica).  35S-UTP-labeled riboprobes were generated (93)  and used for stringent ISH on 
ferret tissues.  Autoradiographic exposure times for ferret specific LEC markers after ISH were 
14 days for LYVE-1 and CCL21 mRNA targets and 21 days for podoplanin, Prox-1, and 
VEGFR-3 mRNA targets.  We note that for reasons not yet clear, in these studies and others, 
ISHs with many probes in ferret tissues have resulted in marginally acceptable signal-to-noise 
ratios.   
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3.5 RESULTS 
Cloning, sequencing, and phylogenetic analysis of ferret LEC marker cDNAs 
Given the paucity of ferret-specific or cross-reactive reagents available for research, particularly 
for lymphatic analyses, we designed primers for use in RT-PCRs to acquire ferret LEC marker 
partial cDNAs based on published canine sequences, a species highly related to the ferret (260, 
261).  These studies were driven by the goal of obtaining primary ferret LECs for ex vivo 
analyses (below) and it was imperative to obtain information on LEC target sequences to allow 
development of assays for measurement of mRNA levels in the LEC populations.  We 
successfully obtained cDNAs containing full-length (podoplanin and CCL21) or partial (LYVE-
1, Prox-1, and VEGFR-3) ORFs from total cellular RNAs prepared from ferret tissues.  
Sequence homology analysis of each of the ferret LEC markers with other species showed the 
highest similarity to the order Carnivora, with Canis lupus being the most related species (Table 
2).  This corroborated earlier findings with ferret immune-related genes (260, 261).  Ferret LEC 
markers shared between 74% to 98% sequence homology to the corresponding human sequences 
at the nucleotide level and between 60% to 100% sequence homology at the amino acid level.  
Analysis of the Prox-1 partial ORF showed it is well conserved across multiple species at both 
the nucleotide (98%) and amino acid (99-100%) levels.  Phylogenetic analysis of the podoplanin 
complete ORF revealed that ferret sequences clustered together with species in the order 
Carnivora (Figure 5).  Phylogenetic trees constructed for the other ferret LEC markers revealed 
highly similar results (data not shown).  
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Table 2. Nucleotide sequence relatedness of ferret LEC marker cDNAs to other animal species. 
 
Sequence identity (%) 
  Podoplanin  LYVE-1 Prox-1  VEGFR-3  CCL21 
  (complete ORF)  (partial ORF) (partial ORF)  (partial ORF)  (complete ORF) 
Species 
Dog   81a (73)   91 (85)        98 (100)  92 (96)   89 (85)    
Cat   82 (65)   90 (83)        98 (100)  94 (99)   90 (88) 
Pig   71 (53)   80 (71)        98 (100)  92 (95)   84 (78) 
Human   74 (60)   80 (65)        98 (100)  91 (94)   86 (80) 
Rhesus   73 (59)   80 (67)        98 (100)  91 (95)   82 (77) 
Mouse   78 (48)   76 (56)        95 (100)  87 (94)   80 (79) 
Rat   80 (48)   76 (53)        95 (100)  86 (94)   76 (70) 
Guinea pig  42 (37)   75 (63)        97 (99)  89 (94)   80 (76) 
Syrian hamster  82 (46)   76 (60)        94 (99)  88 (96)   80 (71) 
 
Data shown are the percent relatedness to the corresponding stretch of nucleotide sequences in the ferret cDNAs obtained here.  The numbers in parentheses 
represent the percent relatedness of the corresponding deduced amino acid sequences. 
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 Table 3. Primers and sequences used for standard and real-time RT-PCR. 
 
RT-PCR  Primer name  Primer sequence (5’3’)  Amplicon size (bp)  Source 
Standard CaPDPNF1 AGATGTGGAGGGTGCCAGT 534 This study. Designed based 
CaPDPNR1 AATTCTTCAGCTCTTTAGGGCGAG   on NM_001003220. 
Standard CaLYVE-1F1 CTGGTGGTTGTCTGCTTCCAT 761 This study. Designed based 
 CaLYVE-1R2 TGCAAAGAAGAGGAGTGCGAG  on XM_003639783. 
Standard CaProx-1F1 AATAGCCTCTAAACAGTTTC 382 This study. Designed based 
 CaProx-1R1 TATCCTCCTGATGTACTTCG  on XM_853042. 
Standard CaVEGFR-3F3 GAGCTCTATGACATCCAGCTGT 537 This study. Designed based 
 CaVEGFR-3R3 GGCACATTCACCACCAGCTCCAG  on XM_538585. 
Standard CaCCL21F1 TCCACCTCGCGCACTACTC 414 This study. Designed based  
 CaCCL21R2 CTCTAGGCTGGTCACTGGG  on NM_001005258. 
Standard CaGAPDHF1 ATGGTGAAGGTCGGAGTCAA 300 This study. Designed based  
 CaGAPDHR1 GAAGACCCCAGTGGACTCCA  on NM_001003142. 
Standard FePDPNF1 ATGTGGAGGGTGCCAGTTCT 430 This study. Designed based 
FePDPNR1 CTGTCGCCAGACCATCTTTT   on obtained ferret sequence. 
Standard FeLYVE1F1 GCCAAATGCTTCAGCCTGGT 564 This study. Designed based 
FeLYVE1R1 AGCCCGAGCAGAAGTAGGAG   on obtained ferret sequence. 
Standard FeProx-1F1 ATGCCTGACCATGACAGCAC 286 This study. Designed based 
FeProx-1R1 GCTGGGAAATTATGGTTGCT   on obtained ferret sequence. 
Standard FeVEGFR3F1 TGAGCTCTATGACATCCAGC 482 This study. Designed based 
FeVEGFR3R1 CCTTTAGTACCAGGGCATGC   on obtained ferret sequence. 
Standard FeCCL21F1 ATGGCTCAGTTACTGACTCC 310 (smaller fragment) This study. Designed based 
 FeCCL21R1 TACAGCCCTGGACTTGTTTC ~500 (larger fragment) on obtained ferret sequence. 
Standard FeGAPDHF1 CATCGTGGAGGGCCTCATGA 215 This study. Designed based 
FeGAPDHR1 ATACATTGGGGGTGGGGACAC  on obtained ferret sequence. 
Real time SYBRfPDPNF1 GAGGATGGGCCAACTCAAGA 79 This study. Designed based 
 SYBEfPDPNR1 GTTGTGGTGCTCTGGCTTTCT  on obtained ferret sequence. 
Real time SYBRfLYVE1F1 GCTTCAGCCTGGTGTTGCTT 79 This study. Designed based 
 SYBRfLYVE1R1 GATGTGACCAGGAGCCTTGTG  on obtained ferret sequence. 
Real time SYBRfGAPDHF TTGCTGACAATCTTGAGGGAGTT 81 This study. Designed based 
 SYBRfGAPDHR CTGCTGATGCCCCCATGT   on obtained ferret sequence. 
Real time SYBRfCCL20F TGCTCCTGGCTACTTTGATGTC 89 This study. Designed based 
SYBRfCCL20R TGCTTGCTGCTTCTGACTTG  on published ferret CCL20 (261)  
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Figure 5. Phylogenetic analysis of the ferret podoplanin cDNA nucleotide sequence. 
 
The ferret podoplanin cDNA sequence obtained here was examined for its relatedness to podoplanin sequences from 
other species available from the NCBI/GenBank database.  Predicted complete podoplanin ORF sequences derived 
from genomic DNA are indicated by (*).  The phylogenetic tree was generated by the neighbor-joining method 
using the PHYLIP free program with 1000 bootstrap analyses and was drawn with Tree View 1.6.6 (Molecular 
Evolution). 
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Isolation and characterization of primary ferret LECs 
To obtain LECs from ferrets, we isolated a total of six primary ferret LEC populations from three 
different ferrets and four different tissue types (skin, lung, trachea, and mesenteric LN).  
Cultured primary ferret LECs formed confluent monolayers approximately 10 to 14 days after 
initial plating onto collagen-coated plastic surfaces, these cultures being designated as passage 
zero (P0).  The primary ferret LEC monolayers showed the typical cobbled-stone morphology of 
endothelial cells observed in conventional 2D culture systems (Figure 6).   
The primary cultures were characterized first by standard RT-PCR for expression of the 
LEC markers podoplanin, LYVE-1, Prox-1, VEGFR-3, and CCL21 (Figure 7).  All of the 
primary ferret LEC populations isolated from all tissues types expressed podoplanin and Prox-1 
mRNAs to high levels.  In contrast, the expression of LYVE-1 and VEGFR-3 varied among the 
LEC populations.  LYVE-1 expression was not detected in the primary ferret LECs isolated from 
skin (F1 skin), whereas VEGFR-3 expression was not detected in the skin (F1 skin) and trachea 
(F2 trachea) LEC populations.  CCL21 mRNA was detected in all cultured primary ferret LECs, 
although the CCL21-specific primers yielded two differently sized bands.  Gel extraction and 
sequencing of both bands revealed that the larger fragment contained all sequences present in the 
smaller fragment as well as what was likely an additional intron, consistent with alternative 
splicing of an mRNA precursor.   
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 Figure 6. Ferret lung LECs grown in culture show the typical cobblestone shape. 
 
Shown is a phase contrast micrographic image of confluent ferret lung LECs at passage 3 and at 11 days after 
plating.  (Original magnification at 100X).   
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 Figure 7. Ferret LECs express multiple LEC marker mRNAs. 
 
Standard RT-PCR was used to examine the expression of podoplanin, LYVE-1, Prox-1, VEGFR-3, and CCL21 in 
total RNA preparations from six ferret LEC populations.  The ferrets and tissue types are noted above each column 
of bands, whereas the target gene is noted to the right of each gel image.  The two lung LEC populations, noted by 
the asterisks (*), were derived from the left or right lobes of lung from the same animal.   
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Ferret LECs respond to TLR ligand stimulation 
To determine whether the ferret LECs responded to PAMPs, we first exposed all LEC 
populations for 24 hr to poly I:C, a double-stranded viral mimetic and a known TLR3 and RIG-I 
ligand,.  Since two of the primary lung LEC populations were derived from the same ferret and 
revealed similar LEC marker expression profiles by standard RT-PCR, we included just one of 
the populations in these and subsequent studies.  Responsiveness was assessed by measurement 
of proinflammatory cytokine (TNF-α, IFN-α, IL-6, and IL-10), chemokine (CCL5, CCL20, and 
CXCL10), and IFN-stimulated gene (ISG) Mx1 mRNA levels using newly designed or published 
(187, 260) ferret-specific real-time RT-PCR primers (Table 3).  All primary ferret LEC 
populations responded to poly I:C, with increases in levels of all eight mRNAs examined 
(p<0.05 for all mRNAs; Figure 8).  The levels in increase ranged from 5-fold (IL-10) to 633,031-
fold (Mx1), as determined from the ratio of the geometric means for the treated and control 
groups.   
To determine further whether LECs derived from lung tissues, which comprise a major 
host/pathogen/environment interface, are responsive to multiple TLR ligands, one of the primary 
ferret lung LEC populations (F2 lung LEC, left lobe) was exposed to different TLR ligands 
(TLR1-9) for 24 hr.  Responsiveness was measured again by real time RT-PCR.  The ferret lung 
LECs responded strongly to most of the TLR ligands examined (Figure 9), although this varied 
depending upon the TLR ligand and the mRNA measured.  The gene showing the greatest 
overall response across TLR ligands was CCL20 (Figure 9) with a mean induction (geometric 
mean) of 5,041-fold across all TLR ligands.  In contrast, the mean induction levels for TNF-α, 
IFN-α, and IL-10 were all less than 1.5-fold across all TLR ligands.  Analysis of the LEC 
responses across all genes for the individual TLR ligands revealed that poly I:C was the most 
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potent TLR ligand under these conditions inducing the eight genes examined an average of 
2,424-fold (geometric mean).  The low molecular weight form of poly I:C induced these genes 
an average of 288-fold.  In contrast, all of the other TLR ligands induced the same genes only 
0.9-fold (LPS and flagellin) to 10.2-fold (FSL-1).   
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 Figure 8. Primary ferret LECs respond strongly to poly I:C. 
 
Confluent monolayers of ferret skin (1 population), lung (1 population), trachea (2 populations), and mesenteric LN 
(1 population) LECs were exposed to poly I:C for 24 hours and responses were measured by SYBR Green real time 
RT-PCR for mRNAs encoding the indicated cytokine, chemokine, or ISG.  Data are presented as values normalized 
to the endogenous control GAPDH calculated as 2(-∆Ct).  The arrow denotes the data obtained from the lung LEC 
population used in Figure 9.   
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To unveil possible relations among the mRNA expression changes induced in the ferret 
LECs by TLR ligands, we performed Spearman correlation analyses (Table 4).  Pairwise 
correlation analyses revealed that IL-6 mRNA levels correlated with four other mRNAs (CCL5, 
CCL20, CXCL10, and Mx1).  Similarly CXCL10, CCL5, and CCL20 mRNA levels were all 
positively correlated with each other and with a total of three other mRNAs.  Amongst this small 
set of host response genes, the levels of IFN-α, TNF-α, and IL-10 were not correlated with the 
levels of any other mRNAs (Table 4).  The lack of correlation between IFN-α and the ISGs 
CXCL10 and Mx1 was surprising, but induction of other IFNs like drove the induction of these 
two ISGs.  Additionally, these collective analyses are complicated by the analysis of this data set 
driven by stimulation and signaling through nine different TLRs and their respective signaling 
pathways.   
 
Primary ferret lung LECs stimulated with TLR ligands produce functional CCL20  
Given that the chemokine CCL20 was the most responsive of the genes examined after TLR 
stimulation, and that we have previously developed a chemotaxis assay for ferret CCL20 (261), 
we measured the CCR6-responsive activities of supernatants collected from the TLR ligand 
treated LECs.  Chemically synthesized ferret CCL20 protein was used as a positive control for 
cell migration and media alone was used as a negative control.  Migration of the ferret CCR6+ 
responder cells to serial dilutions of the synthetic peptide generated the typical bell-shaped, dose-
dependent responses (Figure 10B), with maximum migration at 10nM, yielding a chemotactic 
index (CI) of 393 (with 20,000-30,000 cells typically migrating).  Among the TLR ligands 
examined, the supernatant from the Pam3CSK-treated LECs induced the greatest cell migration 
with a CI of 169, followed by supernatant from the FSL-1-treated cells (CI of 162), poly I:C-
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treated cells (CI of 111), flagellin-treated cells (CI of 27), and ssRNA40-treated cells (CI of 30) 
(Figure 10A).  Although the real-time RT-PCR data showed that all of the TLR ligands increased 
the levels of CCL20 mRNA (Figure 9), although only five out of eight LEC-stimulated culture 
supernatants recruited ferret CCR6+ responder cells above medium alone.  It is possible that the 
concentrations of CCL20 protein in the other LEC culture supernatants were at or higher than 1 
µM, which is a concentration above which a responder cell is unable to distinguish a 
concentration gradient from the front and the back of the cell (Figure 10B). 
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 Figure 9. Ferret lung LEC responses to different TLR ligands. 
 
Ferret lung LECs (Ferret 2, left lobe lung LEC) were grown until 80 – 90% confluent and exposed to the indicated 
TLR ligands for 24 hr.  The levels of the indicated mRNA targets were measured by real-time RT-PCR as presented 
in Figure 7.  The dashed line notes the level of expression of each mRNA in untreated cells.  The dark grey bar 
denotes the basal expression of the target gene without any stimulation (mock).  The light grey bar denotes the poly 
I:C responses as a frame of reference for comparison to Figure 8. 
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Table 4. Spearman’s correlation analyses of mRNA expression levels in TLR ligand treated ferret LECs. 
 
 CCL5 CCL20 CXCL10 IFN-α IL-6 IL-10 Mx1  TNF-α  
CCL5 IDa 0.95b (<0.0001) 0.76 (0.009) 0.46 (0.155) 0.93 (0.0001) 0.36 (0.286)  0.56 (0.076) 0.37 (0.261) 
CCL20  ID 0.75 (0.011) 0.37 (0.261) 0.89 (0.0005) 0.30 (0.371) 0.53 (0.100) 0.25 (0.468)  
CXCL10   ID 0.12 (0.735) 0.85 (0.0018) 0.06 (0.860) 0.56 (0.082) 0.46 (0.173)  
IFN-α     ID 0.41 (0.2141) 0.21 (0.539) 0.45 (0.173) 0.51 (0.114)  
IL-6      ID  0.17 (0.615) 0.67 (0.028) 0.58 (0.066)  
IL-10      ID 0.41 (0.214) -0.33 (0.327)  
Mx1        ID 0.56 (0.076) 
TNF-α        ID 
 
aID, identical with r = 1.00.   
bShown are the r-values with the p-values presented in parentheses.   
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 Figure 10. Chemotactic responses of ferret CCR6+ responder cells to LEC culture supernatants after TLR 
ligand stimulation. 
 
(A).  Chemotaxis was performed using responder cells expressing ferret CCR6 and supernatants from control and 
TLR ligand treated ferret lung LECs.  Chemotactic index (CI) was calculated relative to the medium only control 
(M).  (B).  Chemically synthesized ferret CCL20(261) was used as a control (right).  The data presented were 
combined from two independent experiments. 
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Distribution of LEC markers in ferret tissues 
Given the essential role of the LE for transport of soluble antigens and immune cells for host 
responses and immune surveillance, we examined the distribution of the LV in multiple ferret 
tissues by using in situ hybridization (ISH).  To do this, we generated 35S-radiolabeled riboprobe 
for detection of ferret LE-associated mRNAs in ferret LN, lung, spleen, and jejunal tissues.  
These attempts to map the LV in ferret tissues using podoplanin or VEGFR-3 specific ISH 
probes was complicated by high background signals and low specific signals, whereas the 
LYVE-1 and CCL21 probes yielded signals that were reasonable and robust, respectively.  In LN 
tissues, these ISHs revealed a distribution of LYVE-1 mRNA at the subcapsular sinus (Figure 
11) with limited expression in LN parenchyma, consistent with expression by the LV.  In LN, 
CCL21 mRNA was abundant in the cortical and paracortical regions (not shown) as we (93) and 
others have observed in other animals models.  In jejunum, LYVE-1 (Figure 11) and CCL21 (not 
shown) were in the lacteals of villi, which are part of the LV immediately beneath the intestinal 
epithelium.  We also observed networks of LV expressing high levels of CCL21 in the jejunal 
smooth muscle layer (not shown).  In lung tissues, ferret CCL21 mRNA was expressed by 
widely distributed, small, thin-walled vessels in areas near (Figure 11) and distal to conducting 
airways.  Parallel hybridization of subjacent tissue sections with a sense control riboprobe 
yielded no specific signal for any of the tissues examined (Figure 11).  Overall these findings 
provide a first analysis of lymphatic structure in ferret tissues and reveal the LV to be widely 
distributed in ferret lung.   
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 Figure 11. In situ hybridization localization of ferret CCL21 mRNA in ferret lymph node, lung, spleen, and 
jejunal tissues. 
 
In situ hybridization localization of lymphatic marker mRNAs in ferret ferret lymph node, jejunal and lung tissues.  
35S-UTP-labeled riboprobes specific for ferret LYVE-1 or CCL21 were generated and used localize cells expressing 
the respective mRNAs in the indicated tissue from normal ferrets.  ISH signal is visualized by collections black 
silver grains over cells.  Parallel ISHs were performed with the cognate sense control probe (micrographs on the 
right).  Exposure times were 21d.   
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3.6 DISCUSSION 
The LV system is a critically important vascular system that drains interstitial fluids, particulates, and 
cells from peripheral tissues, disruption of which leads to lymphedema.  Despite serving this 
important function, the LECs that serve as the major constituents of lymphatic vessels are 
understudied in comparison to their counterparts, blood endothelial cells (BECs), in blood vessels.  
Identification of LEC markers has facilitated research on LECs and helped in distinguishing them 
from BEC.  The findings presented here describe the first isolation, culture, and functional 
characterization of ferret LECs, paving the way for studying LEC contributions to health and 
disease processes in ferret models.   
An approach used for isolation and characterization of primary LECs from humans, mice, 
or rats involves mechanical and enzymatic dissociation of tissues followed by enrichment using 
LEC marker-specific antibodies (51, 109, 126, 127).  Due to lack of ferret-specific or cross-
reactive LEC marker-specific antibodies we were unable to enrich primary ferret LECs.  Not 
surprisingly, though, immunosorting of LECs using marker-specific antibodies can contribute to 
differences observed in the molecular and functional profiles of isolated LECs (123), which 
could be expected to be heterogeneous in different anatomic and microanatomic compartments.  
Therefore, it will be important to keep in mind this potential for bias towards enrichment of 
subpopulations of LECs expressing moderate to high levels of surface antigens (123).  On the 
other hand, cell types other than LECs can express the markers used for enrichment (267), such 
as with LYVE-1, which is expressed by heterogeneous populations of cells, including 
subpopulations expressing CD68, CD206, or CD208 (111), which in turn could lead to inclusion 
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of non-LECs in the immune-enriched populations obtained and studied.  A recent study showed 
that LECs obtained by digesting pooled brachial, axillary, inguinal, and popliteal LNs from wild-
type C57BL/6J mouse and simple bulk culture in the common DMEM medium, yielded LECs 
that preserved their LEC characteristics over at least 20 passages (130).  
The LE is actively involved in the regulation of cellular traffic from peripheral tissues to 
draining LNs, which is important for the initiation and maintenance of antigen-specific immune 
responses during infection and vaccination.  Primary human LECs express functional TLRs that 
sense PAMPs and secrete proinflammatory cytokines and chemokines at peripheral sites for 
recruitment of APCs to and through the LV (34, 247).  However, little is known about primary LECs 
from other species commonly used as animal models for human diseases.  The ferret is an attractive 
small animal model to study human respiratory viruses, especially influenza virus, due to the unique 
physiologic and anatomic similarities of its respiratory tract relative to humans (178, 182-184).  The 
ferret model has been utilized as an animal model to study seasonal and avian influenza virus 
pathogenesis, as well for vaccine and therapeutic development and studies of viral transmission (185, 
186, 258, 268).  We describe here for the first time the isolation of primary ferret LECs and their 
responses to TLR ligands.  A comprehensive analysis of ferret lung LEC responses to TLR1-9 
ligands revealed that they respond to a large repertoire of TLR ligands.  This ability to recognize and 
respond to a diverse set of microbes is consistent with our previous findings with commercially 
obtained human LECs (247).  This information will be useful in extrapolating information on 
LEC-involved host responses to infection and mechanisms of vaccine-mediated protection in 
ferret animal models to humans.     
Due to its primary function in gas exchange the lung is widely exposed to the external 
environment and to diverse microorganisms.  The lung, however, has evolved a number of 
mechanical and physiological barriers that inhibit colonization by pathogenic microbes (269).  
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There is a necessarily delicate balance in the lung among the different host immune responses, 
including inflammation (270).  Initiation of host immune responses against invading pathogens 
in the lung mucosal surface requires recognition of PAMPs and activation of complement and 
other innate and then adaptive immune responses.  At the same time, exacerbation of these 
responses through overproduction of proinflammatory cytokines and chemokines could result in 
severe immunopathological damage to the lung.  Recent studies have provided evidence for the 
direct involvement of the lymphatics in both the induction and the resolution of inflammation 
(55, 271, 272).  Such findings can provide assistance in the development of strategies to 
modulate innate immune responses to limit inflammation and lung injury during infection.  
Chemokines are important mediators of host homeostatic processes and also of host immune 
responses to pathogens.  However, chemokines, such as CCL20, can contribute to the pathology 
of a number of chronic and severe inflammatory pulmonary diseases (273, 274).  We have 
shown here that TLR stimulation of ferret lung LECs led to high levels of production of 
functional CCL20.  The CCL20 and overall patterns of responsiveness to TLR ligands were 
similar to that of human pulmonary LECs (247).  Given that the receptor for CCL20, CCR6, is 
expressed on immature DCs and IL-17-producing Th17 cells (275), LECs could play 
fundamental direct and indirect roles in immune surveillance and mucosal homeostasis.   
In summary, our findings represent the first isolation and functional characterization of 
LECs isolated from ferret, an increasingly commonly used animal model for human diseases.  In 
addition, these cells and supporting cDNA resources provide a foundation for deeper studies of 
lymphatic structure and function in ferrets.  Our data also report for the first time a 
comprehensive analysis of the TLR ligand responsiveness of ferret lung LECs.  These 
observations provide further evidence that the LV is not simply a passive conduit, but that LECs 
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have more active roles in induction of host innate immune responses and in regulation of 
inflammation after infection.  In sum, the LV presents ongoing opportunities for development of 
improved vaccine, infection control, and inflammation control strategies.    
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This chapter is comprised of the studies on the isolation and establishment of primary rhesus 
macaque LEC populations ex vivo, as well as assessment of their phenotypic gene expression 
profiles and functional properties response to known PRR ligands including exposure to SIV.  
All of the experiments generating and analyzing macaque LECs were performed by Stella Joan 
Berendam. 
 
 
 
(Manuscript in preparation) 
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4.1 PREFACE  
I extended the effort to obtain and establish primary LEC cultures from another commonly used 
animal model for human diseases, namely the rhesus macaque.  In addition to characterization 
and evaluation of the primary macaque LECs at the mRNA and protein levels, I was able to 
determine the functionality of these LECs by measuring their ability to respond to known PRR 
ligands and assessing their susceptibility and permissiveness to infection by genetically 
engineered SIV and HIV-1 viruses as well as wild-type SIV.  Studies in this chapter were also 
designed to dissect the potential innate immune contribution of LECs during SIV, HIV-1, or 
other infections by (1) sensing of the viral pathogens through multiple functional PRRs, (2) 
creating local proinflammatory microenvironments through secretion of cytokines/chemokines, 
and (3) blocking of early stages of viral infection and inter-species transmission through 
endogenous expression of intrinsic viral restriction factors.  Studies were performed to partially 
compare the ability of LECs to take up and process antigens, an innate immune hallmark of DCs.  
These comparisons corroborated the potential innate immune function of LECs during pathogen-
host interactions. 
79 
4.2 ABSTRACT 
Despite their known involvement in controlling immune cell trafficking, the role of LECs during 
pathogen-host interactions is understudied.  Due to the location of the initial lymphatic vessels, 
often closely beneath the mucosal epithelium, LECs are likely to come in contact with pathogens 
that translocate across the epithelium, including SIV/HIV-1.  We hypothesized that LECs are 
involved in host innate immune responses via initial sensing of invading microbes (including 
SIV/HIV-1) through expression of functional pattern recognition receptors (PRRs) including toll-
like receptors (TLRs).  In this role, LECs could potentially influence the transmission and 
establishment of infection.  To address this in a nonhuman primate model, we generated primary 
rhesus macaque LEC populations from multiple animals and tissue types and assessed their 
ability to respond to known PRR ligands.  We also examined the susceptibility of these macaque 
LECs to SIV entry and infection.  Comprehensive phenotypic characterization revealed that 
macaque LECs express known SIV/HIV-1 viral entry and viral restriction factors to differing 
extents and were resistant to infection with engineered single-cycle competent or wild-type 
SIV/HIV-1.  They also responded to treatment with poly I:C alone or with different PAMPs to 
varying degrees and were capable of performing antigen capture and processing under in vitro 
environments that mimic physiological conditions.  In summary, we have established primary 
macaque LEC populations that will serve as new tools to study the immunobiology of LECs 
during pathogen-host interactions in the context microbial transmission, pathogenesis, and 
vaccination. 
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4.3 INTRODUCTION 
The human body has two major vasculature systems, namely the blood and the lymphatic 
vasculature.  Although these two systems share many overlapping functional, structural, and 
physiological similarities, the lymphatic vasculature (LV) has been slightly overlooked and 
understudied compared to its counterpart, the blood vasculature (BV).  Lymphatic endothelial 
cells (LECs) are major constituents of the LV.  LECs contribute to immunological functions of 
LV by regulating the migration of immune cells such as dendritic cells (DCs) and leukocytes into 
LV and their transport from the peripheral tissues to the draining lymph nodes (LNs) through 
secretion of chemokines (29-32, 91, 276, 277) and expression of adhesion molecules (33, 89, 
148, 250, 278-280).  In vitro studies using primary human LECs showed that they expressed 
multiple functional toll-like receptors (TLRs) (281, 282) that responded to pathogen-associated 
molecular patterns (PAMPs) by production of proinflammatory cytokines/chemokines for 
recruitment of immune cells to sites of inflammation.  Despite their known involvement in 
immunomodulation of host immune responses, LECs’ contributions and involvement during 
pathogen-host interactions are not yet well-characterized.   
The macaque model is the most commonly used nonhuman primate model in the 
biomedical research of human diseases.  Since the discovery of SIV, the rhesus macaque model 
has become an indispensable animal model to study disease pathogenesis as well as disease 
progression of HIV-1 infection to AIDS as SIV infection in macaques resembles closely the 
HIV-1 infection in humans (193, 283).  Rhesus macaques share more than 90% similarity to 
humans at the genome level (284) and thus share many orthologous genes that are responsible 
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for immune response to infection by HIV-1 (193, 284), making them highly relevant models to 
study human diseases including virus-host interactions and host immune responses.  Rhesus 
macaques are considered the “gold standard” animal model for development and validation of 
therapeutics and vaccines for HIV-1 (202, 240).  The rhesus macaque model has been used in 
evaluation of antiviral therapeutic drugs against HIV-1 (202) and testing of TLR agonists as 
adjuvants for improved HIV-1 vaccine formulations to induce better innate as well as adaptive 
host responses (231-233, 254, 285, 286).  Functional TLR expression by LECs makes LEC an 
attractive target for development of TLR ligands as adjuvants in vaccines.  Therefore, it is 
important to understand the involvement of LECs in host innate immune response during 
infection/vaccination as this could benefit the development of future vaccines and therapies.  
The study of LECs is hampered due to the challenge of studying these cells in vivo and 
also the difficulties in obtaining pure LECs to study in cultures ex vivo.  However, recent 
identification of gene markers to distinguish LECs from BECs has contributed to the 
advancement of LEC research (42, 43, 50, 52, 53).  In this study, we adapted a previously 
published protocol for human LEC (108) isolation and established primary rhesus macaque LEC 
populations from multiple animals and tissue types.  We proposed that LECs are involved in 
initiation of host innate immune response via sensing of invading microbes (including SIV/HIV-
1) through expression of functional PRRs including TLRs and thus, could potentially influence 
the initial establishment and/or transmission of these pathogens.  To address this, we derived 
multiple macaque LEC populations, characterized their mRNA expression profiles, and 
measured their responsiveness to TLR ligands and exposure to SIV. 
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4.4 MATERIALS AND METHODS 
Animals and tissues 
These studies were performed under the approval and guidance of the University of Pittsburgh 
Institutional Animal Care and Use Committee. 
 
Isolation and culture of primary macaque LECs 
LEC isolation was performed as described (108) and then cultured and passaged as describe 
(248).  All primary macaque LEC populations used in this study were between passages 3 to 9.   
 
Cell culture 
293 cells and Hela cells were culture in using complete DMEM (Life Technologies, Rockville, 
MA, USA) supplemented with 10% FBS (HycloneTM, Thermo Scientific), L-glutamine (Life 
Technologies, Rockville, MA, USA), and penicillin-streptomycin (Life Technologies, Rockville, 
MA, USA) at 37°C, 5% CO2.  CEMx174 cells were cultured using RPMI medium (Life 
Technologies, Rockville, MA, USA) supplemented with 10% FBS (HycloneTM, Thermo 
Scientific), L-glutamine (Life Technologies, Rockville, MA, USA), and penicillin-streptomycin 
(Life Technologies, Rockville, MA, USA) at 37°C, 5% CO2.  All cell lines were plated at the 
same cell density and treated in similar manner as the macaque LECs. 
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Real-time RT-PCR characterization of macaque LECs 
Total cellular RNA extraction was carried out using Trizol (Life Technologies, Rockville, MA, 
USA) followed by column purification and RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s recommendation.  cDNA synthesis was then performed as 
described (266).  Detection of mRNAs of target genes of interest were performed using 
purchased Taqman real-time RT-PCR assays (Applied Biosystems) whenever available or in-
house design primers using SYBR Green-based real-time RT-PCR assays (Table 5).  Gene 
clustering analysis was performed using the R software for statistical computing.  Detection of 
SIV and HIV-1 gag DNA by real-time PCR were performed as described (216).  
 
Flow cytometry 
Confluent monolayer of macaque LECs was detached by enzymatic reaction using Accutase® 
(Sigma-Aldrich, St. Louis, MO, USA).  Detached cells were treated with a final concentration of 
0.1 mg/ml of DNAse I (Roche, USA) for 30 minutes at 37°C, followed by live-dead exclusion 
with LIVE/DEAD® Fixable Aqua Dead Stain Kit (Molecular Probes, Eugene, OR, USA) for 20 
minutes at RT each according to the manufacturers’ recommendations before staining with Abs 
in ice-cold FC Receptor Blocker (Innovex, Biosciences, USA) staining buffer for 45 minutes at 
4°C with anti-human podoplanin-PE (AngioBio, Del Mar, CA, cat. No. 11009-PE) and anti-
human LYVE-1-APC (R&D Systems, USA, cat. no. FAB20892A) antibodies.  After staining, 
cells were washed twice with 1XPBS and fixed in a final concentration of 0.25% 
paraformaldehyde (PFA) before data acquisition using BD LSRII Fortessa and analyzed using 
FlowJo software (Tree Star, Ashland, OR).  Data acquisition was compensated using BD 
Compensation Beads (BD Biosciences, San Diego, CA).  Unstained cells, cells stained with 
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isotyped- and concentration-matched Abs controls, and “fluorescent minus one” controls were 
used to allow appropriate acquisition parameters to be established, and to aid proper gating 
during data analysis.   
 
Stimulation with PRR ligands 
Primary macaque LECs were grown to approximately 80-90% confluency and were exposed to 
TLR1-9 ligands (Human TLR1-9 Agonists Kit, InvivoGen, San Diego, CA, USA, cat. no. tlrl-
kit1hw), NLR ligand (MurNAc-L-Ala-γ-D-Glu-mDAP (M-TriDAP), InvivoGen, San Diego, 
CA, USA, cat. no. tlrl-mtd), CLR ligand (Zymosan, InvivoGen, San Diego, CA, USA, cat. no. 
tlrl-zyn), and CDS ligand (poly(deoxyadenylic-deoxythymidylic) (Poly(dA:dT)), InvivoGen, San 
Diego, CA, USA, cat. no. tlrl-patn).  The final concentration for each ligand was as follows:  
Pam3CSK4 (1 µg/ml) (TLR1/2 ligand); heat killed Listeria monocytogenes (HKLM, 108 
cells/ml) (TLR2 ligand); high molecular weight poly(I:C) (25 µg/ml) (TLR3 ligand); low 
molecular weight poly(I:C) (25 µg/ml) (TLR3 ligand); Escherichia coli K12 lipopolysaccharide 
(LPS, 100 ng/ml) (TLR4 ligand); Salmonella typhimurium flagellin (1 µg/ml) (TLR5 ligand); 
FSL1 (1 µg/ml) (TLR6/2 ligand); imiquimod (2.5 µg/ml) (TLR7ligand); ssRNA40 (2.5 µg/ml) 
(TLR8 ligand); ODN2006 (10 µg/ml) (TLR9 ligand); MTri-DAP (10 µg/ml) (NOD1/NOD2 
ligand); Zymosan (100 µg/ml) (Dectin-1 ligand), and poly(dA:T) (5 µg/ml) (AIM2 
inflammasome  inducer). 
 
NanoString mRNA expression analysis 
NanoString nCounter analysis was performed using custom-synthesized CodeSet probes (N = 
223) for Type I Interferon stimulated genes and housekeeping genes (287).  Cells were treated as 
85 
described above to obtain total RNA, and a total of 1 µg of primary macaque jejunal LECs 
RNAs (equal mass volume), primary human dermal LECs (CloneticsTM, Lonza), each with or 
without poly I:C treatment were pooled was directly hybridized to the custom designed gene 
expression CodeSet and analyzed on an nCounter Digital Analyzer (Nanostring Technologies). 
Counts were normalized to housekeeping genes.  Gene clustering analysis was performed using 
the R software for statistical computing of NanoString data.   
 
Antigen uptake and processing 
Final concentrations of 10 µg/ml BODIPY-conjugated DQ-BSA, 10 µg/ml and 5 µg/ml 
BODIPY-conjugated DQ-Ovalbumin (DQ-OVA) (Molecular Probes, Life Technologies, USA) 
in complete EGM2 media (as described above) were added to a confluent monolayer of macaque 
LECs grown and incubated at 37°C or 4°C for 1 hr.  After incubation, cells were washed with 
1XPBS to remove unbound DQ-BSA and DQ-OVA molecules and detached from plate using 
Accutase® (Sigma-Aldrich, St. Louis, MO, USA).  Detached cells were treated with a final 
concentration of 0.1 mg/ml of DNAse I (Roche, USA) for 30 minutes at 37°C, followed by live-
dead exclusion with LIVE/DEAD® Fixable Aqua Dead Stain Kit (Molecular Probes, Eugene, 
OR, USA) for 20 minutes at RT each according to the manufacturers’ recommendations, washed 
once in 1XPBS before fixing with final concentration of 0.25% PFA prior to analysis using flow 
cytometry.   
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Infectivity study using single-cycle competent VSV-G pseudotyped SIV/HIV-1 and wild-type 
SIVmac239 
Single-cycle EGFP expressing VSV-G pseudotyped SIV and luciferase expressing VSV-G 
pseudotyped HIV-1 viruses stocks were made as described (288, 289).  For the infectivity study 
using the VSV-G pseudotyped viruses, macaque LECs and Hela cells (control population) were 
seeded at the initial density of 10,000cells/cm2 (20,000 cells per well) in a collagen coated 24-
well plate and cultured as described above until 80 – 90% confluency.  Viruses were added onto 
cultured cells at m.o.i of 0.5, with or without inhibitor (FTC, final concentration of 25 µM), and 
left in the culture at 37°C, 5% CO2 for 4 hours before washing twice with 1X PBS followed by 
addition of fresh growth media.  Upon harvest, cell pellets were analyzed by flow cytometry 
(eGFP-expressing virus), luminescence (luciferase activity), and real-time PCR for SIV or HIV-1 
viral gag DNA.   
For infectivity study using the WT SIVmac239, macaque LECs and CEMx174 cells 
(control population) were grown to 40 – 50% confluency.  WT SIVmac239 virus was then added 
onto cultured cells at m.o.i of 0.5 and left in the culture at 37°C, 5% CO2 for 4 hours before 
washing twice with 1X PBS followed by addition of fresh growth media, and further incubated at 
37°C, 5% CO2.  CEMx174 cells were spun down and washed twice also with 1XPBS, before 
addition of fresh growth media, followed by further incubation at 37°C, 5% CO2.  Culture media 
were replenished by replacing half of the culture media with fresh media at day 3, 7, and 10.  
Supernatants from virus exposed cultures were collected at day 1, 3, 7, 10 and 14 post exposures 
and analyzed by real-time RT-PCR for SIV gag RNA as described (266).  Cell pellets were also 
collected at day 14 by trypsinization and subjected to real-time PCR for SIV gag DNA as 
described above.   
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Statistical analysis 
Statistical analysis was performed using paired Student t-test with Prism software (GraphPad, 
San Diego, CA).  Results are shown as mean ± SD, and p values of <0.05 was considered 
significant.  
Table 5. List of purchased Taqman assays and in-house designed primer sequences for real time RT-PCR. 
Gene Species Reactivity Catalog number/Primers sequences 
LEC Markers 
Podoplanin Human   Hs00366766_m1 
Podoplanin Rhesus (in house designed) F:5’-GTGACTGGTTGCCACATTTGA-3’ 
R:5’-TCCACGCCCAAGGACAA-3’ 
LYVE-1 Human Hs00272659_m1 
LYVE-1 Rhesus  Rh01119302_m1 
Prox-1 Human Hs00160463_m1 
Prox-1 Rhesus  Rh00896293_m1 
VEGFR-3 Human Hs00176607_m1 
VEGFR-3 Rhesus  Rh02742716_m1 
CCL21 Human/Rhesus Hs00171125_m1 
CD31 Human/Rhesus Hs01065279_m1 
Stabilin-1 Human/Rhesus Hs01109068_m1 
COLEC-12 Human/Rhesus Rh02852855_m1 
Reelin Human/Rhesus Rh02856443_m1 
BEC Markers 
NRCAM Human/Rhesus Rh01031595_m1 
MCAM Human/Rhesus Hs00174838_m1 
CXCL1 Human Hs00236937_m1 
CXCL1 Rhesus  Rh03456656_m1 
Viral Restriction Factors 
APOBEC3G  Human Hs00222415_m1 
APOBEC3G  Rhesus  Rh02788475_m1 
Tetherin (BST2) Human/Rhesus Hs00171632_m1 
Trim5-α Human Hs01552559_m1 
Trim5-α Rhesus  Rh02788631_m1 
SAMHD1 Human/Rhesus Hs00210019_m1 
Schlafen-11  Human/Rhesus Rh02885088_m1 
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Viral Entry Factors 
CD4  Human Hs00181217_m1 
CD4  Rhesus  F:5’-CAGCAAGGCCACAATGAACC-3’ 
R:5’-GCCCAGCACCACTTTCTTTC-3’ 
CCR5 Human Hs00152917_m1 
CCR5 Rhesus  F:5’-TCTGGGCTCCCTACAACATTG-3’ 
R:5’-GGCTTGGTCCAACCTGTTAGAG-3’ 
CXCR4 Human Hs00237052_m1 
CXCR4 Rhesus  F:5’-AGCGCAAGGCCCTCAAGAC-3’ 
R:5’-GGAGTCGATGCTGATCCCAAT-3’ 
D6 Human Hs00174299_m1 
D6 Rhesus  F:5’-CAGGCAGATGACTGAGGTCTATC-3’ 
R:5’-GAAGGGCAGTGTCACCAGAAAC-3’  
CXCR6 Human/Rhesus Rh03043279_s1 
GPR15 Human/Rhesus Rh02915721_s1 
DC-Associated Markers 
MMR (CD206) Human/Rhesus Hs00267207_m1 
DC-SIGN (CD209) Human Hs01588349_m1 
DC-SIGN (CD209) Rhesus  Rh02788032_m1 
DEC-205 (CD205) Human/Rhesus Hs001588966_m1 
Siglec-1 (CD169) Human/Rhesus Rh00988061_m1 
CD40   Human/Rhesus Rh02621776_m1 
Other Genes 
IL-7-RA Human/Rhesus Rh02841231_m1 
IL-7  Human/Rhesus Rh02621732_m1 
Spinster-2 Human/Rhesus Hs01390449_g1 
CD26 (DPP4) Human/Rhesus Hs00175210_m1 
MIR-21 Human/Rhesus Hs04231424_s1 
GUSB  Human/Rhesus Hs99999908_m1 
TLR3 Human Hs01551078_m1 
RIG-I Human Hs00204833_m1 
RIG-I Rhesus  Rh02789252_m1 
CCL5 Human/Rhesus Hs00174575_m1 
CXCL10 Human Hs00171042_m1 
CXCL10 Rhesus  F:5’-TGTCCACATGTTGAGATCATTGC-3’ 
R:5’-TCTTGATGGCCTTAGATTCTGGAT-3’ 
CCL20 Human/Rhesus Hs00171125_m1 
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Table 5 Continued
4.5 RESULTS  
Primary rhesus macaque LECs are heterogeneous 
To study the LECs involvement in host response to pathogens, we generated a total of 22 
primary macaque LECs from multiple jejunal, LN, skin, lung, and thoracic duct of 10 different 
rhesus macaques (Table 6).  These cultures were established by plating single cells obtained 
from an enzymatic digestion of tissues directly onto collagen-coated surface matrix using 
specialized endothelial and pushed using recombinant human VEGF-C for better survival of 
LECs.  Cultured primary macaque LECs typically formed confluent monolayers 10 – 14 days 
after the initial plating and were designated as passage zero (P0).  The established macaque LEC 
monolayers showed the typical cobbled-stone morphology of endothelial cells observed in 
conventional 2D culture systems (Figure 12).   
 
Table 6. Animal IDs and type of tissues for derivation of primary macaque LECs. 
 
Type of Tissues 
Macaque Jejunum Mesenteric LN Skin  Lung  Thoracic duct 
R74  Xa  
R507  X  X   X  Xa  X 
R59  X  Xa   X  Xa 
R70  X 
R564  X  X 
R24  X  X   X  Xb  X 
R58  Xa  Xa   X  Xa  X 
R704  X 
R69    Xa   X  Xb 
R701    X         
    
X = Denotes one derived LEC population 
a = Denotes LEC population that was not viable after several passages 
b = Denotes slower growth LEC population
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Figure 12. Primary macaque LECs show the typical cobbled-stone morphology of endothelial cells and form 
monolayers when cultured on collagen-coated 2D surfaces. 
 
Cultured primary macaque LECs formed confluent monolayers approximately 10 to 14 days after initial plating onto 
collagen-coated plastic surfaces, these cultures being designated as passage zero (P0). The macaque LEC 
monolayers showed the typical cobbled-stone morphology of endothelial cells observed in conventional 2D culture 
systems.  Showed here is one representative macaque jejunal LEC population (rhR564 Jejunal), cultured at passage 
3. 
 
 
To determine whether the cell populations cultured in endothelial cell growth medium 
with VEGF-C were LECs, we determined their expression profiles for LEC and other markers, in 
comparison to commercially available model human dermal LECs.  We first characterized all of 
the macaque LEC populations using real-time RT-PCR and found that they expressed not only 
the pan-endothelial marker, CD31 but also most of the accepted LEC markers, including 
podoplanin, LYVE-1, PROX-1, and VEGFR-3 (43) and newly-assigned LEC markers 
COLEC12, reelin, and stabilin-1 (42, 50, 52, 53) (Fig. 13A and 13B).  Podoplanin, considered to 
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be a marker strongly distinguishing LECs from BECs, was the most abundant LEC marker 
mRNA measured in macaque LECs and its expression level was comparable to that in human 
dermal LECs (Figure 13 A).  Interestingly, there are wide variability in VEGFR-3 mRNA levels 
in all of the macaque LEC populations, possibly a consequence of 2D culture adaptation (290).  
The expression of newly identified LEC markers reelin, and stabilin-1, were mutually exclusive 
with only the rhR24 LECs expressing stabilin-1.  It is possible such variation was due to 
anatomical differences in the locations of the jejunal tissues used for isolation. 
 
(A) 
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(B) 
 
Figure 13. Primary macaque LECs are highly heterogeneous. 
 
Comprehensive phenotypic analysis of (A) 8 macaque jejunal LEC populations and (B) 14 primary nonjejunal 
macaque LECs by real-time RT-PCR.  Data were normalized to relative expression of beta-glucuronidase (GUSB) 
(2-dCt values).  * indicates species specific assays were used, Hu denotes human-specific assays, Rh denotes rhesus-
specific assays, and (SG) denotes that SYBR Green based assays were used with in-house design primers. 
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We next examined whether these cultured macaque LECs expressed other markers 
known to be associated with their counterparts, the blood endothelial cells (BECs).  We 
performed real-time RT-PCR to measure the expression levels of BEC markers and found that 
most of the BEC markers were expressed to relatively high levels by the macaque jejunal LECs 
(Figure 13A).  However, these BEC markers were also expressed by the model human dermal 
LEC population used for comparative purposes in this study, suggesting to us that these markers 
are not exclusively expressed by BECs.  A recent publication also showed that endothelial 
progenitor cells of BEC lineage (CD34+) that expressed VEGFR-3 were able to differentiate 
towards LECs after stimulation with VEGF-C in vitro (114). 
We also investigated whether the macaque LECs expressed markers associated with DCs, 
which are innate immune cells that are potent APCs.  Our data showed that although the human 
dermal LECs expressed multiple DC-associated markers (CD206, CD209, and CD40), only the 
expression of CD40 was observed in all of the macaque jejunal LEC populations (Figure 13A).  
CD40 is a known master regulator of rapid and global response of endothelial cell after 
activation by T cells (107).  We also asked whether the macaque LECs expressed other genes 
that have been directly or indirectly associated with LV functions in vivo (Figure 13A).  CD26 is 
also known as dipeptidyl peptase (DPP4) and is interesting because it has been shown to be used 
by virus as entry receptor and we observed abundant CD26 expression in all of the macaque 
jejunal LEC populations consistent with an earlier finding that CD26 in expressed strongly by 
LECs compared to BECs (291).  CD26 was initially reported as potential coreceptor for HIV-1 
virus entry (292) and more recently reported as the receptor for the Middle East respiratory 
syndrome coronavirus (MERS-CoV) (293).  We also found that out of eight macaque jejunal 
LEC populations analyzed, only three of them expressed Spinster-2 mRNA.  Spinster-2 is a 
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transporter molecule for Sphingosine-1-phosphate (S1P), a potent lipid mediator that plays an 
important role in lymphocytes traffic and egress from the LN in mice (56).  It is possible that 
differences in Spinster-2 expression could be a consequence of differences in LEC function in 
different microanatomical compartments.   
These gene expression profiles of macaque jejunal LECs were also examined by 
hierarchical clustering analysis (Figure 14).  The resulting heat map re-analysis of the mRNA 
expression profiling revealed that the macaque jejunal LEC expression profiles closely 
resembled that of the human dermal LECs, with LEC marker podoplanin being the most 
abundantly expressed gene and the DC-associated markers, CD205 (DEC-205), CD169 (Siglec-
1), CD209 (DC-SIGN), and CD206 (MMR) being the least abundantly expressed. 
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Figure 14. Macaque jejunal LECs share similar gene expression profiles with model human dermal LECs. 
 
Heat map analysis was performed using real-time RT-PCR data (relative expression values to beta-glucoronidase, 
GUSB) (2-dCt values) for 33 genes endogenously expressed by the macaque jejunal LECs and model human dermal 
LECs.  The most abundance gene expressed by both macaque and human LEC populations was podoplanin, which 
is a known LEC marker.  CD31, which is a pan-endothelial marker was also one of the most abundant gene detected.  
COLEC12, which is a newly designated marker for LECs was also one the most abundant genes detected.  
Interestingly, both primary macaque and human LECs had low levels of expression of DC-associated markers such 
as, CD205 (DEC-205), CD169 (Siglec-1), CD209 (DC-SIGN), and CD206 (MMR). 
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Macaque jejunal LECs express LEC surface marker, podoplanin and LYVE-1 
We next examined whether these macaque LECs expressed known surface markers for LECs 
using flow cytometry.  Gating was based on flow cytometric profiles using unstained cells, cells 
stained with isotype- and concentration-matched control antibodies, and fluorescence minus one 
controls.  Our data revealed that more than 90% of macaque jejunal LECs (live, singlets) 
expressed cell surface podoplanin, of which 19–61% co-expressed cell surface LYVE-1 (Figure 
15).  Altogether, these flow cytometric data and the mRNA expression profiling data support the 
interpretation that the macaque populations isolated by culture in endothelial growth medium 
with VEGF-C are indeed LECs. 
 The expression profiles of these macaque jejunal LECs were compared to a macaque 
lymph node LEC culture that was established after live cell sorting based on surface expression 
of podoplanin and LYVE-1.  Macaque LN LECs derived by live cell sorting for podoplanin and 
LYVE-1 expression had remarkably a similar expression profile compared to unsorted, VEGF-C 
treated jejunal LECs at mRNA and protein levels (Figure 16).  These data indicated that the 
culture conditions used to obtain LECs from jejunum (108) did not grossly effect the expression 
of the LEC markers examined. 
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            Representative macaque jejunal LEC population (rhR24 Jejunal) 
 
 
Figure 15. Macaque jejunal LECs express the LEC surface markers podoplanin and LYVE-1. 
 
Dual color flow cytometry staining was performed using PE-conjugated anti-human podoplanin and APC-
conjugated anti-human LYVE-1 antibodies for five macaque jejunal LEC populations and one model human LEC 
population (Lly).  Shown here is a representative figure for one population (rhR24 Jejunal) by FlowJo software 
(Tree Star, Ashland, OR).  Gating strategy was first determined based on the forward and side scatter, followed by 
single cells analysis (at 45 degree angle, slope of 1), and then live-dead selection staining before dual color flow 
staining using PE-conjugated anti-human podoplanin and APC-conjugated anti-human LYVE-1 antibodies.  
Unstained cells, cells stained with isotyped- and concentration-matched Abs controls, and “fluorescent minus one” 
controls were used to allow appropriate acquisition parameters to be established, and to aid proper gating during 
data analysis.  Data acquisition was compensated using BD Compensation Beads (BD Biosciences, San Diego, CA).  
The table showed the summary of five primary macaque jejunal LECs and one primary human lung LECs with the 
percentage of cells expressing the LEC surface marker, podoplanin, and the percentage of cells coexpressing the 
surface marker, LYVE-1. 
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Figure 16. Primary macaque LECs sorted with antibodies against LEC surface markers (anti-human 
podoplanin and anti-human LYVE-1) share similar profiles as the unsorted primary macaque LEC when 
cultured in collagen-coated 2D surface. 
 
One macaque LEC population was established by prior sorting from a LN tissue using PE-conjugated anti-human 
podoplanin and APC-conjugated anti-LYVE-1 antibodies showed similar mRNA expression profiles to the unsorted 
primary macaque jejunal LECs when culture at low passage number in collagen-coated 2D surfaces.  Reanalysis of 
the sorted macaque LN LECs by dual color flow cytometry staining using PE-conjugated anti-human podoplanin 
and APC-conjugated anti-LYVE-1 antibodies showed similar profiles as observed earlier with the unsorted primary 
macaque jejunal LEC populations and the models human LECs (Figure 15), in which more than 90 percent of the 
LECs express podoplanin (95.3%), and a fraction coexpressed the LEC marker, LYVE-1 (24.1%). 
 
 
Macaque LECs respond to poly I:C treatment 
We have previously reported that primary human and ferret LECs respond to treatment with poly 
I:C, a known double-stranded RNA virus mimetic, by producing proinflammatory cytokines and 
chemokines, including CCL5, CXCL10, and CCL20 (248, 281).  We asked whether the macaque 
LECs derived from jejunal and nonjejunal tissues were able to respond to poly I:C in the same 
manner as their human and ferret counterparts.  To evaluate the responsiveness of the macaque 
LECs (N = 16) to a 24hr exposure to poly I:C, we performed real-time RT-PCR for detection of 
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proinflammatory chemokines, CCL5, CXCL10, and CCL20 (Fig. 17A-C).  Our data showed that 
all of the macaque jejunal (N = 7) (Figure 17A) and nonjejunal (N = 9) (Figure 17B) LECs 
responded robustly to poly I:C with p values of 0.0012 and <0.0001 for CCL5, p values of 
0.0065 and <0.0001 for CXCL10, and p values of 0.0412 and 0.0008 for CCL20, respectively.  
Interestingly, one macaque jejunal LEC population (rhR704 jejunal) and one macaque nonjejunal 
LEC population (rhR24 mesenteric LN) showed decreased CCL20 mRNA expression after poly 
I:C stimulation.  These data indicated that macaque LECs were able to sense and respond to a 
viral RNA mimetic in similar fashion as their human and ferret counterparts. 
 
 
Figure 17. Poly I:C induces robust proinflammatory chemokines production by primary macaque LECs. 
 
Confluent monolayers of primary macaque LECs were exposed to a final concentration of 25 µg/ml poly I:C for 24 
hr.  Response to poly I:C was measured by production of proinflammatory chemokines, CCL5, CXCL10, and 
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CCL20, mRNAs by real-time RT-PCR.  (A) Analysis of primary macaque jejunal LECs (N = 7) showed increased 
production of CCL5 (p = 0.0012), CXCL10 (p = 0.0065), and CCL20 (p = 0.0412), and similarly (B) analysis of 
nonjejunal primary macaque LECs (N = 9) showed increase production of CCL5 (p = <0.0001), CXCL10 (p = 
<0.0001), and CCL20 (p = 0.0008).  (C) All primary macaque LECs (N = 16) significantly induced CCL5 (p = 
<0.0001), CXCL10 (p = <0.0001), and CCL20 (p = 0.0001) after stimulation with poly I:C. Data were normalized to 
relative expression of beta-glucuronidase (GUSB) (2-dCt values), and were transformed to log10 values. 
 
 
Macaque jejunal LECs express SIV/HIV-1 viral entry receptors 
We also examined whether these macaque LECs expressed known receptors and coreceptors 
used by SIV/HIV-1 for viral entry.  We measured the expression of CD4 and CCR5 mRNAs in 
all of the macaque (jejunal and nonjejunal) LECs (Figure 18A and Figure 13B).  Although CD4 
was expressed by most of the LEC populations, there were variability in its expression. CCR5 
was detected in all macaque LECs to varying degrees.  We then focused on the jejunal LEC 
populations for expression of other known coreceptors (CXCR4, CXCR6, GPR15) and an 
alternative viral entry factor, and D6, which is an atypical chemokine receptor (Figure 18A).  
CXCR4 expression was detected in all macaque jejunal LEC populations, CXCR6 was high in 
all of the LEC populations, and expression of GPR15 was variable.  Both CXCR6 and GPR15 
have been reported to be utilized by HIV-1 virus as coreceptors albeit to low efficiency (294). 
D6 was highly expressed in agreement with findings in human LECs by others (55).  
Interestingly, the dermal human LECs did not express CD4 and CCR5 mRNAs, suggesting there 
are differences in their abilities to serve as targets for HIV-1 or SIV viral entry.   
To determine the innate immune potential of LEC, we next asked whether these primary 
macaque LECs expressed intrinsic cellular viral restriction factors known to work against 
lentiviruses, such as APOBEC3G, tetherin, Trim5-α, SAMHD1, and Schlafen-11.  Viral 
restriction factors act as frontline defenses during a viral infection as they can be constitutively 
expressed by host cells, are induced by IFNs, and are able to impede productive viral infection.  
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The expression of viral restriction factors can contribute to the permissiveness of a cell to a virus 
and in some cases they can contribute to limiting cross-species transmission and tropism of a 
virus (295, 296).  Our data showed that primary human and macaque LECs constitutively 
express the viral restriction factors APOBEC3G, tetherin, Trim5-α, SAMHD1, and Schlafen-11, 
to a high level (Figure 18A).   
 
Response to poly I:C induced antiviral factors and immune receptors by rhesus macaque LECs 
In addition to proinflammatory chemokines, poly I:C stimulation induced the expression of viral 
restriction factors and other immune receptors (Figure 18B and 18C).  APOBEC3G, tetherin, 
Trim5-α, and SAMHD1 mRNAs were significantly increased after poly I:C treatment with p 
values of 0.0076, 0.0096, 0.0096, and 0.0098, respectively, but not Schlafen-11 (p = 0.2239) 
(Figure 18B).  In addition, levels of mRNAs encoding TLR3 and RIG-I, both known receptors 
for poly I:C, were significantly upregulated upon stimulation with poly I:C suggesting that there 
is broad coverage in the sensing of PAMPs by both PRRs during local viral infections (Figure 
18C).  We also examined the effects of poly I:C exposure on the levels of known alternative 
virus entry factors for SIV/HIV-1 and found that the expression of D6 (p = 0.0081) and CD26 (p 
= 0.0303) were significantly upregulated, whereas Siglec-1 (CD169) (p = 0.0514) was 
marginally upregulated (Figure 18C).  
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Figure 18. Primary macaque LECs express known viral restriction and entry factors for SIV and HIV-1 
endogenously and their expression levels are upregulated by poly I:C treatment. 
 
(A) Analysis by real-time RT-PCR showed that the primary macaque jejunal LECs and the model human LECs 
expressed multiple innate effector mechanisms that inhibit virus replication, such as APOBEC3G, BST2 (tetherin), 
Trim5-α, SAMHD1, and Schlafen-11, as well as known viral entry factors for SIV and HIV-1, such as CD4, CCR5, 
CXCR4, CXCR6, GPR15, and D6 (an atypical chemokine receptor). (B) Confluent layer of macaque LECs were 
exposed to a final concentration of 25 µg/ml poly I:C for 24 hr. Poly I:C treatment resulted in upregulation of viral 
restriction factors, APOBEC-3G (p = 0.0076), tetherin (p = 0.0096), Trim5-α (p = 0.0093), and SAMHD1 (p = 
0.0098) but not Schlafen-11 (p = 0.2339), which in an inhibitor of viral protein synthesis. (C) Poly I:C also induced 
upregulation of its receptors, TLR3 (p = 0.0129) and RIG-I (p = 0.0035) and other immune receptors, D6 (p = 
0.0081), CD26 (p = 0.0303), and CD169 or Siglec-1 (p = 0.0514). Data were normalized to relative expression of 
beta-glucuronidase (GUSB) (2-dCt values), and were transformed to log10 values. 
 
 
To analyze the responses of macaque jejunal LEC responses to poly I:C more 
comprehensively, we used custom designed probes for type I IFN upregulated genes to examine 
the gene expression profiles of pooled mock and poly I:C treated macaque jejunal LECs and 
compared them to the expression profiles of mock and poly I:C treated primary human dermal 
LECs by NanoString RNA profiling analysis and followed up on some target genes of interest 
using real-time RT-PCR (Figure 19A-C).  Our data not only revealed that these two populations 
shared markedly similar profiles before (mock) and after poly I:C stimulation, they also shared 
overlapping most differentially expressed genes (13 out of 20 genes) in response to poly I:C 
(Figure 19C).  Among the most differentially expressed genes after poly I:C treatment in both 
primary human dermal and macaque jejunal LECs were the proinflammatory chemokines, CCL5 
(p = 0.0035), CXCL10 (p = 0.0022), CCL20 (p = 0.0048), as well as the proinflammatory 
cytokines IL-8 (p = 0.0039), IL1-beta (p = 0.0171), and IL-6 (p = 0.0065) (Figure 19B).  We also 
included the analysis of RNA from uninfected and infected rhesus macaque tissues (ileum), and 
found that their expression profiles were similar to each other but not to the primary LECs (data 
not shown). 
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 Figure 19. Primary macaque LECs share similar RNA expression profiles with primary human LECs before 
and after treatment of poly I:C as examined NanoString RNA profiling. 
 
A total of 1 µg total RNA for each sample preparation was analyzed for a total of 223 host response genes code sets 
by NanoString RNA profiling. Counts were normalized to housekeeping genes and gene clustering analysis was 
performed using the R software for statistical computing. (A) Pooled macaque jejunal RNAs and primary model 
human dermal LECs (Dly) clustered differently from the uninfected and acute AIDS rhesus tissues RNAs, which 
were included as control populations.  Species specific genes in  both pooled primary macaque jejunal LECs and 
primary human dermal LECs were highlighted.  (B and C) Poly I:C treatment (24 hr) induced upregulation of 
similar host response genes in both primary macaque jejunal LECs and primary human dermal LECs.  (B) Follow-
up analysis by real-time RT-PCR showed significant increase of mRNA levels of CCL5 (p = 0.0035), CXCL10 (p = 
0.0022), CCL20 (p = 0.0048), IL-8 (p = 0.0039), IL1-β (p = 0.0171), and IL-6 (p = 0.0065) by paired t-test analysis. 
Data were normalized to relative expression of beta-glucuronidase (GUSB) (2-dCt values), and were transformed to 
log10 values.  (C) Fold-change analysis of 20 most differentially expressed genes in primary human and macaque 
LECs after poly I:C by NanoString analysis showed several overlapping genes.  
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Macaque jejunal LEC responsiveness to other PRR ligands 
Having demonstrated the ability of the macaque jejunal LECs to respond to poly I:C, we then 
explored the ability of these macaque jejunal LECs to respond to other known TLR and PRR 
ligands by producing proinflammatory chemokines CCL5 and CXCL10 (Figure 20A and 20B).  
We first examine the endogenous expression of TLR1-9 by these primary rhesus jejunal LECs 
(Figure 21), and our data showed that TLR1-6 were expressed to high levels by these macaque 
LECs but not TLR7-8, which were consistent with previous studies using human LECs (281, 
282).  Interestingly, we did not detect TLR9 expression in these primary macaque jejunal LECs, 
although that could be due to the sensitivity of the real-time RT-PCR assay detection.  We found 
that Pam3CSK (TLR1/2 ligand), high molecular weight poly I:C (TLR3 ligand), flagellin (TLR5 
ligand), and MTri-DAP (NOD1/NOD2 ligand) significantly induced CCL5 and CXCL10 
expression in all primary macaque jejunal LEC populations, with p values of 0.0052, 0.007, 
0.0087, and 0.0086 for CCL5, and p values of 0.0015, 0.0183, 0.0193, and 0.0216 for CXCL10 
(Figure 20A and 20B).  Interestingly, FSL-1 (TLR6/2 ligand) only induced the expression of 
CCL5 (p = 0.0403) but not CXCL10, meanwhile Imiquimod (TLR7 ligand) only induced the 
expression of CXCL10 (p = 0.0389) but not CCL5.  It is also worth noting that although the high 
molecular weight poly I:C significantly upregulated the expression of both proinflammatory 
chemokines (p = 0.007 for CCL5, and p = 0.0183 for CXCL10) by macaque jejunal LECs, their 
levels were only marginally induced using stimulation with low molecular weight poly I:C (p = 
0.0736 for CCL5, and p = 0.0813 for CXCL10), suggesting to us that exposure to microbes with 
almost identical PAMPs may not induce similar host responses.   
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Figure 20. Primary macaque jejunal LECs respond in varying degrees to stimulation with several 
PRR ligands.
 
Confluent monolayer of primary macaque jejunal LECs were exposed to different PPR ligands (refer to methods 
for final concentrations used) for 24 hr.  Respond to different PRR ligands were measured by 
production of proinflammatory chemokines, (A) CCL5 and (B) CXCL10 mRNAs by real-time RT-PCR.  
CCL5 and CXCL10 mRNA levels were significantly induced by treatment with Pam3CSK (TLR1/2 ligand), high 
molecular weight poly I:C (TLR3 and RIG-I ligand), flagellin (TLR5 ligand), and MTri-DAP (NOD-like receptor 
ligand) by paired t-test analysis.  Interestingly, CCL5 mRNA levels was significantly induced with FSL-1 
(TLR6/2 ligand) treatment but not CXCL10 mRNA levels by the primary macaque jejunal LECs.  And CXCL10 
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mRNA levels was significantly induced imiquimod (TLR7) but not the CCL5 mRNA levels by the primary macaque 
jejunal LECs.  ** denotes p < 0.05 and * denotes p < 0.01. Data were normalized to relative expression of 
beta-glucuronidase (GUSB) (2-dCt values), and were transformed to log10 values. 
Figure 21. Primary macaque jejunal LECs express multiple endogenous TLRs. 
TLR1 to 6 were abundantly expressed in all five primary macaque jejunal LEC populations with slightly lower 
expression of TLR2 and TLR3 in one population, rhR24 Jejunal.  All five primary macaque jejunal LEC population 
expressed low levels of TLR7, TLR8, and TLR9. Data were normalized to relative expression of beta-glucuronidase 
(GUSB) (2-dCt values).  Primer sequences for real-time SYBR Green RT-PCR were published (297). 
Macaque jejunal LECs are able to perform antigen uptake and processing          
The ability of LN-derived LECs to take up and process exogenous antigens has been reported 
recently in mice (163, 164, 166).  We explored the ability of the macaque jejunal LECs, which 
were derived from different species and tissue origin, to perform antigen uptake and processing 
too by exposing them to BODIPY-conjugated DQ-OVA and BODIPY-conjugated DQ-BSA, 
known substrates for antigen uptake and processing.  We found that macaque jejunal LECs were 
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comparable to the model human lung LECs in their ability to take up and process antigen when 
incubated in an environment that closely mimics the physiological condition (37°C) but were 
less efficiently in doing so when incubated at 4°C (Figure 22).    We also found that the antigens 
were taken up and stored in endosomal compartments within the cytoplasm of the macaque 
jejunal LECs (data not shown).  However, it was not determined how long these antigens were 
stored and whether they were subjected to antigen presentation. 
 
 
Figure 22. Primary macaque jejunal LECs are able to take up and process antigen. 
 
Confluent monolayer of primary macaque jejunal LECs were exposed to different final concentrations of BODIPY-
conjugated DQ-Ovalbumin and BODIPY-conjugated DQ-BSA for 1 hr.  Cells were detached by enzymatic reaction 
(Accutase®), subjected to live/dead selection using cellular amines reactive dye, fixed with PFA (final concentration 
of 0.25%), and analyzed by flow cytometry.  Model human lung LECs and macaque jejunal LECs were capable of 
antigen uptake and processing at 37°C but not 4°C.  293 cells were used as negative control population.  Media only 
(o) wells were used as basal level comparison to DQ-OVA (final concentration of 5 µg/ml) (•).  Geometric mean of 
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mean fluorescence index (MFI) of individual primary human lung LECs (N = 2), primary macaque jejunal LECs (N 
= 5), and 293 cells (N = 2) were from two independent experiments. 
 
 
Macaque jejunal LECs were resistant to infection with single-cycle VSV-G pseudotyped SIV and 
HIV-1 viruses 
We next asked whether macaque jejunal LECs were susceptible and permissible to infection with 
SIV/HIV-1 viruses.  We investigated this by using genetically engineered VSV-G pseudotyped 
SIV and HIV-1 viruses that were designed to bypass receptor-mediated entry into cells and 
poised to perform a single-cycle reverse transcription in permissible cells upon entry (Figure 
23A and 23B).  Our data showed that unlike the HeLa cells (positive control population), the 
primary macaque jejunal LECs were not susceptible to infection by both VSV-G pseudotyped 
SIV (Figure 23A) and VSV-G pseudotyped HIV-1 (Figure 23B) viruses and their cellular 
milieus were not permissible for viral reverse transcription of both viruses to take place.  Real-
time PCR for detection of SIV and HIV-1 viral gag DNA copies showed marked decrease of SIV 
and HIV-1 gag copies after treatment with FTC, a nucleoside reverse transcriptase inhibitor 
(NRTI) in the HeLa cells but not the macaque jejunal LECs, suggesting to us that the blocking of 
these genetically engineered viruses potentially occurred before the reverse transcription step in 
the macaque jejunal LECs. 
 Our data showed that the macaque jejunal LECs expressed known viral entry factors for 
wild-type SIV such as CXCR6 and GPR15 (Figure 18A).  Therefore, we sought to determine 
whether the macaque jejunal LECs were susceptible and permissible to infection with wild-type 
virus, SIVmac239.  We used CEMx174 as control population for susceptibility and 
permissibility of SIVmac239 and determined the susceptibility and permissibility of these cells 
for viral replication through detection of SIV viral gag RNA in the culture supernatants and also 
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through detection of SIV viral gag DNA in the cell pellets (Figure 23C).  Our data revealed that 
CEMx174 were readily infected by wild-type SIVmac239, and the viral SIV gag RNA copies 
per ml in the culture supernatant peaked by day 3 post-infection.  Real-time PCR for detection 
for SIV viral gag DNA from the CEMx174 cell pellets by day 14 evidently showed presence of 
SIV gag DNA indicating productive replication of the wild-type SIVmac239 virus.  
Interestingly, although the SIV viral gag RNAs were detected to comparable levels to the 
CEMx174 in the culture supernatants of the macaque jejunal LECs at day 1, the SIV viral gag 
RNA copies were markedly decreased by day 3 post-infection.  Additionally, the SIV viral gag 
RNA copies per ml in these macaque jejunal LECs were somewhat sustained at low levels up to 
day 14 post-infection.  Real-time PCR data for SIV gag viral DNA showed presence of low copy 
number of SIV gag viral DNA in the macaque jejunal LEC cell pellets, suggestive of low levels 
(and perhaps controlled) viral replication.   
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Figure 23. Macaque jejunal LECs are not susceptible to infection VSVG-pseudotyped SIV and HIV-1 virus as 
well as wild type SIV (SIVmac239), and their cellular milieus are not permissible for viral reverse 
transcription to occur. 
 
(A and B)  Confluent monolayer of HeLa cells (control population) and macaque jejunal LEC populations were 
exposed to genetically engineered VSV-G pseudotyped SIV expressing eGFP (m.o.i. = 0.5) and VSV-G 
pseudotyped HIV-1 expressing luciferase (m.o.i. = 0.5) viruses that were able to undergo single cycle reverse 
transcription upon entry into permissible cells after 48 hr post-infection.  Evidence for viral entry and reverse 
transcription was measured by either flow cytometry analysis or luciferase activity for cells infected with virus 
expressing the eGFP or luciferase proteins and by performing real-time PCR on cell pellets of mock and virus 
infected cells. (A) HeLa cells were susceptible and permissible for reverse transcription of VSV-G pseudotyped SIV 
expressing eGFP as measure by flow cytometry and real-time PCR for SIV gag DNA copies.  Detection of SIV gag 
DNA copies was markedly reduced with addition of FTC, a nucleoside reverse transcriptase inhibitor (NRTI).  The 
macaque jejunal LECs were resistant to infection by the VSV-G pseudotyped SIV expressing eGFP, as shown by 
the flow analysis and SIV gag DNA real-time PCR data. There were no difference in the number of SIV gag DNA 
copies in the macaque LECs exposed to virus only and with presence of the inhibitor, suggesting that the cellular 
milieus of the macaque LECs were not permissible for viral reverse transcription to occur. (B) Similarly, the HeLa 
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cells were susceptible and permissible for reverse transcription of VSV-G pseudotyped HIV-1 expressing luciferase 
as measure by relative luciferase activity unit (RLU) and real-time PCR for HIV-1 gag DNA copies.  Detection of 
HIV-1 gag DNA copies was markedly reduced with addition of FTC, a nucleoside reverse transcriptase inhibitor 
(NRTI).  The macaque jejunal LECs remained resistant to infection by the VSV-G pseudotyped HIV-1 expressing 
luciferase, as shown by relative luciferase activity unit (RLU) and HIV-1 gag DNA real-time PCR. There were no 
difference in the number of HIV-1 gag DNA copies in the macaque LECs exposed to virus only and with presence 
of the inhibitor, suggesting that the cellular milieus of the macaque LECs were not permissible for viral reverse 
transcription to occur. (C) Confluent monolayer of macaque jejunal LECs and CEMx174 cells (control population) 
were exposed to wild-type SIVmac239 (m.o.i. = 0.5) and viral supernatants sampled from day 1, 3, 7, 10, and 14 
were subjected to real-time RT-PCR for detection of SIV gag RNA.  Culture media were replenished at day 3, 7, and 
10. On day 14, cell pellets from mock and virus exposed populations were harvested and subjected to real-time PCR 
for detection of SIV gag DNA.  CEMx174 (control population) were susceptible to infection by the wild-type 
SIVmac239 and virus replication peaked by day 3 post-infection.  Real-time PCR of the cell pellets obtained from 
day 14 showed presence of SIV gag DNA in the CEMx174 cells.  The primary macaque jejunal LECs showed 
evidence for SIV gag RNA detection in the culture supernatants of SIVmac239 exposed populations.  However, the 
number of SIV gag RNA copies detected in all macaque jejunal LECs decreased by approximately 100-fold by day 
3 and were sustained at low levels until day 14. Real-time PCR analysis of cell pellets obtained from day 14 showed 
low copy numbers of SIV gag DNA in the primary macaque jejunal LECs.  Data showed for both VSV-G 
pseudotyped viruses and wild-type SIV were mean ± SD obtained from two independent experiments. 
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4.6 DISCUSSION 
Identification of LEC markers has facilitated research on LECs by allowing them to be 
distinguished them from BECs (42, 50, 52, 53, 298).  One approach for isolation and 
characterization of primary LECs from humans, mice, or rats involves mechanical and enzymatic 
dissociation of tissues followed by enrichment using LEC marker-specific antibodies (112, 125, 
128, 298-300).  Although this approach yields fairly pure populations of cells, it can result in 
bias through selection of subpopulations of LECs with high surface expression of the surface 
markers recognized by antibodies used for selection (301).  Another factor is that some 
dissociation methods may preferentially isolate sub-populations of LECs while omitting others 
that are more resistant to mechanical and/or enzymatic dissociation procedure (123).  Our study 
presents a comprehensive analysis of phenotypic and functional characteristics of primary 
macaque LECs obtained by direct plating onto collagen coated surface matrix and pushed with 
the endothelial growth factor, VEGF-C for enhanced survival.  We and others (123, 302) have 
shown that this is an effective approach for bulk isolation of LECs.  One caveat in utilizing this 
method is that there is a potential for contamination by other cell types.  To evaluate this, we 
compare the phenotypic and surface markers characteristics of LECs derived by plating and 
provision with VEGF-C to an LEC population that was live cell sorted.  Our findings revealed 
that these populations were remarkably similar in both their phenotype and surface marker 
expression profiles, suggesting that a direct plating method in the presence of VEGF-C yields 
pure LEC populations as representative as cell sorting and short-term culturing.  In preliminary 
studies, the effect of exogenous recombinant human VEGF-C on macaque LEC growth appeared 
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to affect the overall health and appearance of the LECs, but did not seem to affect their overall  
growth rates (data not shown).  It is conceivable that endogenous VEGF-C or VEGF-D in the 
culture media contributes to a nurturing environment for the LECs.  A recent study using the 
zebrafish model showed different lymphatic growth factors can be involved in lymphatic 
development and that the loss of VEGF-C can be compensated by VEGF-D (138). 
Intestinal epithelial mucosal barrier disruption is one of the hallmarks of progression to 
AIDS following HIV-1 infection (303, 304).  Translocation of pathogenic bacteria or 
gastrointestinal microflora into the lamina propria and eventually into the systemic circulation 
may be responsible, at least in part, for the chronic immune activation that follows pathogenic 
HIV-1 and SIV infections.  Although the exact mechanism of immune activation is not entirely 
clear, the main players in activation of host innate immunity seem to be via sensing of microbial 
products by TLRs and other PRRs.  Studies have shown that blocking of early microbial 
translocation in a nonhuman primate model infected with SIV reduced virus-mediated 
inflammation and viral replication (198) and the use of TLR agonist as adjuvants in mucosal 
vaccine formulations reduced mucosal SIV translocation in the gut (286).   
We present here for the first time a detailed analysis of the responsiveness of macaque 
jejunal LECs to PRR ligands.  Our data revealed that macaque jejunal LECs express functional 
TLRs and other PRRs, thus unmasking them as attractive targets for development of mucosal 
vaccines against SIV/HIV-1 in the gut, of course alongside other innate immune cells, such as 
DCs and macrophages.  SIV infection has been shown to cause accumulation of plasmacytoid 
DCs in the gut (305) and it will be interesting to study the cross-talk between LECs and other 
immune cells in the context of SIV/HIV-1-induced chronic inflammation in the gut.   
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Enhanced innate viral restriction factors following an infection with SIV has been 
reported as one of the contributing factors for enhanced mucosal recovery in the gut of some 
animals despite the lack of complete CD4+ T cell restoration (306).  Our data revealed that 
macaque jejunal LECs highly express multiple viral restriction factors including APOBEC3G, 
tetherin, Trim5-α, SAMHD1, and Schlafen-11.  Thus, LECs, if targets for viral entry or uptake, 
then have the potential to impose strong barriers to pathogens (including SIV/HIV-1) and limit 
the initiation of early infection or transmission by these pathogens.  Through viral PAMPS, viral 
infection stimulates cellular factors through PRRs, which leads to increased IFN production that 
in turn upregulates expression of IFN stimulated genes (ISGs), including viral restriction factors 
(307, 308).  Although the precise mechanisms are not fully clear, LECs are resistant to infection 
with VSV-G pseudotyped and WT SIV/HIV-1 (Figure 23A-C), and viral restriction factors likely 
play some role in this restriction.   
The roles of LECs in innate and adaptive immunity is becoming increasingly appreciated 
(24).  Recent studies showed that LEC plays a critical role in not only in initiation (92) but also 
the resolution (163) of inflammatory conditions.  In addition, LECs have been reported to 
mediate tolerance to self-antigens via MHC-I in tissue graft and transplant rejection (161, 165, 
309).  LN-derived LECs in mice express MHC-II molecule as well as functional costimulatory 
molecules after treatment with exogenous IFN-γ although interestingly, the MHC-II expressed 
was unable to activate allogeneic naïve T cells and impaired their proliferation stimulated by 
DCs (162).  In addition, LECs are able to take up tumor antigens and process them for cross-
presentation to naïve T cells via MHC-I (164) and LECs are major archiving cells for storage of 
persisting antigens following viral challenge or vaccination in a mice model (166).  Our data and 
others’ data (166) have shown that the LECs are not only able to take up and process antigens 
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but they also can store the captured antigens for an extended period of time, the latter resulting in 
increased effector and protective function of memory CD8+ T cells.  These findings highlight a 
potential innate immune function of LECs as the ability to perform antigen uptake and 
processing is a hallmark of antigen presenting cells (APCs) such as DCs.  A reasonable 
extrapolation is that LECs are potentially actively involved in innate immunity during pathogen-
host interactions, not only through sensing via functional PRRs and through expression of viral 
entry and/or restriction factors, but also through the ability to capture and store antigens without 
becoming infected themselves.  This in turn provides them with a key role in controlling and 
halting pathogen infection and transmission, defining them as having potential barrier functions 
in addition to their structural role within the conduit of the lymphatic vasculature.  The macaque 
LEC populations presented here will be beneficial in exploring further the innate immune 
functions of LECs and to study their cross-talk with other immune cells such as T cells and DCs, 
in SIV, HIV-1, and other microbial infections and resulting inflammation, as well as vaccine-
elicited host responses.   
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5.0  FINAL DISCUSSION 
LECs were initially thought have passive roles as conduits for transport of immune cells from the 
periphery to the draining lymph nodes during immune surveillance under homeostasis conditions 
or during initiation of host immune responses to infections or vaccinations.  However, a growing 
number of studies have shown that LECs play an active role in regulating the kinetics of antigen 
presentation by APCs, and that LECs also are important contributors in shaping the cellular 
milieus during host immune responses to pathogens.  LECs help initiate the host innate immune 
response through PRR sensing of microbes, and continue to modulate the local proinflammatory 
microenvironments through expression of multiple cytokines and chemokines, signaling 
molecules, and adhesion molecules to recruit immune cells to sites of infection (247).  
Nevertheless, LEC modulation of the local cellular milieu might potentially be a double-edged 
sword for the host.  Whilst LEC-derived proinflammatory cytokines and chemokines, signaling 
molecules, and adhesion molecules are crucial for recruitment of naïve immune cells and for the 
migration of effector immune cells to the sites of infection, these inflammatory signals or 
molecules likely modulate and alter the functions of the immune cells and cause autoimmunity 
diseases (252).  Similarly, LEC-induced inflammatory conditions are beneficial in wound 
healing but are a likely cause of graft rejection during organ transplantations (65, 144).  During 
cancer metastasis, lymphangiogenesis enables the spread of cancer cells to distal organs (65).   
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5.1 OVERVIEW OF DISSERTATION FINDINGS 
Due to their emerging roles in multiple aspects of human health and diseases, LECs and the 
lymphatic vascular system should no longer be neglected or regarded as a vascular system of 
secondary importance to the body (3).  LEC function is less well understood compared to BEC 
function due to challenges in studying LECs.  Discoveries of LEC markers as well as improved 
culture conditions have advanced the field substantially in the last decade (43, 108).  However, 
one of the major challenges that still remains in establishing ex vivo cultures of LEC is obtaining 
pure LECs given that they are a rare cell type in tissues.   
In the first aim of this study, we first sought to establish pure cultures of primary LEC 
populations from multiple animals and tissue origins in order to understand better the basic 
characteristics and functions of LECs in different organs (Chapter 3 and 4).  These homotypic 
primary LEC cultures were first established in a 2D in vitro culture system, and can be used in 
the future to develop in vitro three-dimensional (3D) cell cultures of primary LECs, alone or with 
other cells.  We have successfully established and characterized six primary LEC populations 
from the skin, lung, mesenteric lymph node, and trachea from four different animal ferrets 
(Chapter 3).  We also have successfully established and characterized 22 primary LEC 
populations from the jejunum, skin, mesenteric lymph node, thoracic duct, and lung from 10 
different animal macaques (Chapter 4).   
In the second aim of this study, I sought to begin to understand the potential involvement 
and contributions of LECs during pathogen-host interactions (Chapter 3 and 4).  I utilized 
primary LECs that were cultured in low passage number in 2D in vitro cultures and assessed 
their ability to respond to known PRRs ligands (PAMPs).  I measured the ability of these 
primary LECs to respond to PAMPs by their ability to secrete proinflammatory cytokines and 
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chemokines.  I found that LECs were able to secrete functional cytokines and chemokines upon 
stimulation with multiple PAMPs, suggesting that they were able to sense, recognize and 
respond to microbes.  Interestingly, poly I:C, which is a double-stranded RNA viral mimetic was 
the most potent inducer of robust proinflammatory responses in primary human, macaque, and 
ferret LECs.  The ability of primary LECs to respond to a viral RNA suggested that LECs may 
have an active contribution in shaping the initial host responses to an early stage viral infection, 
such as by SIV/HIV-1, and can potentially be manipulated to block the initial local establishment 
and/or amplification of these viruses.  I then examined whether primary LECs were susceptible 
and permissible to infection with single-cycle, genetically engineered VSV-G-pseudotyped SIV 
and HIV-1, as well as wild-type SIV (Chapter 4).  We found that primary LECs were not highly 
susceptible to infection by VSVG-pseudotyped and wild-type viruses, and that their cellular 
milieus were not highly permissive for reverse transcription of the viral genome of the single-
cycle, genetically engineered VSV-G-pseudotyped viruses.  However, prolonged culture of 
primary LECs post-exposure to wild-type SIVmac239 indicated that low levels of infection 
occured, which resulted in low level production of viral RNA and DNA.   
In the third aim of this study, we evaluated the potential of LECs to act as innate immune 
players and barriers during pathogen-host interactions by comparing them to a subset of DC 
phenotypes, well-known immune cells at the interface between innate and adaptive immunity 
(Chapter 4).  We found that LECs – human LECs in particular – shared the expression of several 
phenotypic markers with DCs, and that LECs and DCs shared the functional ability to take up 
and process model antigens.  However, it was not determined if these processed antigens were 
subjected to terminal degradation or antigen presentation by the primary LECs. 
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Thus, taken together these findings highlighted the innate immune potential of LECs 
during pathogen-host interactions that merit further examination in order to advance our 
knowledge of LECs and their crosstalk with pathogens and other immune cells, therefore 
potentially targeting LECs for development of new and improved therapeutics or vaccines for 
human diseases. 
5.2 IMPORTANCE OF IN VITRO MODELS FOR STUDYING LYMPHATIC 
ENDOTHELIAL CELLS  
The main objective of an in vitro culture of mammalian cells is to provide a more uniform 
population of cells and a more controlled environment for investigators to study the basic 
physiological and biochemical properties of the different cell types (310).  Typically, cells are 
obtained from tissues by treating them with proteolytic enzymes that digest the proteins in the 
extracellular matrix, and including treatment with agents that chelate Ca2+, which is important 
for cell-to-cell adhesion.  The dissociated cells are then grown as a monolayer on a plastic or 
glass surfaces (hence the term in vitro, which means “in glass” in Latin) with medium containing 
source of nutrients, and maintained at body temperature (37°C) (311).  Since the first in vitro 
establishment of the “L cell line” by Earle and colleagues in 1940s, in vitro culture has been an 
instrumental tool in some of the most important scientific discoveries in human medical history 
(312).  The first human “transformed” cell line was derived from human cervical carcinoma in 
the 1950s, and is still used extensively to this day in biomedical research.  The ability of polio 
virus to grow in in vitro cultures of human kidney cell lines enabled the development of the Salk 
vaccine for prophylaxis against polio virus infection.  Subsequently, the live-attenuated version 
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of the polio virus known as the Sabin vaccine, was produced also in in vitro kidney cell lines.  
The production of these vaccines eventually led to the near world-wide eradication of polio virus 
infection.  Since then, more vaccines for important human diseases were produced using in vitro 
cell culture methods.  Vaccines for measles, mumps and rubella, as well as other veterinary 
diseases such as foot-and-mouth disease were produced using in vitro culture of cell lines of 
human and other species origins (313). 
 The rapid advancement in establishment of 2D in vitro cultures of primary LECs from 
humans and other animal species has been facilitated by the discoveries of LEC specific markers, 
which allows for isolation and enrichment of pure LEC populations using target-specific 
antibodies (108).  Further advancement has come through the development of specific culture 
conditions and growth factors that enhance the survival and growth of LECs in vitro.  Our 
observations and those of others have shown that in vitro cultured LECs initially grow in 
clusters, and expand to form a confluent monolayer with the typical cobbled-stone morphology 
of endothelial cells (248, 314).  Individual LEC cells appear to be flattened on the 2D surface, 
and are slightly elongated during their proliferative stage.  However, the morphological 
characteristics of LEC change in higher subculture passages, in which LECs become slightly 
increased in size, have a more flattened appearance, and are slightly hexagonal in shape, 
suggestive of a move toward senescence (unpublished observations).  In our experience as well 
as others, primary LECs isolated and cultured in vitro can be successfully subcultured, frozen, 
and thawed with minimal changes in phenotype (108).  We have successfully subcultured 
primary macaque and ferret LECs up to nine passages, and characterization at the mRNA level 
by standard and real-time RT-PCR, and at the protein level by flow cytometry analysis showed 
stable and sustained expression of LEC markers (Chapter 3 and 4).   
125 
Establishment of in vitro cultures of primary LECs has enabled studies focused on 
understanding the molecular mechanisms that are involved in lineage commitment and 
development of the lymphatic vasculature, as well as its functions in health and disease.  Primary 
LECs have been isolated and established from different tissues of human and other animal 
species of origins in 2D in vitro culture systems (51, 53, 108, 109, 117, 123-127, 129, 160, 248, 
314, 315).  Phenotypic and functional characterization, such as measurement of gene expression 
profiles and responses to cytokines and growth factors, suggested that LECs from these animal 
models expressed similar gene profiles and are able to response to exogenous stimuli to 
comparable extents as their human counterparts (248, 272).  These findings suggest that data 
obtained using the primary LECs from other species are relevant to study human diseases.  This 
knowledge has led to development of therapeutics for treatment and management of diseases that 
depend on the lymphatics drainage and transport functions, such as lymphedema, which is 
caused by dysfunctional lymphatics.  To date, several targets for lymphedema therapies have 
been discovered through transcriptomal profiling of in vitro models of LECs isolated from 
healthy donors and comparing them to lymphedema patients (111, 290).  Among the most 
studied therapeutic target is VEGFR-3, and its ligand VEGF-C, and their additional roles in 
lymphangiogenesis (113).  VEGF-C signaling through VEGFR-3 has been demonstrated to 
induce lymphangiogenesis and improve lymphatic drainage functions in several animal models, 
suggesting its potential as a therapeutic target for lymphedema.  Surgical lymphedema is still the 
most common complications for cancer survivors, in which 25–56% of breast cancer patients 
develop mild-to-severe cases of lymphedema after cancer treatment.  In vitro cultures of LECs in 
inflammatory conditions have also contributed to identification of LEC-derived adhesion 
molecules that are utilized by cancer cells for their dissemination to distal organs during 
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metastasis.  Additionally, transcriptional profiling of in vitro cultured LECs from healthy and 
diseased human tissues have enabled investigators to identify new target genes that serve as 
biomarkers for improved diagnosis and prognosis of diseases in patients.  More recently, in vitro 
models of LECs have been used to study the crosstalk of LEC with immune cells in promoting 
tolerance or autoimmunity, and also to study the role of LEC as one of the major regulators of 
host immune responses (309).   
Two-dimensional (2D) in vitro culture system does not faithfully recapitulate the 
physiologic conditions of native tissues in vivo.  Cells in native tissues exist in conditions that 
allows for cell-to-cell and cell-to-extracellular matrix (ECM) interactions that are not modeled in 
2D culture environments (316).  As a result, many of the complex biological cues as well as 
molecular processes and functions these cells in vivo are lost in the 2D in vitro culture system.  
Therefore, there have been growing efforts to improve the routinely used 2D in vitro cell culture 
system by switching to a 3D in vitro cell culture system that mimics closer the spatial 
organization of ECM microenvironments, cell-to-cell adhesions, and polarity of cells in vivo 
(317, 318).  Several studies have demonstrated that the 3D in vitro cell culture 
microenvironments were able to improve cell viability, proliferation, differentiation, and lifespan 
in vitro (319).  Cells grown in 3D in vitro culture also showed improved cell-to-cell 
communication, cell migration, and response to stimuli (319).   
To date, there are several upcoming and promising methods of 3D in vitro cell culture, 
depending on the types of native tissue microenvironments that individual model attempts to 
mimic.  The multicellular spheroid (MCS) format relies on the ability of cells to aggregate and 
adhere to themselves.  MCS can be generated through several methods including the forced-
floating method (coating of culture flask with poly-2-hydroxyethyl methacrylate or poly-HEMA 
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to create non-adherent surface) and the hanging drop method.  The MCS is becoming 
increasingly popular 3D in vitro culture method for high-throughput screening of efficacy and 
toxicity of drugs using tumor cells from patients or cancer cell lines (316).  Liver cancer cells 
and breast cancer cells have been shown to form pathologically and physiologically relevant 
MCS that are “tissue-like”, and thus improved the accuracy and efficacy of tested drugs.  In this 
study, we observed that primary human and macaque LECs were able to form MCS that were 
intact and tightly packed with little variability in sizes using both poly-HEMA forced floating 
and hanging drop method (Appendix).  Another group demonstrated that primary human LEC 
MCS cultured for extended period of time demonstrated the ability to sprout, suggestive of 
lymphangiogenesis (320).  Another 3D in vitro culture method that is gaining popularity due to 
its relevance to mimic the ECM microenvironments in the tissue is the gel matrix system.  In this 
system, cells are embedded within organic substance (collagen or matrigel), or scaffold 
(synthetic fiber) to mimic the ECM.  Primary LECs cultured using the matrigel 3D in vitro 
system were able to form tubular structures that resembled the lymphatic vessels (114).   
Establishment of 2D in vitro cultures of primary LEC is a step forward to advancing our 
knowledge of LEC biology.  However, due to the limited ability of the 2D in vitro culture system 
to recapitulate the environment found in tissues, there is a need to develop 3D in vitro culture 
system of primary LECs that closely mimic their physiological and molecular functions in vivo.   
5.3 HETEROGENEITY OF LYMPHATIC ENDOTHELIAL CELLS 
Endothelial cells have remarkable heterogeneity and plasticity in different organs and vascular 
beds.  LEC and BEC diversity is reflected at the molecular level during embryonic pre-
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development and also post-development of the vasculature systems.  LEC heterogeneity and 
plasticity are often associated with anatomical compartments and disease related pathological 
conditions in different organs or tissue types, which could be reflective of their specific functions 
in health and disease.   
5.3.1 Plasticity and heterogeneity of lymphatic endothelial cells 
Transcriptomal analysis of human dermal LECs and BECs revealed that the two types of 
endothelial cells shared approximately 95% of their genes (53).  We found that primary LECs 
isolated from different animals and tissue types shared the same expression of LEC markers, 
podoplanin, LYVE-1, Prox-1, VEGFR-3, and CCL21, albeit to varying levels, suggestive of their 
heterogeneous phenotypes.  However, in primary ferret and macaque LECs, Prox-1, which is a 
known transcription factor for LEC commitment and lineage, was expressed to an abundant 
degree in all primary LEC populations irrespective of the tissue and species origins.  Prox-1 was 
highly conserved at the nucleotide and amino acid levels when compared among different 
species, which could potentially be mean that it has highly preserved function as LEC-lineage 
regulator too.  Prox-1 induces the expression of other LEC markers and down regulates the 
expression of BEC-specific markers (50).  Overexpression of Prox-1 resulted in lymphatic 
reprogramming of the BECs to become more LEC-like (50).  In addition, inhibition of Prox-1 
during embryonic developmental stage of lymphatic vasculature formation resulted in the loss of 
LEC-phenotype in both in vivo and in vitro experimental settings (78).  Thus, Prox-1 is not only 
required to maintain LEC identity and phenotype but is also required to maintain the 
heterogeneity and also plasticity of LEC. 
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The LEC specific surface marker, podoplanin, was also found to be abundantly expressed 
by all primary LEC populations from different species and tissues types, and by far in our 
observation was the strongest and most robust LEC marker.  Podoplanin expression by in vitro 
cultured primary macaque jejunal LECs were detected very strongly by flow cytometry analysis 
as well as real-time RT-PCR even after several subculture passages.  These data suggest that 
combination of podoplanin and other LEC surface markers, such as LYVE-1 and VEGFR-3, are 
suitable for isolation and establishment of pure populations of LECs.  However, heterogeneity in 
podoplanin expression was observed in vivo, in which two types of LECs with high and low 
expression of podoplanin were observed and isolated by flow cytometry (267).  LECs with 
higher podoplanin expression showed higher ability to express CCL21, and were mostly located 
in the initial lymphatics, meanwhile LECs with lower expression of podoplanin demonstrated 
higher expression of CCL27, and were most located at the precollecting and collecting lymphatic 
vessels.  These differences in chemokines secretion could potentially explain the anatomical 
specific functions of LECs in vivo.  We found that VEGFR-3 was expressed to varying levels in 
the in vitro cultured primary LECs, and the variability was observed across different animal 
species and tissue types.  This could be due to a number of contributing factors.  Firstly, the 
survival rate of LECs from the different anatomical parts of the tissue.  Secondly, the adaptation 
to the 2D in vitro culture conditions, such pushing the LECs to be more LEC-like using VEGF-
C, caused some of the LEC populations to down regulate their expression of its receptor, 
VEGFR-3.   
We also found that primary LECs shared some overlapping markers with BECs.  This 
could be due to contaminants BECs in the culture or the fact that LECs were derived from BECs 
in early embryogenesis, and did not completely lose some of the BEC markers.  However, it is 
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quite possible that the functions of these BEC markers in LECs are suppressed by Prox-1 
activity.  Studies by others have shown that BECs have a remarkable ability to become more 
LEC-like under the control of their microenvironments, both in vitro and in vivo.  BECs cultured 
in a 3D in vitro culture system using collagen and matrigel showed altered gene expression 
profiles to be more LEC-like, and reverted back to BEC expression profiles when cultured in a 
2D in vitro culture system (321).  CD34+ VEGFR-3+ endothelial progenitor cells isolated from 
human cord blood and cultured in vitro in presence of VEGF-C showed the propensity to 
differentiate into LEC-phenotypes (322).  More recently, macrophage-derived LEC progenitor 
cells (M-LECPs) have been reported to have the ability to integrate themselves into the 
peripheral lymphatic vessels in LPS-induced lymphangiogenesis in mice (145).  MLECPs also 
were demonstrated to express LEC markers such as podoplanin, LYVE-1, and VEGFR-3 upon 
exposure to LPS, although it was not determined if Prox-1 expression was also induced and if 
this LEC-like phenotype was reversible as observed in as CD34+ VEGFR-3+ endothelial 
progenitor cells.  Mouse DCs when cultured in different in vitro culture conditions were shown 
to upregulate the expression of endothelial markers as well as angiogenic factors (323).  We 
found that primary LECs expressed several overlapping phenotype markers that are known to be 
associated with DCs, such as DC-SIGN, MMR, CD169, and CD40.  CD40 was expressed to high 
levels endogenously in all of the primary macaque jejunal LECs, suggestive of the potentials of 
LECs as immune modulators in vivo.  CD169 expression was really low and almost undetectable 
endogenously, but its expression was increased significantly in the primary macaque jejunal 
LECs when exposed to poly I:C, a double-stranded RNA virus mimetic (Figure 18C).  We found 
that primary macaque jejunal LECs also shared the functional ability to take up and process 
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antigens in a similar fashion and almost as efficient as DCs (Figure 22).  Although, it was not 
determined further if LECs were also capable of antigen presentation. 
5.3.2 Lymphatic endothelial cell and tissue microenvironments 
It has been well established that LEC gene expression profiles and functions are influenced by 
the surrounding ECM and organ compartments, as well as the types of physiological conditions 
they are in, whether steady-state or inflammatory (321).  LEC heterogeneity in the lymph node 
has been shown in the defined distribution of LEC markers in uninfected, SIV infected, and 
Mycobacterium tuberculosis infected cynomolgus macaques (93).  Although LEC markers 
podoplanin, Prox-1, and VEGFR-3 were reported to be expressed in both afferent and efferent 
lymphatics, CCL21 expression was only observed in the afferent lymphatics whereas LYVE-1 
expression was only observed in the efferent lymphatics.  These findings suggest that LECs in 
different anatomical compartments within an organ may have different biological functions.  
Similarly, genome-wide comparative studies of intestinal versus dermal LECs showed that 
although the two LEC populations showed similar overall gene expression profiles, however 
there were more than 200 genes that were differentially expressed (324).  Studies of LECs 
isolated from different human secondary lymphoid organs such as the lymph node, spleen, 
thymus, palatine tonsil, and iliac lymphatic vessels displayed differential expression profiles of 
LEC and vascular markers (314).   
Our data also revealed that primary LECs expressed other genes that were known to be 
important for lymph node remodeling and immune processes such as the egress of lymphocytes 
from the efferent lymphatics.  IL-7, a homeostatic survival cytokine for naïve and memory T-
cells, was shown to be important for lymph node remodeling after a viral infection as well as 
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lymph node reconstruction after avascular transplantation (57).  Furthermore, LEC-derived IL-7 
also contributed to de novo lymphangiogenesis of LYVE-1-positive vessels within the lymph 
node and surrounding tissues after transplantation.  Our data corroborated the findings that LECs 
express IL-7 and its receptor IL-7R, which have been showed to work in autocrine fashion in 
vivo to promote lymphatic drainage as well as lymphangiogenesis.  We also found that primary 
LECs expressed Spinster-2, an important transporter molecule for sphingosine-1-phosphate, a 
known mediator for lymphocytes egress from secondary lymphoid organs (156).     
In addition to physiological conditions, LEC heterogeneity has been demonstrated to be 
associated with several pathological inflammatory conditions within tissue microenvironment, 
including tumor-induced lymphangiogenesis.  Crosstalk between LEC and cancer cells induced 
the expression of LEC-mediated signals, which can promote lymphangiogenesis and 
proliferation of cancer cells (325).  Tumor-associated LECs upregulated the expression of 
several adhesion molecules that have been shown to be involved in regulating the permeability of 
LEC tight junctions, and thus promoting dissemination of cancer cells during metastasis.  
Tumor-induced lymphangiogenesis upregulates the expression of LYVE-1 in both LECs and 
BECs, which mediates the adhesion of hyaluronan-expressing cancer cells to the lymphatic 
vessel and induces tumor invasion.  Similarly, abnormal expression of VEGFR-3 in BECs 
promotes lymphangiogenesis and neovascularization in multiple tumors and granulomas.  
Several other LEC markers as well as adhesion molecules including Stabilin-1, mannose receptor 
(CD206), and Thy-1 (CD90) have been demonstrated to contribute to adhesion to and subsequent 
infiltration of cancer cells into the lymph node via the lymphatics.  LEC-secreted chemokines 
such as CCL21 and CCL5 recruit cancer cells that express their respective receptors, CXCR4 or 
CCR7 and CCR5, and thus promoted transport of cancer cells into the draining lymph node via 
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the lymphatics (325).  Our data revealed that primary LECs expressed CCL21 and CCL5 
endogenously amongst other cytokines and chemokines, and the expression of these cytokines 
and chemokines were increased in proinflammatory conditions. 
Recently, LEC-induced modification of the local tissue microenvironments have been 
associated with host immune tolerance of tumor antigens.  Cross presentation of VEGF-C-
expressing tumor cells antigens by lymph node LECs via their MHC I molecules resulted in 
tolerance of peripheral tissue antigens derived from tumor cells by tumor-specific CD8+ T cells 
(164).  In addition, LECs have been shown to transfer exogenous antigens to DCs, which 
resulted in impaired antigen presentation function by DCs via MHC II molecules, and thus 
resulting in tolerance of to CD4+ T cells (162).  In addition, inflammation-induced 
lymphangiogenesis during corneal transplantation resulted in rejection of the transplanted graft 
(144, 165).  However, the graft survival was improved greatly after administration of antibody 
targeting the LEC marker, VEGFR-3.   
5.3.3 Lymphatic endothelial cell reprogramming and viral infections 
Heterogeneity and plasticity of endothelial cells in pathological conditions are best exemplified 
in the case of HHV8-associated Kaposi’s sarcoma (KS).  KS is the most common malignant 
tumor in AIDS patients.  KS tumor is highly vascularized, suggestive of the endothelial origin of 
the disease pathogenesis.  Initial studies of gene expression profiles of KS tumor suggested that 
they were of LEC origin.  In addition, in vitro infection of LECs and BECs with the HHV8 virus 
showed greater susceptibility to infection in LECs compared to BECs (3).  However, that HHV8 
infection caused BECs to reprogram into LEC-like phenotypes and functions.  HHV8 encodes a 
viral homolog of the IL-6 protein, which signals through various proinflammatory and 
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proangiogenic pathways that are sufficient to induce Prox-1, and subsequently other LEC 
markers such as podoplanin, LYVE-1, and VEGFR-3 (326).  Another latent viral protein, known 
as Kaposin B, stabilizes the Prox-1 mRNAs in BECs upon infection, thus induced the 
reprogramming of BECs to LECs (327).  Furthermore, additional mechanism of Prox-1 
activation in BECs has been proposed.  Activation of IL3-Rα signaling pathway in BECs and 
LECs leads to up regulation of Prox-1 and Prox-1 mediated lymphatic reprogramming, while at 
the same time induces the down regulation of Notch and COUP-TFII, which are essential for 
maintaining BEC phenotypes (328). 
 Overall, both LECs and BECs showed remarkable heterogeneity and plasticity in 
physiological and pathological conditions.  Understanding of the molecular mechanisms that 
control the heterogeneity and plasticity in LECs is important to understand the underlying 
pathologic processes that could facilitate design of improved therapeutics, as well as discovery of 
novel therapeutic strategies that target LECs.  
5.4 LYMPHATIC ENDOTHELIAL CELLS INNATE IMMUNITY ROLE IN 
PATHOGEN-HOST INTERACTIONS 
5.4.1 Pattern recognition receptors 
The concept of innate immunity was first proposed by Charles A. Janeway Jr. in the late 1980s 
(329).   Janeway suggested that innate immune system recognition is based on germ-line 
encoded receptors, known as pathogen recognition receptors (PRRs) that recognizes the 
conserved motifs on microbes and microbial products known as pathogen-associated molecular 
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patterns (PAMPs) (329, 330).  Since then several groups of PRR families have been discovered, 
including toll-like receptors (TLRs), retinoic acid-inducible gene 1-like receptors (RLRs), 
nucleotide-binding oligomerization domain-like receptors (NLRs), and C-type lectin receptors 
(CLRs).  Viral detection of PRRs through sensing of viral nucleic acids and proteins leads to 
initiation of type I interferon (IFN) responses in the host, which includes increase production of 
proinflammatory cytokines and chemokines, as well as interferon stimulating genes (ISGs) such 
as intrinsic cellular viral restriction factors (331).  
The expression of TLRs by LECs is well established.  Primary human LECs from 
different organs have been demonstrated to express multiple functional TLRs and responded to 
their known ligands to varying degrees (160, 247).  We found that primary ferret and macaque 
LECs too expressed multiple functional TLRs that responded to known PAMPs in a similar 
fashion as their human counterparts.  We found that poly I:C, a double-stranded RNA virus 
mimetic and a known ligand for TLR3 and RIG-I was the most potent inducer of 
proinflammatory responses in primary ferret and macaque LECs.  A more comprehensive 
analysis of primary ferret lung LECs and primary macaque jejunal LECs demonstrated that 
Pam3CSK4 (TLR2 ligand), LPS (TLR4 ligand), flagellin (TLR5 ligand) were also able to induce 
significant induction of proinflammatory responses in in vitro cultured LECs upon treatment.  
Analysis of a more comprehensive list of ISGs by Nanostring analysis revealed that primary 
macaque jejunal LECs shared similar gene expression profiles with primary human LECs before 
and after treatment with poly I:C, suggesting that LECs from different species responded to 
PAMPs in similar manner.  Therefore, in vitro cultured primary macaque and ferret LECs 
derived from this study are invaluable tools to study LEC-pathogen interactions of human viral 
pathogens, and the potential of LECs as target for improved vaccine designs that induce more 
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robust host innate immunity and  subsequently more effective host adaptive immunity to 
pathogens.   
Our data also revealed that poly I:C treatment of primary LECs induced production of 
other ISGs such as the intrinsic viral restriction factors.  Viral restriction factors such as 
APOBEC3G, tetherin (BST2), Trim5-α, and SAMHD1 were expressed endogenously to relative 
high levels and were significantly increased after exposure to poly I:C by primary macaque 
jejunal LECs.  Intrinsic viral restriction factors have been shown to counteract productive viral 
infection and replication in the host cells.  In addition, intrinsic cellular viral restriction factors 
have also been demonstrated to contribute to permissiveness of the host cells to infection by viral 
pathogens. 
Taken together, the ability of LECs to sense incoming viral pathogens and induce type I 
IFN responses as well as other ISGs demonstrate their potential innate immune functions.  LEC 
sensing of PAMPs via PRRs can potentially be exploited for improved designs of vaccine 
formulations that incorporated the use of PRR ligands as adjuvants.  Similarly, LEC-induced 
ISGs such as the intrinsic viral restriction factors also suggest their innate immune capability 
during early phase of infection in blocking different stages of viral life cycle.  In addition, LECs 
may also act as barrier to prevent transmission of these viral pathogens.    
5.4.2 LECs as targets for TLR ligand vaccine adjuvants 
The use of adjuvants in vaccine formulations is first to increase the magnitude of host innate 
immune response to the vaccine administered, which will then contribute to enhanced host 
adaptive immune response (332).  The second aim of the use of adjuvants is to shape the type of 
host innate immune response triggered by the vaccine administered, which will then lead to more 
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targeted activation of the host adaptive immune response.  The PRRs are attractive targets for 
vaccine adjuvants as they are key players in priming, activation, expansion, and polarization of 
host innate immunity through induction of cytokine, chemokine, and costimulatory molecules 
that are essentials in these cellular processes (333-335).  Moreover, PRRs are expressed by both 
hematopoietic cells and stromal cells, and are integral components of crosstalk of these cells with 
each other and also their local tissue microenvironments (336, 337). 
PRR ligands can be used as adjuvant either alone or in combination with existing vaccine 
formulations (332).  Currently, there are several PRR ligands undergoing preclinical as well as 
clinical development for both efficacy and safety for use in multiple applications related to 
human and veterinary diseases candidate vaccines.  For example, several synthetic analogs of 
poly I:C (TLR3 and RIG-I ligand) have been used as adjuvants for development of soluble 
proteins, DC-targeting construct, and inactivated viral vaccines (338, 339).  The use of poly I:C 
in these vaccine formulations enhanced the magnitude of innate immunity and resulted in 
prolonged durability of adaptive immunity in vaccinated host (339).  Initial development of LPS 
(TLR4 ligand) as vaccine adjuvants led to the discovery of a much less toxic LPS-derivative 
called monophosphoryl lipid A (MPL), which is a potent inducer of TLR4 (332).  MPL has been 
used as vaccine components in combination with alum for HBV and HPV vaccines in humans 
(340).  It was documented that combination of MPL and alum stimulated a polarized Th1 
response in contrast to mixed Th1 and Th2 response when using alum alone (340-342).  
Similarly, bacterial flagellin (TLR5 ligand) was reported to induce mixed Th1 and Th2 response 
when used as vaccine adjuvants alone (343).  Therefore, the current development of flagellin as 
vaccine adjuvant focused on generation of recombinant fusion proteins expressing the vaccine 
antigens and flagellin.  The production of the fusion protein required TLR5 signaling and thus 
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target both hematopoietic cells and stromal cells when tested in mouse model (344).  Similarly, 
the development of subunit vaccines candidates that incorporates covalently coupled TLR7-
TLR8 ligands and TLR9 ligand was able to enhance the uptake and subsequent presentation of 
the vaccine antigens by DCs (332).     
Evidently, the use of TLR ligands as vaccine adjuvants has been proven to mediate 
enhanced immunity towards the vaccine antigens administered.  However, there are lingering 
safety issues when it comes to the use of TLR ligands as vaccine adjuvants in humans, such as 
the increased risk of autoimmune disease.  Thus, there is a need to develop in vitro models as 
well as animal models that faithfully predict PRRs response and immune activation in humans.  
In conclusion, it is possible to shape the desired immune responses through incorporation of PRR 
ligands as adjuvants, alone or in combination with other non-PRR adjuvants, for both 
prophylactic and therapeutic vaccines for infectious diseases and cancer.       
5.4.3 Viral restriction factors 
Intrinsic cellular viral restriction factors are important component of the host intracellular innate 
immune system.  Unlike PRRs, intrinsic cellular viral restriction factors are able to act 
immediately and inhibit viral replication by binding directly to viral components (296).  These 
viral restriction factors exist endogenously in host cells although their expression can be induced 
further upon contact with viral proteins or components.  The expression of these viral restriction  
factors often determine the susceptibility and permissiveness of a cell type to virus infection as 
well as an important determining factor of virus tropism.  Many of these restriction viral factors 
are by products of strong coevolutionary process between the host and the virus, thus a native 
viral restriction factors may not be as efficient or are only weakly efficient in blocking the viral 
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infection in its natural hosts.  However, interspecies inhibition of viral replication is highly 
efficient, thus viral restriction factors have important in innate immune barrier function in 
preventing the spread of interspecies zoonotic diseases to humans.  This interspecies barrier 
function of viral restriction factors is exemplified in the efficiency of the simian APOBEC3G 
protein to confer resistance to degradation mediated by HIV-1 Vif protein, and thus resulted in 
successful inhibition of the viral genome reverse transcription process by genome editing and 
introducing premature stop codon into the new viral genome (345-348).  In addition, 
APOBEC3G inhibition of HIV-1 is through its function as a cytidine deaminase that induces 
hypermutations (G to A) in the negative strand of the viral genome, thus preventing its 
integration into host genome (349).  Innate mechanism of APOBEC3G has also been proposed to 
occur prior to the reverse transcription stage of the viral RNA, thus making it an attractive target 
for anti-HIV agent (350).  Similarly, human Trim5-α restricts murine leukemia virus (MLV) 
infection but not HIV-1 and SIV, and rhesus Trim5-α restricts HIV-1 but not SIV (296).  Trim5-
α promotes rapid uncoating of HIV-1 capsid in vitro, and also acts as ubiquitin E3 ligase in both 
proteasome-dependent and proteasome-independent pathways.  In addition, viral restriction 
factor may also contributed to species specificity and shaping the evolution of virus genomes, 
such as in the case of primate lentivirus (351).  For example, most SIV isolates do not encode the 
viral protein Vpu, which promotes degradation of tetherin (BST2).  Tetherin (BST2) promotes 
degradation of newly formed HIV-1 virion by tethering the virion to the infected cell membrane 
and prevent viral release (352).  These virions are then internalized back into the cells by 
endocytosis and subjected for degradation in the endosomes.  SIV Nef protein is unable to 
antagonize the human tetherin activity due to missing amino acids for binding of the viral protein 
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(296, 353).  SAMHD1 blocks HIV-1 virus reverse transcription process by depleting the dNTPs 
pool in myeloid cells (354). 
Mucosal expression of viral restriction proteins along with other type I IFN molecules 
have been correlated with enhanced mucosal recovery in the lung and restoration of CD4+ T 
cells in after HIV infection in macaque model (355).  Viral restriction factors are expressed by a 
number of different cell types including DCs, macrophages, and also other stromal cells such as 
LECs.  Thus, viral restriction factors may have additional role in innate immune signaling during 
viral infection.  Trim5-α also acts as sensory mechanism for viral capsid protein during infection 
with MLV, SIV, and HIV-1 virus, and sensing by Trim5-α triggers type I IFN responses in host 
(296).  However, the involvement of viral restriction factors in immune signaling may not always 
have positive effect on the host and can be more advantageous to the virus.  Tetherin binds to a 
membrane receptor selectively expressed by plasmacytoid DCs, known as ILT7, which leads to 
inhibition of TLR-mediated effector function of DCs. 
Investigation of host viral restriction factors will elucidate how viruses evade the host 
innate immune system and use it to their advantage.  At the same time, this knowledge will allow 
us to understand the mechanisms of evasion utilized by these viruses as targets to design better 
therapeutics for viral infections in humans. 
5.5 LYMPHATIC ENDOTHELIAL CELLS AS POTENTIAL TARGETS FOR 
PATHOGENS 
LECs and BECs that line the lymphatic and blood vasculature are poised to come in contact with 
infectious agents that are transported in the lymph to the draining lymph node or in the blood 
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circulation.  There are several human pathogens of bacterial and viral origins that have been 
designated as truly endothelium-targeted (356).  Most of these pathogens are able to enter and 
replicate within endothelial cells throughout the course of infection.  In addition to that the 
clinical pathological hallmark of these diseases are the loss of endothelial vasculature 
permeability possibly as a result of infection of the endothelial cells themselves or damaging 
effect of inflammatory cytokines and chemokines.  Most of the endothelial-targeting pathogens 
we know currently targets BECs and very few pathogens are known to target LECs.  For 
example, hemorrhagic fever viruses including bunyaviruses (Hantavirus), phleboviruses (Rift 
Valley Fever virus), filoviruses (Ebola virus and Marburg virus), and flaviviruses (Dengue virus) 
target and infect BECs in both in vitro and in vivo models.  In some cases, even though BECs 
may not be the direct target for infection by viral pathogens, production of costimulatory 
molecules and adhesion molecules by the BECs could contribute to pathophysiological 
consequences in vivo.  In the case of Nipah virus infection, increase permeability of the blood 
brain barrier function of BECs enabled the virus to enter the brain and infected its target cells, 
the neurons, and thus caused viral encephalitis.  Furthermore, endothelial infection by viral 
pathogens may be species-species such as in the case of lung endothelial infection by highly 
pathogenic avian influenza virus (HPAIV) (357).  HPAIV targets the lung endothelial cells for 
infection in terrestrial poultry and wild bird species however in human infections of HPAIV the 
lung endothelial cells have been shown to be less susceptible to viral infection and play a more 
important role in controlling the local inflammatory milieu upon exposure to the virus.    
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5.5.1 Viral entry factors 
BECs and LECs are similar in many aspect of their gene expression profiles, and thus it is highly 
possible that LECs are also potential targets for pathogens that infect BECs.  We found that 
primary human dermal LECs express the macrophage mannose receptor (MMR or CD206), 
which has been proposed for viral entry of dengue virus into host cells (358).  We also found that 
CD26 was highly expressed in both primary human and macaque LECs.  CD26 was recently 
proposed to be the viral entry factor for Middle Eastern Respiratory Syndrome Coronavirus 
(MERS-Cov) (293, 359).  A more comprehensive analysis of the expression of viral entry factors 
and coreceptors by LECs showed that primary macaque LECs of different tissue origins express 
the CD4 and CCR5 molecules, which are known receptor and coreceptor for HIV-1 virus entry.  
Our data also demonstrated that primary human dermal LECs and primary macaque jejunal 
LECs showed that these primary LECs express several other molecules that have been shown to 
be utilized by both HIV-1 and SIV for entry into susceptible host cells such as CXCR4, CXCR6, 
GPR15, and D6, suggestive of their potentials as target for SIV and HIV-1 infection.  LECs 
involvement in the pathogenesis of HIV infection and AIDS development may not be only 
restricted to their potentials as target cells.  Our group and others have demonstrated the ability 
of LECs to take up and archive exogenous antigens.  We also found that primary macaque LECs 
were resistant to infection with genetically engineered VSVG-pseudotyped SIV and HIV-1 and 
also wild-type SIV when compared to control cell populations, the CEMx174 cells and the HeLa 
cells.  However, analysis for SIV RNA and DNA from culture supernatants and cell pellets of 
wild type SIV-exposed primary macaque jejunal LECs suggested that low level and possibly 
controlled SIV virus replication had occurred.   
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 The restricted susceptibility of BEC to different strains of HIV-1 and HIV-2 viral 
infection has been demonstrated (360).  BECs that lined the larger blood vessels did not express 
the CD4 molecule but were infected through their constitutive expression of CXCR4 molecule 
(361).  It was reported that mature virus production in infected endothelial cells was evident 
during the first few days post-infection but declined to undetectable levels in both supernatants 
and virus-exposed endothelial cells (362).  HIV-infected BECs did not result in syncytia forming 
cytopathic effect when culture alone in in vitro model.  However, coculture of HIV-infected 
BECs with CD4+ lymphoid and mononuclear cells resulted in formation of syncytia in these 
cells, suggesting that BECs might have been infected by HIV-1 although syncytia formation was 
not observed.  Other studies have also demonstrated that HIV-1 infection in in vitro culture of 
microvascular BECs from brain, kidney glomeruli, hepatic sinusoid, and bone marrow 
potentially resulted in productive infections that were devoid of syncytia formation and cell 
cytolysis as well (361).  HIV-1 infection of brain endothelial cells is highly studied due to its 
relevance in HIV-associated neurological diseases.  Brain endothelial cells were reported to be 
able to endocytose HIV-1 virus through interaction of the virus gp120 glycoprotein with CCR5 
and CXCR4 molecules expressed by the cells (363). 
Taken altogether, these data suggest that LECs could potentially be infected to some 
extent and act as a low level viral reservoir and facilitate the dissemination as well as chronic 
infection of the SIV and HIV-1 virus.    
5.5.2 Other immune receptors 
Our data also revealed that primary LECs expressed the atypical chemokine receptor, D6, which 
binds to homeostatic and proinflammatory chemokines, and then internalizes them for recycling 
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(54, 364).  Thus, D6 is an important regulator of the homeostasis as well as inflammatory 
processes.  D6 has been demonstrated to control the interaction of inflammatory leukocytes with 
LECs and also discrimination of mature and immature DCs by LECs (55).  In addition, D6 
expression by LECs could potentially be involved in KSHV virus pathogenesis through 
interaction with the viral homolog of IL-6 protein (55).  Although the exact mechanism is still 
unknown, it was proposed that the KSHV viral IL-6 homolog increased D6 expression in KSHV-
infected cells, and resulted in impaired release of proinflammatory CC chemokines from the 
tumor microenvironment, and compromised clearance of the tumor cells by tumor-specific host 
immune cells.  Our data also revealed that CD40 was endogenously expressed to high level in 
primary LECs.  CD40 has been proposed to play a role in KS tumor pathogenesis.  In vitro 
culture of KS tumor cells revealed high level of CD40 expression, and addition of IFN-γ 
increased the anti-apoptotic and pro-angiogenic properties of these tumor cells (365).  Thus, 
CD40 is potential contribute to KS pathogenesis through mechanisms that stimulate tumor 
growth, neoangiogenesis, and anti-apoptosis processes.   
 Taken together, these data suggested that LECs can either directly or indirectly contribute 
to pathogenesis due to viral infections.  LECs can be targeted for infection by pathogens, which 
then potentially alter or impair their physiological and immunological functions.  LECs can also 
modulate the local microenvironment through production of proinflammatory cytokines and 
chemokines, which can alter or impair the effector functions of host immune cells as well as host 
cells processes.  Understanding of the mechanisms involved in contribution of LECs in 
pathogen-host interactions and disease progression would offer the possibility of developing 
endothelium-specific therapeutics and vaccines for important human viral infections.         
145 
6.0  OVERALL SUMMARY 
Due to their unique anatomical locations, LECs are poised to come in contact with incoming 
pathogens or vaccine antigens and are actively involved in the initial development of host innate 
immune responses to these foreign antigens.  Based on our findings and others, I propose three 
different models to frame LEC innate immune involvement and contributions in pathogen-host 
interactions during infection or vaccine administration.  Each of these models is discussed in 
detailed below.   
6.1 MODEL ONE:  PATHOGEN RECOGNITION RECEPTOR SENSING OF 
PATHOGENS AND PRODUCTION OF PROINFLAMMATORY CYTOKINE AND 
CHEMOKINES 
We demonstrated that LECs express multiple functional PRRs and were able to respond to 
PAMPs by producing proinflammatory cytokines and chemokines.  Thus, we propose that LECs 
are actively involved in host innate immune responses through initial sensing of incoming 
pathogens or vaccine antigens by PRRs and subsequent secretion of proinflammatory mediators.  
These LEC-derived proinflammatory signals will then recruit immune cells including immature 
DCs.  Consequently, antigen-loaded mature DCs will carry these foreign antigens to the draining 
lymph node to further activate the host adaptive immune response.   
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Figure 24. Innate Immune Potential of LECs - Model One 
 
PRR sensing of pathogens results in production of proinflammatory chemokines/cytokines by LECs, which leads to 
recruitment of naïve immune and immune effector cells. 
6.2 MODEL TWO: ANTIGEN UPTAKE, PROCESSING, AND ARCHIVING 
We have also demonstrated that primary LECs are able to take up and process exogenous 
antigens in in vitro 2D models.  Other have shown that in vivo LECs also share the same 
functional capability (166).  Thus, we propose that LECs contribute to host innate immunity 
through their ability to perform antigen uptake and processing, and also archiving of these 
exogenous antigens for optimal contact with APCs, such as immature DCs.    
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Figure 25. Innate Immune Potential of LECs - Model Two 
 
LECs potentially capture and archive pathogens by antigen uptake/processing, and thus enable optimal contact of 
antigens with immune cells. 
6.3 MODEL THREE: EXPRESSION OF INTRINSIC CELLULAR VIRAL 
RESTRICTION FACTORS  
We also found that LECs endogenously expressed known intrinsic viral restriction factors 
against HIV-1, SIV, and other RNA viruses.  It is possible that LECs also endogenously express 
additional as of yet unknown intrinsic viral restriction factors against other important human 
viral pathogens.  Thus, we propose that LECs can act as an innate immune barrier in pathogen-
host interactions during viral infection, and prevent initial establishment of infection, productive 
viral replication, and also viral transmission.  We also propose that LEC-derived viral restriction 
factors contribute to their resistance to infection by viruses. 
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Figure 26. Innate Immune Potential of LECs - Model Three 
 
LECs potentially act as barriers to viruses through expression of several intrinsic and viral restriction factors that 
presumably control and block productive infection to prevent establishment and transmission of the viral pathogens. 
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7.0  PUBLIC HEALTH SIGNIFICANCE 
Vaccines are an effective public health measure to prevent and eliminate the spread of infectious 
diseases.  Despite many successful vaccines, there are still no vaccines available for a vast 
number of important human pathogens of viral origins, such as HIV-1, Dengue, Ebola, and many 
others.  Most successful vaccines are based on live-attenuated or inactivated (killed) forms of 
viruses, as well as viral antigenic subunits, such as proteins, synthetic peptides, polysaccharides, 
and glycoconjugates.  These vaccines mimic the real pathogens and are designed to induce 
robust and long-term protective immunity in the host.  As we understand more about the human 
immune system, we begin to appreciate the importance of innate immunity for generation of 
robust and adaptive immune responses as a result of vaccination.  It is well established that the 
quality of adaptive immune responses is dependent on the magnitude of innate immune 
responses.  Stromal cells such as LECs are integral players in initiation of host innate immunity 
during pathogen-host interactions through their ability to sense pathogens via PRRs, secrete 
proinflammatory molecules for recruitment of immune cells, and also crosstalk with 
hematopoietic cells, including antigen presenting cells such as DCs.  Therefore, LECs are 
attractive target cells in our efforts to improve current vaccines and to develop effective vaccines 
strategies against emerging and chronic viral infections.  In the context of HIV-1 vaccine 
development, LECs can potentially be manipulated to generate more robust responses for 
development of pre- or post-exposure prophylaxis therapeutics using PRR ligands as adjuvants, 
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thus preventing the initial establishment of the small founder virus population.  LECs are 
involved in transport of vaccine antigens from the peripheral tissues to the draining lymph node 
during vaccination, and thus crosstalk of LECs with antigen presenting cells (DCs) and T cells 
can be useful in revising current methods of vaccine delivery.  Improved understanding of the 
mechanisms involved in innate immune barrier functions of LECs through the expression of 
intrinsic viral restriction factors could potentially lead to discovery of new antiviral mechanisms 
against HIV-1 and other viruses, which can potentially be applied to development of novel 
antiviral therapeutics.   
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8.0  FUTURE DIRECTIONS 
This body of work has expanded our understanding of LEC immunobiology and provided us 
with the tools to investigate further the important aspects of LEC crosstalk with other immune 
cells during pathogen-host interactions.  Over the course of this study, our findings led to more 
exciting possibilities and questions that could not be addressed here due to time constraints.  The 
sections below outline some of the key areas that warrant future investigations in order to expand 
our understanding of innate immune potential of LEC. 
8.1 DEVELOPMENT OF 3D IN VITRO CULTURE OF LECS 
I have isolated, characterized, and established 2D in vitro cultures of primary LECs from 
different animals and tissues types.  These primary cells can now be used as tools to develop 3D 
in vitro cultures of primary LEC that mimic closer the physiological and functional conditions of 
these cells in vivo.  Three-dimensional in vitro cultures of LEC can then be used to investigate 
further the crosstalk of LECs with microbes including HIV-1 and SIV, as well as cell-to-cell 
interactions of LECs with other immune or nonimmune cells.  These future studies will 
hopefully give us more accurate representation of the innate immune potentials of LECs. 
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8.2 PROFILING OF IMMUNE RECEPTORS EXPRESSED BY PRIMARY LECS 
My data showed that primary LECs expressed a set of immune receptors that potentially 
contribute to their innate immune ability as well as their ability to modulate the local tissue 
microenvironments during homeostasis or as part of pathogen-host interactions.  However, there 
is a need to confirm these findings functionally in in vitro and in vivo models.  In addition, a 
more comprehensive analysis of the immune receptor profiles expressed by LECs in absence or 
presence of an infection is needed.  This knowledge will not only expand our understanding of 
LEC contributions and involvement in host innate and adaptive immunity but could also lead to 
discoveries of novel strategies to improve current therapeutics and vaccines against important 
human pathogens such as HIV-1. 
8.3 PROFILING OF MICRORNAS EXPRESSED BY PRIMARY LECS   
MicroRNAs (miRNAs) are short, non-coding cellular RNAs that bind to host mRNAs based on 
sequence complementarity and are important regulators of genes that control the key cellular 
processes including cellular lineage, differentiation, and death.  More recently, host miRNAs 
have been reported to directly target HIV-1 and influence cells permissiveness to infection.  
More importantly, additional evidence showed that miRNAs modulate the expression of host 
defense factors, including PRRs and other immune receptors, during HIV-1 infection.  
Comprehensive analysis of the primary LEC miRNA profiles in the absence and presence of 
HIV-1 infection could lead to discovery of new biomarkers for virus-induced disease progression 
in HIV-1-infected individuals. 
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8.4 ANTIGEN PRESENTATION VIA MHC I AND MHC II BY LECS     
Data from this study corroborated the findings that LECs were capable of performing antigen 
uptake and processing, albeit less efficient than DCs.  However, it was not clear whether these 
exogenous antigens were subjected to terminal degradation, transferred to incoming naïve DCs 
for antigen presentation, or were directly presented by the LECs via MHC I or MHC II 
molecules to T cells.  In addition, it will also be interesting to examine further whether potential 
antigen presentation by LEC-derived MHC I and MHC II to autologous T cells results in the 
same outcomes as antigen presentation by DCs.   
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APPENDIX: 3D MODEL OF PRIMARY HUMAN AND MACAQUE LECS 
 
                                                                                                                                     (100X) 
3D multicellular spheroid culture of model human dermal LECs using poly-HEMA coating method at day 3 
after plating.  
 
A total number of 500 live cells were plated onto each well of a round bottom 96-well plate coated prior with poly-HEMA.  Cells 
were cultured using EGM2-MV media (Lonza) supplemented with 5% FBS at 37°C, 5% CO2 for three days.  Image was taken 
using a brightfield microscope using Nikon camera. 
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                                                                                                                                     (100X) 
3D multicellular spheroid culture of one primary jejunal LEC polulation (rhR564 Jejunal) using poly-HEMA 
coating method at day 3 after plating.  
 
A total number of 500 live cells were plated onto each well of a round bottom 96-well plate coated prior with poly-HEMA.  Cells 
were cultured using EGM2 media (Lonza) supplemented with 2% FBS at 37°C, 5% CO2 for three days.  Image was taken using a 
brightfield microscope using Nikon camera. 
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                                                                                                                                     (100X) 
3D multicellular spheroid culture of model human dermal LECs using hanging drop method at day 3 after 
plating.  
 
A total number of 500 live cells were plated in a final volume of 25 µl of final concentration of 20% methyl cellulose in EGM2-
MV (Lonza) supplemented with 2% FBS and cultured at 37°C, 5% CO2 for three days.  Image was taken using a brightfield 
microscope using Nikon camera. 
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